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ABSTRACT 
The Class C subfamily of the G protein coupled receptor (GPCR) family is one of the 
most important in the central nervous system (CNS), and includes the glutamatergic and 
GABAergic metabotropic receptors (mGlu and GABAB). The mGlu receptors are 
fundamental in modulating the efficiency of chemical neurotransmission in the CNS 
and, as a consequence, they are also involved in several neurological and 
neurodegenerative disorders. Recently, dimerization of these receptors has become an 
important topic of investigation and it has been proposed to be crucial to physio-
pathological processes in the CNS, as well as to the impact of therapeutics in patients. 
In this thesis, I will discuss the basic properties of Class C GPCRs focusing on the first 
and second group of mGlu receptors (Group I and II) and their possible dimerization 
and/or cross talk with other receptors. I will focus on recent findings concerning these 
processes that have been mainly obtained by using purified isolated nerve endings (here 
referred to as synaptosomes), a subcellular preparation of choice for studying 
presynaptic release regulating receptors. Starting from the pharmacological 
characterization of Group I and II mGlu receptors, I will then discuss different examples 
of cross-talk linking these receptors to other ones (i.e. the GABAB and the 5-HT2A 
receptors). I will also show results obtained using electrophysiology to study the role of 
these receptor subtypes in the modulation of synaptic transmission in hippocampal 
slices. The resulting picture is undoubtedly complex and highlights how the cross-talk 
and dimerization of these receptors represent a new frontier in neuropharmacological 
studies. 
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ABBREVIATION 
5-HT2A 5-hydroxy-tryptamine-2A receptor 
7-TM 7-transmembrane domain 
[
3
H]D-ASP [
3
H]-D-aspartate 
Ao active orientation 
AC adenyl cyclase  
ACPD amino-cyclopentanedicarboxylic acid 
ACPT-11S,3R,4S-1-aminocyclopentane-1,3,4-tricarboxylic acid  
ADP adenosine disphosphate 
AGS G protein signalling 
APS1 autoimmune polyendocrine syndrome type 1  
BBB blood brain barrier 
BRET Bioluminescence Resonance Energy Transfer 
c.f. final concentration 
CA1 Cornu Ammonis-1 
cAMP cyclic adenosine monophosphate 
CaS Calcium-sensing receptor 
CNS Central Nervous System 
CRD Cysteine rich domain  
Cs Close state 
CSF cerebrospinal fluid 
CXCR C-X-C chemokine receptor 
DAG diacylglycerol 
DG Dentate Gyrus 
EDAM extracellular domain allosteric modulator 
 8 
ER endoplasmatic reticulum 
ERK-1/2 extracellular signal-regulated kinases 
EVH-1 Enabled / Vasp homology-1 
FRET Fluorescence Resonance Energy Transfer 
GABA gamma-Aminobutyric acid 
GDP Guanosine disphosphate 
GFAP Glial Fibrillary Acidic Protein  
GIRK G protein-gated inwardly rectifying potassium 
GNAS  
GPCR G Protein Coupled Receptor 
GPRC6a G protein receptor Class C 6a 
GTP Guanosine trisphospate 
HPLC High Performance Liquid Chromatography 
IMP inositol monophosphate 
IP3 inositol trisphosphate  
MAP4 (S)-2-amini-2-methyl-4-phosphonobutanoic acid  
MAPK mitogen-activated  protein kinase 
mGlu metabotropic glutamate receptor 
MCPG amino-cyclopentanedicarboxylic acid 
MHC melatonin-concentrating hormone 
MPEP 2-methyl-6-(phenylethynyl) pyridine  
MRI Magnetic Resonance Imaging 
NAAG N-Acetylaspartylglutamic acid 
NAM negative allosteric modulator 
NF-κB nuclear factor- κB 
NMDA N-metil-D-aspartate 
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Os open state 
PAM positive allosteric modulator 
PDZ post synaptic density protein (PSD95)/Drosophila disc large tumor suppressor 
(Dlg1) / zonula occludens-1 protein (zo-1). 
PKC protein kinase C 
PLC phospholipase C 
PTx Bordetella pertussis toxin  
Ro resting orientation 
RAIG retinoic acid induced receptor 
RAP1GAP Ras-proximate-1 GTPase activating protein 
Rho-GEF Ras homologous protein - GDP/GTP exchange factor 
RNA ribonucleic acid 
TAS taste receptor 
TBS Tris-Buffered Saline 
TNFα Tumor Necrosis Factor α  
TR taste receptor 
VFT Venus Fly Trap 
VIP-PACAP vasoactive intestinal peptide – Pituitary adenylate cyclase-activating 
polypeptide 
vs versus 
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1 INTRODUCTION 
1.1 G Protein-Coupled Receptors: the Class C 
1.1.1 General considerations 
While discussing on cell communication, signal mechanisms or neurotransmission in 
the organisms, we cannot ignore the centrality of one of the mostly recognized super 
family of proteins: the G protein coupled receptor (GPCR) family. GPCRs are among 
the ancient machines involved in the signal transduction in vertebrates and plants. They 
are typified by a widespread distribution, different characteristics and peculiar structural 
conformations. Owing to give an overall definition of the function of these proteins, I 
could mention these words written by Joel Bockaert: 
 
“GPCRs are involved in the recognition and transduction of messages as diverse as 
light, Ca
2+
, odorants, small molecules including amino-acid residues, nucleotides and 
peptides, as well as proteins. They control the activity of enzymes, ion channels and 
transport of vesicles via the catalysis of the GDP–GTP exchange on heterotrimeric G 
proteins (Gα–βγ)” (Bockaert J. and Philippe Pin J., 1999).  
 
These few words unveil the greatness and the complexity of the subject. Despite the 
importance and the diffusion of GPCR proteins in the organisms, the research has been 
underdeveloped for many years because of technical limitation. For instance, until 2007, 
only few crystal structures were available, like bovine rhodopsin receptors, which 
limited the possibility to approach functional and pharmacological studies with 
computational analysis. This limitation has been partly overcome in the last decade 
opening the road to studies concerning their structures and conformations. Thousand of 
papers were then published about the ability of these receptors to control and modulate 
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signal mechanisms, and it is nowadays recognized their relevance as targets for drugs. 
Indeed, more than 30 % of drugs on the actual pharamcautical market has the GPCRs 
proteins as target. 
Studies about the amino acid sequence allowed to classify the GPCR proteins and to 
further subclassify them in subfamilies. The first classification divided GPCRs in three 
main families:  
 The first family contains most of the so far known GPCRs and it is further 
subdivided in three different groups: receptors for odorants and rhodopsin 
(Group A), peptides (Group B) and glycoprotein hormones (Group C).  
 The second family contains GPCRs recognizing hormones like glucagon and 
secretine (the weight control hormones), different toxins (like Latrotoxin) and 
the VIP-PACAP complex. Curiously, the receptors belonging to this family 
have a morphology comparable to that of the subgroup C of the first family. 
 The third family consists of the metabotropic glutamate and GABA receptors, 
in addition to the Ca
2+
 sensing receptors. This is a very important family for 
the neurotransmission in the CNS and represent the topic of this work. 
Beside these families, three other minor families of GPCR proteins have been 
hypothesized to exist: the receptors for pheromones, the cAMP receptors (expressed 
only in some organisms) and the frizzled/smoothened receptors. Although these GPCRs 
share poor or no sequence similarity one each other, they belong to a common 
superfamily, the GPCR one, that would suggest a molecular convergence of the protein 
evolution to a common organization. 
Starting from 2003, a new classification system was proposed based on crystal 
structures and human genome sequence (Fredriksson R. et al., 2003). According to this 
classification (Vsevolod K. et al., 2012), human GPCRs are divided in : 
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1. the GPCR Rhodopsin family (the so called Class A), which is subdivided in α, 
β, γ and δ groups; 
2.  the Secretin and Adhesion family or Class B; 
3. the Glutamate family or Class C;  
4.  the Frizzled / TAS2 family.  
The study I carried out during my PhD training focused on the functional and 
pharmacological characterization of GPCRs belonging to the Class C and specifically to 
the metabotropic glutamate receptors (mGlu) and the GABAB receptors.  
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1.1.2 Class C GPCR  
The so called Class C or third family of GPCR proteins assumed an important role in 
the study of the control of chemical neurotransmission and, more in general, of CNS 
plasticity during the last decades. This class consist of metabotropic glutamate receptors 
(mGlu), GABAergic receptors (GABAB), Ca
2+
 ions receptors (CaS), sweet and umami 
tastes receptors (T1Rs), basic amino acids receptors (GPRC6a) and some orphan 
receptors (Kniazeff J. et al., 2011).  
Despite the difference in amino acid sequences, function and conformation, these 
receptors share a common structural feature, defined by the large extracellular domain, 
which is in part expressed also in bacterial periplasmic binding proteins and in some 
ligand-gated ion channels. 
The main members of the third family of GPCRs and the first to be cloned were the 
metabotropic glutamate receptors (Masu et al., 1991). The term “metabotropic 
glutamate receptor” was firstly used by professor Sugyjama to indicate a quisqualate-
sensitive receptors expressed in Xenopus oocytes injected with rat brain RNA 
(Sugyjama et al., 1987). In the history of this group, the mGlu1 protein was the first 
crystal structure of the extracellular domain described, which gave important advances 
in understanding the Class C proteins. Soon after, Muto and collaborators reported the 
structures of the mGlu3 and the mGlu7 receptor proteins (Muto et al., 2007).  
The group of metabotropic glutamate (mGlu) receptors is activated by glutamate, the 
major excitatory neurotransmitter in the CNS. They participate to the synaptic 
transmission and to the integration of the information, beyond the cell excitability and 
signal modulation. This explain why they are so extensively studied and they are 
thought to be involved in almost all the neurological impairments. Today, the mGlu 
receptors have been subdivided into three different groups based on their sequence, 
localization and signal transduction:  
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1. The first mGlu group is composed by the mGlu1 and mGlu5 receptors. They 
are mainly coupled to Gαq proteins and they were firstly localized in the post 
synaptic compartment. They are also functionally present in the presynaptic 
elements (Moroni et al.,1998; Pittaluga, 2016) and in non neuronal cells 
(Biber K et al., 1999).  
2.  The second group refers to the mGlu2 and the mGlu3 receptors and, opposite 
to the first group, they couple to Gαi/o proteins. They are widely expressed in 
the CNS, at both the pre and the post synaptic compartments as well as in 
astrocytes/glia cells (Bruno V et al., 2001). 
3. The third group consists of the mGlu4, the mGlu6, the mGlu7 and the mGlu8 
receptor subtypes. As for the previous group, they couple to Gαi/o proteins 
and they are expressed in the nerve terminals where they contribute to the 
modulation of glutamate transmitter release. The mGlu6 receptors are 
expressed only in Bipolar cells of the retina (for the third group and previous 
groups see also the review of Conn & Pin, 1997; Cartmell and Schoepp, 2000 
and Niswender & Conn, 2010). 
The second actor of the Class C GPCRs correlates to the central inhibitory transmission. 
It is the GABAB receptor, which is activated by GABA, the major inhibitory 
neurotransmitter of the mature CNS. Most of the brain regions but also some peripheral 
areas express the GABAB receptors at both the pre and the post synaptic component of 
chemical synapse where they control neurotransmitter exocytosis and regulate the 
excitatory post-synaptic currents (Bettler & Tiao, 2006). Altered GABAB functions are 
involved in different kind of diseases and neurological disorders like depression, 
addiction and autism representing, therefore, a very interesting target for drugs. Even if 
the structure will be deeply analysed in the next chapters, I would like to remember that 
these receptors are obligatory heterodimers composed by the ligand binding GABAB1 
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protein and the G protein coupling GABAB2 protein, which is the main feature of the 
GABAB receptors (Kniazeff J. et al., 2004). 
One of the most important ion for the homeostasis in the organism is calcium that, 
beyond its excitatory functions, is the ligand of the Calcium-sensing receptors (CaS). 
This group of receptors can be also modulated by different amino acids, polyamines and 
other divalent cations (Riccardi et al., 2009). They mainly locate in the periphery at the 
parathyroid gland where they participate to the control of Ca
2+
 metabolism, which is 
fundamental at least for kidney and bone. Mutations at these receptors are associated 
with the development of abnormal calcemic condition. In addition, CaS receptors have 
been found in the CNS where they were proposed to take part into the process of nerve 
outgrowth. Interestingly, these receptors can switch between the “on” and the “off” 
states with a very fine and high sensitivity (Riccardi et al., 2009). 
The Class C GPCR proteins also includes the umami and the sweet taste receptors, two 
groups of the family of the taste receptors. They are localized in the taste buds and they 
are displayed as heterodimeric receptors (T1R2 and T1R3 for sweet receptors, T1R1 
and T1R3 for umami receptors) (Nelson et al., 2002). Sweet receptors are linked to the 
Gα-transducin for the transduction signal pathway and they do not only respond to 
sweet ligands but they are also modulated by sweetener, sweet protein and some D-
amino-acids, which affinity is reported to change between species. The umami receptors 
are commonly associated to the Japanese and oriental foods. They are stimulated by L-
amino acids but, only in the human phenotype, they are activated by sodium glutamate 
and L-aspartate. They are also potentiated by inositol monophosphate (IMP), guanosil 
monophosphate (GMP) and adenosil monophospate (AMP) molecules. Undoubtedly, 
these receptors have great interest in the field of the food and sweetener industry 
(Chandrashekar et al., 2006). 
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The last known member of this Class C is the GPRC6A receptor, which has been only 
recently described. In fact some recent studies proposed that the receptor activation is 
triggered by several basic L-amino-acid like arginine, lysine or ornithine. The structure 
of this receptor shares some homology with the CaS and the mGlu receptors and they 
usually form homodimers linked by disulphide bridge. The GPRC6A is expressed in 
different area of the organism such as in kidney, taste buds and CNS. We still do not 
know exactly the function of this receptor but some studies proposed its involvement in 
the modulation of nutrient-dependant process (Wellendorph et al., 2009). 
Finally, some orphan receptors have been correlated to the Class C GPCRs. 
Specifically, the retinoic acid-induced (RAIG) and the GPR156/158/179 receptors. 
Briefly, the first one is particularly expressed in the retina while the second group has 
structure comparable to that of the GABAB receptors. Both receptors lack the 
extracellular domain and, consequently, they would be expected to have particular 
ligand-mediated mechanism of activation (Kniazeff et al., 2011). 
In order to better achieve our aim, in this thesis, when I will talk about Class C, I will 
refer mainly to the mGlu receptors and the GABAB receptors, which are also the most 
known receptors of this class. 
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1.1.3 Structure and function  
The organization and classification of the GPCR proteins rely on the proteins structures 
that strictly correlate to the mechanism of activation of the receptors and to the coupled 
mechanisms of transduction. X-crystallography or FRET techniques were pivotal to the 
description of GPCRs structure, as demonstrated by many studies performed in the last 
three decades.  
Beyond the specific families and subfamilies, GPCR proteins share a general core 
structure composed of a N-terminal domain and a central core domain characterized by 
seven transmembrane helices (7-TM), linked by three intracellular and three 
extracellular loops and a C-terminal domain (Baldwin, 1993). The most of these GPCRs 
conserved a disulfide link made by two cysteine residues in the first and the third 
extracellular loops, fundamental for the stabilization and the organization of the typical 
conformation of the seven 7-TMs. Differences in the amino acid sequence affect the 
length, the function and the structural organization of the N-terminal extracellular 
domain as well as of the C-terminal intracellular domain and the intracellular loops.  
Among all domains, the 7-TM domain represents the core domain of GPCR proteins, 
and its structure was mainly characterized with crystallization techniques. Specifically, 
based on the results obtained from these studies, we learned the crucial involvement of 
the 7-TM domain in the modulation and in the activation of these receptors. However, 
this domain as well as the other domains show some differences among the various 
families and subfamilies, carrying out some peculiarities in the GPCRs functions 
(Spengler et al., 1993; Bockaert J and Pin P.L., 1999).  
The third family or Class C GPCRs is typified by the presence of a large extracellular 
domain characterized by two lobes separated by a “hinge region”. This domain is the so 
called Venus Fly Trap (VFT) domain. Another common feature of the Class C of 
GPCRs is the large transmembrane core composed of seven helices (7-TM) domain 
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linked to both N-terminal and C-terminal tail. The two main domains, the VFT and the 
7-TM domains, communicate one to each other via an enriched cysteine domain (CRD), 
that is a rigid module characterized by 9 highly conserved cysteine residues. Further, 
CRD and VFT domains are stabilized by a conserved and rigid disulfide bond. The 
function of this enriched cysteine “communicative bridge” or CRD domain is 
associated to the communication of the conformational changes between the “sensorial 
domain” or VFT domain and “transmitter domain” or 7-TM domain (Kniazeff et al., 
2011). 
 
Sensorial domain or VFT domain  
The large extracellular domain or the VFT domain is involved in the orthosteric binding 
momentum of the receptor, hence the name “sensorial domain”. First studies on this 
domain begun with the description of the presence of VFT in bacterial periplasmic 
protein, where these receptor proteins are involved in the transport of various molecules 
(Bockaert J and Pin JP, 1999). 
During the last 30 years, the study of GPCRs has become more and more important in 
the CNS field. Specifically, the most spread excitatory neurotransmitter, glutamate, and 
the central inhibitory neurotransmitter, GABA, played the role of main actors in most of 
these studies. This explained why most of the structural analysis of the Class C GPCRs 
were performed to describe the mGlu and the GABAB receptors. On the basis of the 
results from the X-ray crystallography, the metabotropic glutamate receptor type 1 
(mGlu1) was reported to express the VFT domain. Soon later it was demonstrated that 
the presence of this domain is not restricted to the mGlu1 but that also other mGlu 
receptors possess it (Kunishima et al.,2000; Muto et al., 2007), so that this domain was 
proposed as a characteristic domain of the Class C GPCRs proteins. 
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The VFT domain is characterized by two lobes composed by α-helices around a large β-
sheet in the metabotropic glutamate receptors, with the glutamate binding site in the 
cleft between the two lobes (Muto et al., 2007). This structure was demonstrated to be 
conserved in almost all the other receptors belonging to this class, underling a general 
convergence at this level in this family.  
The structure VFT domain plays a central role in the protein because it is associated to 
the orthosteric binding site. In other words, changes in conformation of this domain lead 
to the first steps of the activation of Class C GPCRs by orthosteric agonists. 
Consequently, it became evident the link between the VFT domain characterization and 
the design of possible new orthosteric compounds acting at this level (Pin J.P. et al., 
2004). 
The study of the bacterial periplasmatic structures gave the firsts insights about the 
possible conformations of the VFT region. The domain can adopt two major state, an 
open state (Os) and a closed state (Cs). The Cs is stabilized by the ligand binding in the 
crevice located in a specific region of the lobe (Quiocho, 1990). Specifically, the 
orthosteric agonist binds the VFT adopting the Os and the occupancy of the binding site 
leads to the closure of lobe-II through specifically interactions. The structural 
modifications that follow the binding of the agonist stabilize the receptor protein in the 
close state (Cs). Orthosteric antagonists mainly act by preventing these interactions 
leading to a block of the conformational changes of the 7-TM domain.  
These conformational changes underline the strict correlation linking the ligand profile 
and the VFT sequence. For instance, genetic alterations that impede the adoption of the 
Cs of the VFT sequence convert the antagonist-like interaction of (S)-2-amini-2-methyl-
4-phosphonobutanoic acid (AP-4), a well known mGlu3 antagonist, and of 1S,3R,4S-1-
aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-1) another mGlu 3 antagonist, into 
full orthosteric agonists (Bessis et al., 2002). In addition, first studies on the three-
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dimensional structure adopted by the mGlu1 receptor showed that the receptor can 
adopt the Os despite the absence of glutamate and the Cs conformation in the presence 
of glutamate (Kunishima et al., 2000). Although it is not the matter of discussion of this 
section, it should be taken in consideration that the mGlu and most of the Class C 
receptors exist in the dimeric form and that this form is pivotal to assure the activation 
of the receptors. The mGlu1 receptor was the first Class C receptor to display a 
“constitutive activity”. This refers to the possibility to find the receptor in the active 
state even in the absence of the agonist (Kniazeff et al., 2004). Paralleled to the studies 
performed in the glutamatergic system, other analysis performed in the GABAergic 
system confirmed the same general mechanism for the VFT domain, showing also that 
the Cs is sufficient for the activation of the receptors. 
The data so far available demonstrated that the binding of the agonist to the VFT region 
of the receptor leads to a large rearrangement of the conformation. Specifically, it has 
been suggested the presence of two general orientations adopted by the VFT domain: 
the resting orientation (here named Ro) and the active orientation (here named Ao). 
These two orientations are normally in an equilibrium state. In the Ro orientation, the 
lobe-I linked to the VFT is separated from the lobe-II while in the Ao orientation, the 
two lobes interact one each other, because of the reorganization of the conformational 
state. It has been proposed that this reorientation bridges the binding of the orthosteric 
ligand with the mechanism of  activation of the 7-TM domain. 
Recently, new advances in this field lead to propose the existence of six different 
possible orientations, here reported as: Ro/o, Ro/c, Rc/c and Ao/o, Ao/c, Ac/c. It is assumed 
that when the orthosteric agonist binds the cleft of the lobe-I forces the VFT dimer to 
pass through the Ro/o, Ro/c, to the Ao/c, Ac/c states, causing a large reorientation. In this 
complex picture, it has been already demonstrated the key role of lobe-II interaction. 
For instance, blocking the VFT dimer by for example N-glycosylation at the surface of 
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lobe-II result of the loss of the G-protein transduction signal in the GABAB receptors 
(Rondard et al., 2008). Also, these studies suggest that a large conformation changes 
through lobe-II is necessarily request to the G protein activation (Kniazeff et al., 2011).   
However, the exact orientation/conformation mechanisms are still not completely clear. 
For these reasons it is essential to continue to investigate about these structures in order 
to completely elucidate the activation mechanism of these receptors. 
 
Transmitter domain or 7-TM domain 
All the families of the GCPRs, including the Class C, share a general common 
component: the 7-TM core domain. It physically connects the extracellular domain with 
the intracellular one, acting as the “Transmitter domain” within the receptor protein. In 
other words, it links the “sensorial domain” to the associated G protein which activates 
intracellular second messenger cascade. The 7-TM domains are typified by the presence 
of a central helix 3 and an amphipathic helix 8 (Pin et al, 2003). In 2003 Pin and 
colleagues showed that the intracellular loops 2 and 3 as well as the helix 8 are 
fundamental for the G-protein coupling. There are several other peculiarities relevant to 
the 7-TM functions which are shared in this Class C of GPCRs proteins. First, the ionic 
lock between the conserved arginine (3.50) in TM3 and the conserved glutamate (3.60) 
in TM6 leads to the mechanism of activation. Second, there is a common 
conformational change which involves a conserved tyrosine (6.48) in TM7. Third, the 
so called “toggle switch” interests the rotamer conformation of the conserved 
tryptophan (6.48) in TM6. All these specific sequence similarities underline a main 
feature already observed for other domains: Class C receptors share common general 
regions in the mechanism of action and transduction signal in the 7-TM region (see Pin 
et al., 2003; Hofmann et al., 2009; Rosenbaum et al., 2009). 
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Another important step in the characterization of this domain is the discovery of the 
binding pockets located in the 7-TM. A very large family of compounds was drowned, 
called positive/negative allosteric modulators, that binds this pocket and that will be 
deepened in the next chapters. 
The crucial role of the 7-TM domain in controlling the function of these receptors has 
been already described by different kind of experiments and works. For instance, the 
VFT and CRD domains were deleted and the C-terminal truncated in these experiments. 
This “minimalistic” version of the original receptor can be completely activated and 
inhibited by molecules acting at its 7-TM domain. In this case, these allosteric 
modulators perform the role of the full agonist/antagonist (Binet et al., 2004; Goudet et 
al., 2004). Indirectly, these experiments and the role of 7-TM domain were confirmed 
by some orphan receptors of Class C like RAG1 receptor, which presents only the 7-TM 
region.  
 
Communicative bridge or CRD domain  
The studies focused on the VFT and 7-TM domains and their dimeric activation 
unveiled another important region that allows the transduction of the signal from the 
“sensorial domain”(VFT) to the “transmitter domain”(7-TM). 
This region is named rich-cysteine domain (CRD). As described in literature, this 
domain connects the VFT region and the 7-TM region and it is characterized by a 
highly conserved sequence consisting of 9 cysteine amino acids. Except for the GABAB 
receptors, this domain was found in the mGlu receptors, CaS receptors, T1R receptors 
and GPRC6A receptors. The structure was firstly elucidated after crystallography 
analysis of the mGlu3 structure (Muto et al., 2007). The domain is characterized by a 
rigid 40 Å long structure that acts like a fundamental gear between the “sensorial 
domain”(VFT) and the “transmitter domain”(7-TM). Experiments carried out in 
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different group of Class C receptors confirmed its important role as a “communicative 
bridge”. Either the deletion or the mutation of the CRD sequence abolished the 
orthosteric agonist-induced mechanism of activation (Hu et al., 2000; Jiang et al., 2004). 
In this gear, the specific disulphide covalent bond which links the CRD domain to the 
VFT core seems to play a key role. Studies focussing on the deletion of the covalent 
bond in this region showed the silencing of the receptor functions despite the binding of 
the agonist to the respective site (Kniazeff et al., 2011).  
To resume, the binding of the orthosteric agonist causes changes in the orientation of 
the VFT domain, that in turn brings the lobe-I and the lobe-II closer one to each other. 
Subsequently, the respectively CRD domains, which are linked by a covalent bond to 
the VFT domains, move closer one to each other to complete the activation process. The 
result of this cascade of events is the continue transition of the “information” from the 
“sensorial domain”(VFT)” to the “transmitter domain”(7-TM) by means of the 
“communicative bridge”(CRD). To further investigate this process of activation, 
Rondard and his colleagues performed “engineered experiments” to modify the cysteine 
bond sequence. Their approach suggested that locking CRD dimer in specific 
conformation mimics the active state of the receptor, even in the absence of the agonist 
(Rondard et al., 2010).  
These overall results confirmed: i) the onset of changes in the relative conformation 
through the involvement of the CRD domains; ii) that CRD modification and 
specifically the disruption of the covalent bond blocks the agonist mediated activation 
mechanism; iii) that CRD bridges the VFT domain and 7-TM domain. 
Some words must be spent about the case of GABAB receptors due it is peculiar 
structure. This receptor does not show the typical CRD domain. In this context, we 
should take in mind the obligatory heterodimeric nature of GABAB receptors, composed 
by the two subunits, the GABAB1 and the GABAB2 receptors. In literature, it has been 
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suggested that the mechanism of activation for these receptors is mediated by a direct 
communication between the VFT domain and 7-TM domain. Specifically, two 
activation ways were proposed to take place:  
i) a trans-activation based on the occupancy of the orthosteric agonist binding site and 
thus the VFT closure of GABAB1 that would directly change the conformation of 7-TM 
of GABAB1 in turn promoting the G protein activation by 7-TM of the GABAB2 subunit. 
ii) the cis-activation based on the closure of the VFT of the GABAB1 receptor subunit 
by an orthosteric agonist which induces a conformational change of the VFT of the 
GABAB2 subunit and consequently of the 7-TM domain of the GABAB2 receptor 
(Monnier et al., 2010).  
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1.1.4 Ligands acting at Class C GPCR 
In general, Class C GPCRs show a well-defined structure mainly represented by the 
VFT and 7-TM domains which are linked through the CRD domain, with some 
exceptions like the lack of the CRD domain in the GABAB receptors group. This 
structure accounts for the existence of different binding sites for the ligands (Rondard et 
al., 2011). Therefore, the Class C receptors display a potential variety for the 
development of drugs which can modulate receptor activity in different ways, 
depending on the sites and on the mechanisms of interaction. In theory, these drugs can 
bring many beneficial effects in different context: from the neurological to the 
psychiatric disorders, from hormonal to the calcemic diseases, to improve the food 
physiology and to face the obesity (Brauner-Osborne et al., 2007). Nonetheless, few 
drugs belonging to this group have been so far approved for the use in therapy. Some 
important examples are Baclofen and Cinacalcet in addition to the group of sweet and 
umani enhancer/modulator compounds. 
In this chapter I am going to describe the general mechanism of action of the ligands 
with respective receptors. The aim is to introduce general concepts that are fundamental 
to understand the physiological and pathological consequences due to different sites of 
modulation of the Class C GPCRs. In other words, I am going to introduce ligand acting 
at VFT domain, at the 7-TM domain and other possible sites. Attention will be also 
dedicated to the new possible pharmacological tools like antibodies, to recombinant 
nanobodies and to “extracellular domain allosteric modulators” or EDAMs. Refer to the 
authors mentioned during the discussion for further information. 
 
Ligands acting at VFT domain 
As described in the previous section, endogenous agonists of Class C GPCRs bind in 
the VFT cleft, stabilizing its close state. This site of action is the so called “orthosteric” 
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binding site. Orthosteric agonists induce the VFT domain closure which is the first step 
in the mechanism of receptor activation. Conversely, the orthosteric or competitive 
antagonists stabilize the VFT domain in the open state, preventing the action of the 
agonists. In addition, compounds acting as “partial agonist” are also overtaken. The 
term “partial” refers to the capability of these molecules to give a partial closure of the 
VFT or, alternatively, to cause a less relevant stabilization of the close state when 
compared to the full agonists (Kunishima et al., 2000; Tsuchiya et al. 2002; Bessis et 
al., 2003; Kniazeff et al., 2004). The first receptor to be studied for its structural 
conformation was the mGlu1 receptor. These studies demonstrated that the receptor 
exists in the open conformation in the absence of glutamate and in the close 
conformation in the presence of glutamate (Kunishima et al., 2000). Another important 
demonstration came from the studies on the consequences elicited by the mutagenesis 
of the crevice of the VFT of mGlu3 receptors, that converts full antagonists like MAP4 
and ACPT-II in full agonists (Bessis et al., 2003). These and other researches in 
literature investigated also how endogenous and/or exogenous synthetic compounds can 
bind with specific interaction in the VFT pocket.  
As far as the mGlu and GABAB receptors are concerned, L-glutamate and γ-
aminobutyric acid (GABA) are the endogenous agonists of these groups of receptors 
respectively. These amino acids interact with the orthosteric binding sites thanks to the 
presence of five residues in the VFT cleft that are involved in the binding process of the 
α-amino and α-carboxy group of these amino acids (Acher and Bertrand, 2005). In the 
same manner, other specific amino acids can act as ligand of other types of Class C 
receptors like CaS, T1R1, T1R3 and GPRC6 receptors.  
The mGlu receptors are divided in three different subgroups (I, II and III) and consist of 
eight different receptor subtypes. Glutamate is the endogenous orthosteric agonist for all 
the metabotropic glutamate receptors and binds the highly conserved binding pocket. 
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The efficacy of glutamate to act as a full agonist at all the eight receptor subtypes 
indirectly indicates that the eight receptors are typified by an important sequence 
homology. The first challenge to pharmacologically characterize these receptors was to 
find compounds able to modulate mGlu receptors but devoid of affinity for the 
ionotropic glutamate receptors. In this sense, the first pharmacological breakout was the 
discovery of the trans-1-amino-cyclopentanedicarboxylic acid (trans-ACPD), a selective 
agonist of mGlu receptors with no activity at ionotropic glutamate receptors (Schoepp et 
al., 1999). Starting from this first molecule, other compounds were derived and typified 
by a different range of action towards the different mGlu subtypes (Cartmell and 
Schoepp, 2000). It was the case of the first selective competitive antagonist: the R,S,-α-
methyl-4-carboxyphenylglycine (MCPG) (Birse et al 1993; Eaton et al., 1993). More 
recently, the impressive work by Jim Monn, David McKinzie and colleagues at Eli Lilly 
industries gave us an important pool of selective compounds for the mGlu2/3 receptors 
with nanomolar potencies. Here, I want just report two of the progenitors of this huge 
family: the (1S,2S,5R,6S) aminobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 
(LY354740) and the (1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-
dicarboxylic acid (LY379268) (see also the review of Schoepp et al., 1999). 
Interestingly, this example gives us the idea of the prolonged and huge involvement of 
the private sector in the study of these receptors.  
A comparable story about the pharmacological design and creation of new compounds 
concerns the orthosteric agonists and antagonists at GABAB receptors. The story began 
from the fundamental study of the group led by Norman Bowery, which underlined the 
difference with the GABAA ion channel receptors and unveiled the GABAB 
involvement in many physiological processes (see next sections and Bowery et al., 
1999; Fan Q.R. and Frangaj A., 2018). An important discovery for the study of GABAB 
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receptors pharmacodynamics was the introduction of Baclofen, which still represents 
one of the most famous examples of GPCR drug approved for therapy.  
The huge amount of studies focusing on these receptors gave also important insights 
about the receptor mechanisms and, as far as the GABAB receptors are concerned, at 
least two main characteristics should be taken into consideration. 
Firstly, the competitive antagonists bind specific sites at the GABAB receptors by 
blocking the 7-TM sequence in the inactive state rather than directly interacting with the 
VFT domain (Grünewald et al., 2002). This is the reason why they are not defined 
“orthosteric” ligand, but rather  “inverse” agonists.  
Secondly, Ca
2+
 ions can modulate GABAB receptors as well as other Class C receptors. 
Specifically, it has been demonstrated that the affinity of agonists at some Class C 
GPCRs is increased by the presence of Ca
2+
. It is the case for the GPCR6 receptors and 
the GABAB receptors, where the change in the affinity of some agonists for the GABA 
receptors elicited by Ca
2+
 is due to the interaction of agonist with a serine 269 that 
follows the binding of GABA at the GABAB1 subunit (Galvez et al., 2000). Despite 
these first observations, the ionic modulation of GABAB receptors appear more 
complex and not completely disserted. In fact it has been demonstrated that some 
agonists like Baclofen as well as some antagonists are insensitive to the presence of 
Ca
2+
.  
Although they are not the subjects of this work, some words must be spent also for 
ligands acting at the VFT domain in the other types of Class C receptors: 
 The sweet and umami taste receptors, T1R, show a impressive range of possible 
orthosteric agonists. These receptors are activated and modulated by i) sweet-tasting D-
amino acids which a similar mechanism of other receptors. ii) sugars including glucose, 
fructose or sucrose present in food. The possibility that also carbohydrates can act as 
ligand is reported as unique characteristic in the Class C GPCRs, which is proposed to 
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be associated with a large crevice of the binding domain and specific interaction(s) in 
the hinge region of VFT. iii) protein detected in food, which mechanism of interaction 
is not completely understood, but it seems to be associate to the so called “sweet 
fingers” of these receptors. The target of the sweet and umami receptors is of interest in 
the food industry research, as the well known examples of some artificial sweetener like 
acelsulfame and aspartame that can act as agonists at these receptors (for more 
information see Nelson et al., 2001; Morini et al.,2005; Assadi-Porter et al., 2010). 
 CaS receptors which are the only Class C receptors which can be activated by ions, in 
particular Ca
2+
, without the presence of other ligands. Ca
2+
 binds the VFT cleft but also 
interacts with the 7-TM. As already said, these receptors are activated by a really 
narrow range of calcium concentration, which is fundamental in calcemic homeostasis 
(Ray et al., 2005). 
 GPCR6 receptors which recognize basic L-amino acids like arginine, ornithine or lysine 
and to lesser extent other small amino acids like alanine and glycine. They are also 
modulated by divalent cations like Ca
2+
 and Mg
2+
( Pi et al., 2005; Wellendorph et al., 
2009). 
Recently, it has been shown that closed to the VFT binding domain there is a small site 
where molecules can interact in order to modulate the affinity of the agonists. This new 
class of small molecules is called EDAM. In this context, first studies were performed 
on IMP and GMP which can interact with T1R receptors as extracellular allosteric 
modulators. In metabotropic glutamate receptors, the EDAM compounds can interact 
also with adjacent binding pocket which is differently built in the eight subtypes in 
contrast to the major VFT cleft. Therefore, EDAMs belong to a new important and 
selective class of compounds which may represent innovative devices to have a narrow 
modulation of the Class C GPCRs proteins. 
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Ligands acting at 7-TM domain 
One of the first discoveries in studying the mGlu receptors is the possibility that they 
can reach the active state even in the absence of the agonist. This possibility was firstly 
showed for the Group I mGlu receptors. These receptors displayed a constitutive 
activity, firstly demonstrated by the high basal IP formation measured in cells 
expressing these receptors compared to mock-transfected cells (Joly et al., 1995; 
Prézeau et al., 1996). The constitutive activity was insensitive to the action of 
competitive antagonist which were associated to the prevention of the closure of VFT. 
This finding rose up the definition and characterization of a new class of compounds: 
the so called “inverse agonists” which prevent such constitutive activity (Lefkowitz et 
al., 1993).  
This class of compound has been demonstrated to interact with a specific pocket in the 
heptahelical 7-TM domain. Interestingly, the mechanism remembers what happens 
when we use antagonists for GABAB receptors. Several studies from Pin J.P. and 
colleagues (2004, 2011) elucidated the mechanism of activation, which also indirectly 
confirms the possibility that the 7-TM domain can reach the active state even in the 
absence of ligands at the orthosteric binding site. In addition, these studies opened the 
discussion about the real mechanism of action of several synthetic compounds 
considered orthosteric antagonists. In fact, it was demonstrated that some of them 
interact with the 7-TM domain and, for this reason, they should be associated to the 
inverse agonists class. As far as the mGlu receptors are concerned, this is the case of 2-
methyl-6-(phenylethynyl) pyridine (MPEP), a mGlu5 selective antagonist (Pagano et 
al., 2000). Finally, it has been already demonstrated that the constitutive activity has 
important physiological consequences, especially in the cerebellum, as the Group I 
metabotropic glutamate receptors is concerned. However, the closure of the VFT 
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domain by this event still represents the necessary condition to reach the full activity of 
the receptor. 
An important step in the study of Class C GPCRs and, in particular, of the 7-TM 
domain is the identification of a crevice within the 7-TM. This binding pocket can be a 
target for synthetic compounds studied for these receptors. This crevice is located 
between TM3, 5, 6 and 7 (Pagano et al., 2000; Pin et al., 2003; Brauner-Osborne et al., 
2007; Conn et al., 2009), and in some cases it is typified by two distinct sites, as for 
example mGlu5 receptors (Chen et al., 2008). Compounds acting at this level are called 
allosteric modulators and, specifically, they are referred to as positive allosteric 
modulator or PAM if they enhance agonist activation and they are referred to as 
negative allosteric modulator or NAM if they reduce the agonist activity. PAMs 
facilitate the activation mediated by the binding of orthosteric agonists which results in 
an increase of the receptors and G protein coupled activation. NAMs block the 
activation of G proteins by stabilizing the inactive form of 7-TM (Rondard et al., 2011). 
Based on their mechanism of action, PAMs and NAMs possess high therapeutical 
potential because they can show a high selectivity on subtype receptors as well as they 
can modulate the endogenous activity of the receptors without forcing a constant 
activation or block of the receptors (Kniazeff et al., 2011). Cinacalcet, a PAM of CaS 
receptors, is a drug already approved and a good example of this class (Tfelt-Hansen 
and Brown, 2005). 
Interestingly, endogenous PAMs or NAMs that can bind the 7-TM pocket were not 
described so far (for the discussion see Kniazeff et al., 2011). On the other side, PAMs 
and NAMs do not show necessarily a completely overlapping in the binding target 
(Miedlich et al., 2004). This is caused by differences between the interactions developed 
by the amino acids residues of NAMs or PAMs with the amino acids sequence of the 
crevice in the 7-TM domains of the receptors.  
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PAM compounds offer the possibility to positively modulate the receptors without 
forcing the constant induction of the active state of the receptor considered mediated by 
the agonist. Moreover, they could induce less pronounced down-regulation through 
desensitization of these receptors (Conn et al., 2009). However, some limitations have 
been reported. For instance, it has already been reported that some PAMs could act as 
partial agonists. Concomitantly, in truncated receptors or when the 7-TM domain of 
mGlu and GABAB receptors are expressed alone, they become full agonists (Binet et 
al., 2004; Goudet et al., 2004). Parallel to these limitations, NAM compounds showed in 
some cases the characteristic of inverse agonist and or full antagonist at truncated or 
mutate receptors. 
Finally, many PAMs and NAMs are under study for the modulation of taste group 
GPCRs. Also some compounds are under deeply investigation to overcome problems 
offered by pure agonist by a pharmacodynamis and pharmacokinetic point of view. In 
this sense, a great example is the hope reserved for the development of PAMs for 
GABAB receptors. 
 
Other ligands for the Class C GPCRs  
Beyond the classical pharmacological tools, other possible targets to modulate these 
receptors are under investigation. One of these possibilities is the so called 
“communicative bridge” or CRD. This domain has a fundamental role in the activation 
mechanisms, as illustrated in the previous chapter. However, only prototype molecules 
have been designed to interact with the CRD domain. It is also difficult to predict the 
range of action and the selectivity of these compounds. 
Recently, the study of central diseases, especially autoimmune and neurological 
disorders, leads to define a new class of compound acting on GPCRs: the antibodies, 
specifically those interacting with the extracellular domain of Class C receptors which 
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have been demonstrated to possess a modulator activity on the target receptor. It is not 
clear which is the specific site of action of this new pharmacological tool and how they 
impact the receptor-mediated functions. Moreover, the production of auto-antibodies 
recognizing the GPCRs were observed in different kind of pathologies. 
One evidence originates from the studies clarifying the existence and the role of auto 
antibodies against the extracellular domains of mGlu1 receptors. These antibodies have 
been proposed to cause paraneoplastic cerebellar ataxia in adult patient suffering from 
Hodgkin‟s disease (Coemans et al., 2003; Marignier et al., 2010). Accordingly, when  
injected into the subarachnoid area in mice, these antibodies produce reversible ataxia. 
Although it is not still completely clarified, the mechanism seems to be associate to the 
block of the activity of mGlu1 receptor protein, which leads to reduction of the G 
protein-mediated inositol phosphate messenger formation, as observed when 
administering mGlu1 antagonists.  
A second evidence came from the study of the CaS receptors. It was found that 
antibodies recognizing these receptors can interact with the VFT domain of this 
structures and can interfere with the function of the calcium ions. Antibodies lead to a 
block of the closure of the VFT domain mimicking the antagonist action. This idea has 
been associated with a familiar hypocalciuric/hypercalcemia pathology because this 
kind of antibodies has been found in the serum of patients suffering from this genetic 
disease (Kifor et al., 2003). On the other hand, autoantibodies were discovered in 
patient suffering from autoimmune polyendocrine syndrome type 1 (APS1), an 
autosomal recessive disorder often associated with hypoparathyroidism (Kemp et al., 
2009). These antibodies mediate the activation of the related receptor by inducing the 
inositol phosphate and calcium-dependent ERK1/2 kinase signalling pathways. Finally, 
Makita and collaborators hypothesized that antibodies can indirectly interfere with the 
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action of CaS receptors by modulating the balance between Ca
2+
/Gq and Ca
2+
/Gi- 
dependent phosphorylation mechanisms (Makita et al., 2007).  
Another study described the identification of auto antibodies recognizing the GABAB1 
subunit of the GABAB receptors in the sera of patients suffering of limbic encephalitis 
with seizures (Lancaster et al., 2010). In this contest, authors proposed that antibodies 
are likely pathogenic, as they induce syndromes similar to experimental phenotypes in 
which the receptor does not function properly, compatible with the conclusion that the 
auto antibodies behave like antagonist(s). 
To briefly resume all these studies, autoantibodies can affect the receptor activity in 
different ways, for instance by acting as agonists or antagonists or allosteric modulators. 
This idea rose up the possibility not only to use antibodies as marker in the diagnostic 
field but, importantly, to use them in pharmacological studies, as a valid tool to 
characterize receptors. This idea will be discussed further in the next sections. 
Further advances in the comprehension of the link between antibodies and GPCRs were 
achieved by recent studies that introduced the idea of using recombinant nanobodies. 
They are defined as the smallest antigen binding fragment derivative from the “heavy 
chain-only” antibodies. Two type of nanobodies raised against the 7-TM of the Class-A 
GPCR CXCR4 chemokine receptors are successfully achieved by the study of Smit and 
colleagues (Jähnicken et al., 2010). These high affinity nanobodies competitively 
inhibited the receptor activity by binding two distinct but overlapping sites in the 
extracellular loops of the receptor, one having a neutral antagonist activity and the other 
one an inverse agonist action. Although no or less other nanobodies have been 
described yet (Scholler et al., 2017), the method illustrated could be proposed also to 
Class C GPCRs to generate powerful pharmacological devices to modulate the function 
of these receptors. 
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1.1.5 G protein 
In the GPCR family, G proteins play the fundamental role to translate the signal coming 
from the extracellular domains to the cytosol. Therefore, the activity of G proteins 
strictly correlates to the receptor activation. The G proteins promote the impulse for the 
activation of the second messenger cascades. As other proteins, they are involved in a 
cycle of activation and deactivation that mainly depends on the enzymatic GTPase 
activity. In the discussion of the G protein function and structure, some critical points 
must be considered: i) G-coupling intracellular signalling depends on differences among 
families and subfamilies of G proteins and on the respective coupled receptors; ii) there 
is a huge number of intra/extracellular factors, like enzymes, channels and proteins, 
which are correlated to the GPCRs activation/inactivation; iii) Class C GPCRs members 
can bind different kind of G proteins when they heterodimerize with other receptors, 
activating consequently different intracellular pathways; iiii) the activity of second 
messengers can reverberate in the G protein life metabolism.  
For these reasons, the detailed discussion of the G proteins is not matter of this work but 
I am going to try to resume the key points in order to have a general picture. For further 
details see references reported in the discussion. 
 
The binding of ligands causes conformational changes within the receptor protein which 
in turn leads to the activation of the receptor(s). These changes reflect the activation of 
the G protein gear and, as a consequence, the mobilization of selected intracellular 
pathways and second messenger production.  
The G proteins are heterotrimeric proteins composed by α-, β- and γ-subunits localized 
in the inner side of the cell membrane (Hamm, 1998). G proteins are divided into four 
families based on the similarity of their subunits: Gi/o, Gs, Gq/11, and G12/13. Each family 
consists of different members which can offer specific activation patterns. However, 
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members of the same family usually share similar intracellular pathways. Every 
subunits which composes the G protein is encoded by different genes, that determine 
the characteristics of the single subunit and the overall function of the G protein.  
The Gα-subunit is characterized by two domains: one is the GTPase domain, crucial for 
the activation and the consequent induction of intracellular pathways, and the second is 
an helical domain masking the GTP within the core domain (Cabrera-Vera et al., 2003). 
The helical domain of Gα-subunit is the most divergent among the G protein families. 
The Gβ-subunit has a typical β-helical-like structure, which plays an important role in 
the specific interaction with the other subunits and activation mechanism.  
The Gγ-subunit interacts with the Gβ-subunit through the N-terminal coil and other 
extensive contacts along the amino acid sequence (Lambright et al., 1996). These two 
last subunits assemble to produce the well-known Gβγ-dimer that is linked to the 
hydrophobic pocket in the Gα-subunit. Specifically, it is proposed that GTP binds the 
Gα in this pocket, then reducing the affinity between α and βγ units and favoring their 
dissociation after the activation (Lambright et al., 1994).  
The crystal structure studies had shown that the G protein can adopt at least three 
different conformational states: the inactive (GDP-bound), the active (GTP-bound) and 
the transition state (GDP-GTP). However, only the active and inactive states are so far 
well characterized (Cabrera-Vera et al., 2013). 
The general mechanism of G proteins is based on an activation/inactivation life cycle. 
Generally, the functional process can be resumed as follow: the Gβγ-complex and the 
Gα-subunit in GDP-bound state are associated one each other. In this conformation G 
protein is not activated. The coupled receptor induces the heterotrimer G protein to 
promote the exchange of GDP in GTP on the Gα-subunit site. The Gα-subunit in the 
GTP-bound state dissociates from the activated receptor and from the Gβγ-complex, 
and both the Gα-subunit and the Gβγ-dimer modulate the activity of a variety of 
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effectors. The deactivation process starts when the signalling is hydrolysed by the 
GTPase enzymatic process, which is inherent to the G protein Gα-subunit site. The 
resulting GDP-bound Gα-subunit gathers again with the βγ-dimer to start a new cycle if 
activated receptors are present (Cabrera-Vera et al., 2003; Birnbaumer L., 2004; 
Wettschureck 
 
and Offermanns, 2005). 
The impressive number of studies carried out in the last decades gives new insights in 
the functional mechanism of the G protein. First, at the beginning, the core function was 
only associated to the Gα component, giving only a support role to the other domains, 
including Gβγ-subunits. Nowadays, we know that both the activation and deactivation 
processes involve the Gα as well as Gβγ domains, indicating a general major complex 
scenario (Birnbaumer L., 2004; Wettschureck and Offermanns, 2005). The study 
performed on the structure of G proteins unveiled some characteristics which are worth 
to be remembered in the context of GPCRs proteins.  
One crucial step in the activation of the G protein component is the interaction with the 
coupled receptor. This interaction is mediated by specific sequences and regions of the 
proteins. For instance, a high conserved region of the C terminus sequence of the Gα 
subunit has been established, specifically defined by four residues. In addition 
modifications, like phosphorylation, of these four residues can be requested for the 
correct interaction between proteins, for example in the mGlu receptors. Opposite, the 
Pertussis Toxin (PTx) carries out an abnormal ADP-ribosylation of these four residues 
which completely blocks the activation process of Gi/Go proteins (Van Dop et al., 1984; 
Unemorl et al., 1997). The so mentioned role of the C terminal region in the interaction 
system can be also observed with antibodies and peptides acting at this level. Both 
antibodies and peptides can bind this terminal region by specific interactions with the 
amino acid sequences. The results could be quite different. For example, it has been 
already reported that antibodies recognizing the C terminal domains in the Gα subunits 
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can abolish receptor G protein signalling (McFadzean et al., 1989). Synthetic peptides 
can stabilize the mechanism of the activation or, in opposite, they can have an 
antagonist like behaviour by binding the C terminal domain (Rasenick et al., 1994). In 
addition to the C terminal region, also some area of the Gα-subunits region are involved 
in the successful interaction between G protein and coupled receptor. However, we 
should remember that the mechanism of communication between G proteins and 
receptors depends on complex interactions, which could differ among the G protein 
families (Cabrera-Vera et al., 2003). 
In order to induce the G protein activation, the coupled receptors need to be activated by 
the proper ligands, like orthosteric agonists. The induction promotes the conversion 
from GDP to GTP within the Gα-subunits. GDP is also spontaneously released from the 
heterotrimeric G protein at a rate that varies depending on the Gα-subunit (Cabrera-
Vera et al., 2003). This rate is mainly based on the characteristics of C terminal domain 
and Gα-subunit. This process is linked to the idea of a “constitutive 
activation/deactivation” process that can be influenced by many factors such as Gβγ 
subunit and the presence of Ca
2+
 or Mg
2+
 ions (Higashijima et al., 1987). Furthermore, it 
has been observed that the spontaneous release have physiological consequences. In 
fact, alterations or mutations affecting this spontaneous activity have been already 
linked to pathologies like pseudohypo-parathyroidism and gonadotropin-independent 
precocious puberty. 
It has been demonstrated the crucial role of the Gβγ-subunits in the GDP/GTP 
conversion. Specifically, Gβγ-subunits take an active role in GDP release creating a sort 
of “exit path” for the guanine nucleotide to move out the G protein. The G proteins 
posses a cavity between Gα and Gβγ, oriented to the plasma membrane. The 
modification of this crevice during the activation process seems to induce the separation 
of Gβγ-dimers from the G protein concomitantly to the GDP/GTP conversion 
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(Lambright et al., 1994; Bohm et al., 1997; Cabrera-Vera et al., 2003). These overall 
characteristics offer another demonstration of the important role of the Gβγ subunits and 
of the complexity of its activation process. 
As far as the G proteins are concerned, the class of “receptor-independent activators of 
G protein signalling ”(AGS) requires some comments. The AGS family can activate the 
G proteins without coupling with a specific receptor. Unfortunately, few information are 
available about their physiological role and mechanism of interaction (see Jamora et al., 
1997; Cismowski et al., 1999). 
 
The two effectors of the G protein: Gα and Gβγ subunits 
The Gα-subunit activity depends essentially on the belonging family. At least four 
different families are recognized. A huge amount of effector proteins is described to be 
specifically linked to a family of Gα-subunit. Despite of this, a relative number of other 
subtypes are discovered every day as well as enzymes/proteins/channels/second 
messengers that could not be linked to the families already described. Therefore, the 
overall picture could become quite confused and complex. 
The G proteins of the Gi (Gi1,2,3 specifically)/Go family are widely expressed in the 
CNS, and they can induce receptor-dependent inhibition of several subtypes of adenylyl 
cyclases (AC) (Sunahara et al., 1996). Similarly to the Gα pathway, these G proteins 
also release Gβγ-dimers, that are almost completely transduce the effects of Go subtype 
while the Gα-subunit controls the opening of the Ca2+ and K+ channels, modulates 
cytoscheletric fibres and the cellular growth. In the modulation of synaptic transmission, 
attention was paid to the capability of Gαi/Gαo to control the N- and P/Q type calcium 
channels as well as the K
+
 channels (GIRKs) which lead to a hyperpolarization, relevant 
at the postsynaptic sites. This second mechanism is also robustly mediated by the Gβγ 
subunits. In addition, it is worth reminding the peculiar Gα subtype called Gαz. Even if 
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the Gαz mechanism of activation is not completely clear, Chen and colleagues 
illustrated a possible way of interaction with the RAP1GAP and GRIN family, 
correlating these proteins to the neuritis outgrowth (Chen et al., 1999). 
The Gαs subgroup of the Gα proteins is strongly coupled to the activation of AC 
pathway which carries out the increase of the cAMP activity. Notably, all these proteins 
are derived from the GNAS gene families which have high numbers of promoters and 
splice variants (Wettschureck 
 
and Offermanns, 2005). In this group, the Gαolf is the 
major subtype coupled to the AC pattern involved in olfactory system modulation. 
These G proteins can be also found in other central regions, like the nucleus accumbens 
and the striatum. Here, they are critically involved in the function of some receptors, 
like the dopamine (D1) and the adenosine (A2) ones (Zhuang et al., 2000). 
The Gαq family is linked to the activation of phospholipase C (PLC) and of a great 
number of kinases like Bruton‟s tyrosine kinases. Mice bearing the genetic deletion of 
Gq develop severe central and peripheral defects and antagonists able to discriminate 
the specific subtypes of this G family proteins are not available. Differently from the 
Gαi, the Gαq subtypes are involved in the activation of the synaptic transmission in the 
CNS, particularly in the LTP and LTD development. Moreover, the Gαq and the 
respective Gβγ dimer induce the mobilization of intracellular calcium. Furthermore, 
there are also evidence that activation of Gαq or Gα11 are involved in the induction of 
endocannabinoid system. Specifically, GPCRs like Group I mGlu receptors can also 
lead to the activation of the retrograde function of cannabinoid system by favouring the 
activation of endocannabinoids pathway (Levenes et al., 2001; De Petrocellis et al., 
2004). 
The Gα12/13 are also involved in the activation of intraterminal pathways, like Rho-GEF 
complex, which modulate the metabolism of GTP/GDP system. Moreover, this class of 
protein also control various other effectors including phospholipase A2, Na
+
/H
+
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exchanger and c-jun NH2-terminal kinase (see Wettschureck 
 
and Offermanns, 2005 and 
relative references). 
While Gα subuntis are classified in different subfamilies, the subclassification of the 
Gβγ subunits is still lacking. In literature, the structure of five Gβ-subunits and twelve 
Gγ-subunits have been characterized. In theory, if Gβ and Gγ combined each other, 
there would be over sixty possible results (Downes et al., 1999). Despite the old idea 
that the dimerization between different β and γ subtypes could be a random event, 
recent studies demonstrated some selectivity and limitation to the dimers formation 
(Wettschureck 
 
and Offermanns, 2005). To note, it is proposed that the Gβγ-dimers 
composition can affect the quality and efficacy of effectors activation and, 
consequently, it can mediate receptor G-coupling specificity. 
The Gβγ-dimers do not present great conformational changes between the active and 
inactive states (Gaudet et al., 1996). Once the Gβγ dissociates from Gα, it can interact 
with a great number of effectors, including ion channels, PLC families, kinases and 
intraterminal messenger like Calmodulin and Dynamin I (Cabrera-Vera et al., 2003). As 
far as the CNS is concerned, the Gβγ is reported to be linked to particular effectors 
controlling synaptic vesicle machinery, beyond the Ca
2+
 and K
+ 
ions channels and the 
PLC pathway. Interestingly, it has been demonstrated that this dimer can directly 
control the SNARE complex by binding syntaxin, SNAP25 and cysteine string domain 
(CSP) (Blackmer et al., 2000, 2001). The complex involving G protein domains, 
SNARE complex and Ca
2+
 channels suggested a possible unique way to control 
synaptic release of vesicle (Betke et al., 2012). 
Therefore, Gβγ subunits can stimulate or block the induction of many effectors, mainly 
dependent on the β and γ subunits as well as on the Gα subunits influence. Recent 
finding have established that Gβγ dimer can directly modulate some important 
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intracellular complexes linked to the genes modulation and protein synthesis, like ERK 
and MAPK families (Bell et al., 1995; Cassier et al., 2017). 
 
G protein inactivation and cycle modulation 
The G protein inactivation process strictly depends on the GTP hydrolysis to GDP 
(Cabrera-Vera et al., 2003). 
The GTPase activity and the inactivating pathway are mediated by a feedback system of 
control triggered by intracellular pathways. The protein  that directly interacts with the 
GTPase site is the so called “regulator of G protein signal” or RGS, that is strictly 
linked to GTPase activating protein (GAP). It is not matter of discussion of this work 
but RGS is a large family of proteins which can interact with different affinity among 
the Gα-subunits (see Hollinger et al., 2002 and Cabrera-Vera et al., 2003). In general, 
RGSs enhance the GTPase activity of Gα-subunits, thereby reducing the duration and 
amplitude of the Gα/Gβγ system (Hollinger et al., 2002).  
Covalent modifications, including the phosphorylation and/or acylation of protein 
processes as well as the “lipidation” process are important in the regulation of G protein 
cycle and expression (Cabrera-Vera et al., 2013). Phosphorylation and acylation are 
controlled by different intracellular patterns and represent general mechanism(s) of 
feedback control of the G proteins.  
As far as the phosphorylation is concerned, protein kinase C enhances the 
phosphorylation of the Gα subunits, inhibiting them. In addition, the same group of 
proteins is involved in the regulation of RGS and GAP as well as of the Gβγ activity. 
The acylation processes act similarly and they influence the stabilization of G proteins 
in cell membranes (Cabrera-Vera et al., 2003). In conclusion, phosphorylation/acylation 
reactions can both indirectly catalyze the dissociation of the components of the G 
protein involved but also directly modulate some Gβγ-dependent effectors.  
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The so called lipid modification involves processes of myristoylation, palmitoylation 
and also carboxymethylation/isoprenylation reactions at the N terminal domain. 
Interestingly, the most important function of the covalent reaction is to modulate and to 
control the surface expression of G proteins, promoting or inhibiting it. Most of these 
reactions are selective for the Gα subfamily. For instance, the Gαi proteins are 
myristoylated while Gαq,11, 13 proteins are mainly palmitoylated (Chen et al., 2001). 
Moreover, some studies suggested that carboxymetilation of the C terminus of Gγ-
subunit can modulate the membrane expression of some G proteins (Fukada et al., 
1994).  
Two are the main consequences of the lipid modifications. One, already mentioned, 
relies on the role that lipid plays as central hydrophobic membrane anchor. The Gαi-
subunits are both myristoylated and palmitoylated, and the “lipidification” contribute to 
the membrane stabilization. In fact, it has been already demonstrated that the lack of one 
of the two mentioned reactions can cause a partial internalization of the G proteins 
(Wilson et al., 1995; Wise et al., 1997). On the other hand, lipids also regulates 
interactions between proteins and second messengers. For example, N-myristoylation of 
Gα modulates the interaction between Gβγ and the relative effectors, while 
palmitoylation increases the affinity of Gαs for Gβγ. In conclusion, lipid modification 
can be associated to a indirect feedback mechanism of control of the receptor activity 
(see Cabrera-Vera et al., 2003 and relative references).  
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1.2 DIMERIZATION 
The GPCRs dimerization process between two monomeric proteins is one of the crucial 
step in the mechanism of activation of the Class C receptors (Kniazeff et al., 2014). 
Dimerization between receptors can modify many characteristics of the receptors 
involved, including the pharmacological profile. Moreover, dimerization, especially 
between receptors of different groups, can influence the impact of these receptors on 
neurotransmitters release and intracellular pathways (Yin et al., 2014; Olivero et al., 
2018).  
 
Definition  
The term “dimer” indicates the interaction linking two receptor subunits or monomers. 
This process carries out functional and structural consequences. The monomers engaged 
in the receptor can either be the same (“homodimers”) or can differ one to each other 
(“heterodimers”). In addition, more than two subunits can interact to create 
“oligomeric” assemblies (Chabre et al., 2009). 
The knowledge of the Class C GPCRs dimerization started early. Romano and 
collaborators first observed the dimerization of mGlu5 receptors in the brain (Romano 
et al., 1996). Then several other studies, either by in vitro or in vivo experiments, 
described the dimerization of GPCRs, including mGlu receptors (Copani et al., 2000, 
Muto et al., 2000), CaS receptors (Ray et al., 1999), taste receptors (Nelson et al., 2001) 
and GABAB receptors (Marshall et al., 1999).  
 
Experimental approaches  
Western Blot analysis is the simplest approach used to demonstrate the presence of 
receptor dimers. In Western blot analysis, the presence of a dimeric association of  
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receptors proteins can be usually suggested by the presence of immunopositivities 
having a mass consistent with the sum of the weight of the two proteins involved. In this 
case, the monomeric form of the protein involved became detectable only when 
applying reducing conditions during the protein extraction. To substantiate the 
conclusion, immunoprecipitation studies are usually carried out to unveil the presence 
of homo or heterodimeric association linking the receptor proteins (Olivero et al., 2018). 
However, these observations suggest but do not definitively prove the existence of 
dimers. 
The study of dimerization events recently improved thanks to the introduction of 
fluorescence techniques (Phizicky et al., 1995). Specifically, Fluorescence Resonance 
Energy Transfer (FRET) permits to monitor the proximity and the orientation of dimers 
of GPCRs proteins. In FRET, one fluorophore (the „„donor‟‟) transfers its excited-state 
energy to another fluorophore (the „„acceptor‟‟), which usually emits fluorescence in a 
different wavelength. This technique offers the possibility to observe the interactions 
between receptors in the native organism, but it is limited by the possible tissue 
damages elicited by the introduction of the fluorophores or the exposure to fluorescence 
excitation. Owing to overcome these issues, another technique, the so called 
Bioluminescence Resonance Energy Transfer (BRET) was introduced, which takes the 
advantage of using natural fluorescence phenomena (Xu et al., 1999). Starting from 
these techniques, other fluorescence analysis and microscope detection (i.e. the time 
resolving FRET or TR-FRET, see Pin et al., 2009) are now currently in use to deeply 
investigate dimers and oligodimers in the Class C receptors.  
 
Structural and functional consequences  
The Class C of the GPCRs form constitutive dimers, which are fundamental for their 
function in cells. Dimerization implies the association of the VFT domains as detected 
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in crystallography studies (Kunishima et al., 2000; Pin et al., 2004). Specifically, the 
two VFT domains interact at the level of lobe-I, favouring the convergence of lobe-II. 
These processes catalyze the change in orientation of VFT structure and, consequently, 
the activation of the receptor (see chapter “Structure and activation mechanism” for 
further details and references).  
The mechanism of activation of Class C of GPCRs requires the presence of dimers, 
even if the closure of only one VFT domain is sufficient to activate the receptors 
(Kniazeff et al., 2011). This conclusion relied on results from the study of metabotropic 
glutamate and GABA receptors. As far as the mGlu receptors are concerning, Kniazeff 
and collaborators demonstrated that the presence of one molecule of the orthosteric 
agonist is sufficient to promote the closure of one VFT domain, reaching the Ao/c state, 
and, consequently, to induce the activation of mGlu receptors (Kniazeff et al., 2004, 
2011). However, the presence and the activation of both VFT units in the dimeric 
assembly is necessary to obtain the full activation of the receptors and to complete the 
transduction of the intracellular second messengers. Similarly, the GABAB1 and the 
GABAB2 proteins are required to express the GABAB receptors (Bowery et al., 2002; 
White et al., 2009), but the occupancy only of the VFT domain of the GABAB1 receptor 
with the orthosteric agonist is required to cause receptor activation (Pin et al., 2004).  
Nowadays, five main characteristics of the Class C GPCR proteins were proposed to 
strictly depend on receptor dimerization (Terrillon & Bouvier, 2004). 
1. The mechanism of exit of receptor proteins from the endoplasmic reticulum 
(ER). The dimeric association can mask the retention signals, favouring the 
correct escape of the protein from the ER. One example of this process is the 
GABAB receptors (Marshall et al., 1999). Specifically, the GABAB1 receptor is 
normally retained in the ER when express alone because of a retention carboxy-
terminal ER motif. The association with the GABAB2 receptor subunit masks the 
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site and favours the passage from ER to the cell surface (Margeta-Mitrovic et al., 
2000).  
2. The binding momentum of the orthosteric ligands (see Terrillon & Bouvier, 
2004 and relative references). Dimerization preferentially is favoured by 
orthosteric ligands acting at the relative binding site, although some few 
evidence also suggest that some receptors of the Class C can adopt the dimeric 
association despite the absence of the agonist/antagonist ligands (it is the case of 
mGlu 1 receptors, see Kunishima et al., 2000).  
3. The pharmacological profile of the receptors. Heterodimerization of the δ and κ 
receptor subtypes increases the affinity to the orthosteric agonists (Jordan & 
Devi, 1999).  
4. The signal transduction process that follows the activation of Class C GPCRs is 
mediated by the G proteins, which in turn control the intracellular pathways. 
Generally, a group of metabotropic receptors is associated to certain G proteins 
that couple specific patterns activation of enzymatic pathways. Dimerization can 
favors the association of the receptors to different G proteins. This is the case of 
μ and δ receptors that when in the dimeric association do not bind Gi protein but 
associate to Gs/Go proteins (Charles et al., 2003).  
5. The internalization processes. Internalization is usually triggered by the 
occupancy of one orthosteric binding site, although also dimerization was 
proved to control or, at least, modulate the endocytosis processes of 
metabotropic receptors (Jordan & Devi, 1999) 
To conclude, dimerization is a process that can influence at different level the life cycle 
of the receptor and reverberate on colocalize receptors.  
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1.2.2 Homo, hetero and oligodimers 
The association of two proteins of the same receptor subunit is called 
“homodimerization”, and it was described for the first time for the mGlu5 receptors 
(Romano et al., 1996). 
Differently, heterodimerization relies on the association of different receptors. 
Heterodimers are the consequence of a multi sited, non covalent amino acid interactions 
(Møller et al., 2017). The term heterodimers refers to a receptor complex: i) composed 
of monomers from the same groups; ii) composed of monomers from different receptor 
groups; iii) composed of receptors from different families. 
A classic examples of heterodimerization between receptors belonging to the same 
group are the association of the mGlu1 and the mGlu5 receptors and of the mGlu2 and 
the mGlu3 receptors (Nicoletti et al., 2011). Differently, the heterodimerization between 
the mGlu2 and the mGlu4 is an example of dimerization of receptors belonging to 
different group within the same family, i.e. the mGlu receptor family (Yin et al., 2014; 
Niswender et al., 2016). The complexity of the heterodimerization largely increased 
because of the demonstration that also receptors belonging to different families can 
associate in heterodimeric assemblies. It is the case of heterodimers composed of the 
GABAB receptors and the CaS receptors, as well as heterodimeric assembly involving 
Class A and Class C receptors, such as the mGlu1 and the Adenosine-1 receptors 
(Kniazeff et al., 2011). These observations are deeply relevant by a therapeutical point 
of view. For instance, a possible involvement of the mGlu1/A1 heterodimers in 
pathological conditions has been already described (see Ciruela et al., 2001). 
Recent studies with FRET and TM-FRET suggested the possibility that receptors 
subunits can form complexes built by more than two units, so called “oligodimers”. 
This has been already well documented for Class A GPCR proteins (Milligan, 2004). 
The mGlu receptors did not show a marked trend to form oligodimers, even among 
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different groups of mGlu receptors (Brock et al., 2007; Doumazane et al. 2011). In 
opposite, oligodimers of GABAB receptors has been found, composed in some case of 
more than tetramers (Maurel et al., 2008). These oligomers were described to exist in 
native tissue and to strictly depend on the involvement of the GABAB1 subunits, as 
supported by data from transgenic mice lacking GABAB1 genes (Maurel et al., 2008; 
Comps-Agrar et al., 2011). The functional consequences of these oligodimers are still 
not clear. For instance, it was found that GABAB receptors oligodimers can modulate 
the receptor signalling. Indeed, it was observed that inhibiting GABAB1-GABAB2 
interactions using either a non-functional GABAB1 subunit as competitor or introducing 
a mutation in the GABAB1 VFT domain increased the signal efficacy by approximately 
50% when compared to control (Maurel et al., 2008; Comps-Agrar et al., 2011). 
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Schematic representation of metabotropic glutamatergic and GABAergic receptor. A) A schematic 
representation of the structure and the mechanism of function of the metabotropic receptors. The VFT 
domain can assume the close state or the open state, but, since the metabotropic receptor is present as 
dimer it is proposed that it can assume three main states (Os/Os, Cs/Os and Cs/Cs), that correlate to the 
absence of ligands, to a partial activation and to a full activation of the receptors respectively. The CRD, 
7-TM and the G protein represent the other core regions of the metabotropic receptors. When ligands bind 
the receptor, GDP is converted in GTP to activate the G protein which in turn induces the separation of 
the α subunit and βγ subunits. These subunits present different isoforms and influence different 
intracellular pathways after their activation. B) GABAB receptor is composed by the GABAB1 and 
GABAB2 receptor subunits, with the peculiar lack of the CRD bridge domain. Notably, the figure 
underlines the main role of GABAB1 for the external binding site, and the role of the GABAB2 for the 
activation of the G protein. C) Beyond the binding to another same receptor (homodimerization, i.e. 
mGlu1), dimerization can be realized with another metabotropic receptor of the same group 
(heterodimerization intra group, i.e mGlu2/3), with many same metabotropic receptor (oligomerization, 
i.e GABAB receptor oligomer) and with different receptors or channel groups/families 
(heterodimerization inter group, i.e. mGlu2/3 and 5-HT2A or mGlu5 and NMDA).  
 51 
1.3 METABOTROPIC GLUTAMATE RECEPTORS 
IN THE CNS 
Glutamate is the major excitatory neurotransmitter in the CNS and the glutamate 
receptors represent one of the crucial machines to control CNS functions and activities. 
However, the few drugs approved in therapy and the lack of information of many 
physiological and pathological mechanisms of the CNS involving glutamate explain 
why we need to continue to investigate glutamate transmission and glutamate receptors.  
The first receptors found to be activated by glutamate were the so called ionotropic 
receptors. Ionotropic receptors are α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptor (also known as AMPA receptor, or quisqualate receptor), Kainate receptor 
and N-methyl-D-aspartate receptor (also known as the NMDA receptor). Beyond them, 
the first observation that quisqualate and glutamate can stimulate inositol phosphate 
production gave us a proof of the presence of non ionotropic glutamate receptors 
(Sladeczek et al., 1985). Few years later Sugiyiama introduced the term “metabotropic 
glutamate receptor” or mGlu receptor (Sugiyiama et al., 1987) From these first steps, 
the knowledge of these receptors hugely increased and the metabotropic glutamate 
receptors are nowadays classified as Class C GPCRs (Nicoletti et al., 2011). These 
receptors are subdivided in three different groups: Group I metabotropic glutamate 
receptors including mGlu1 and mGlu5 receptors, Group II metabotropic glutamate 
receptors consisting of mGlu2 and mGlu3 receptors and Group III metabotropic 
glutamate receptors, including mGlu4, mGlu6, mGlu7 and mGlu8 receptors. It is worth 
to remember that these receptors possess a high sequence homology, especially within 
the same group, so that the development of selective ligands targeting these receptors is 
still an open field of the pharmacological and pharmaceutical researches. 
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Beyond the Group III, the Group I and II of mGlu receptors are the most studies mGlu 
entities and there are a relative high number of evidence that both these groups of 
receptors are involved in many physiological and pathological conditions, like memory 
and learning or psychiatric and neurodegenerative disorders. However, their great 
expression in all CNS, the lack of selective compounds and the possible sides effects 
explain, at least in part, the relative lack of drugs approved in the therapy for these 
receptors. In this picture, the evidence of dimerization of these receptors largely 
improved the complexity of the scenario, at the same time offering an important 
challenge for the future researchers.  
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1.3.1 Group I mGlu receptors 
Definition, structure and pharmacology 
The cloning of the first metabotropic glutamate receptors in the laboratory of Nakanishi 
(Masu et al. 1991) can be consider the ancient milestone that opened the way to the 
mGlu receptors research, especially that concerning the Group I metabotropic glutamate 
receptors. Group I mGlu receptors includes the mGlu1 and the mGlu5 receptor 
subtypes, which are coupled to Gq proteins and that activates a common intracellular 
signalling (Ferraguti et al., 2008; Niswender and Conn, 2010). As described in previous 
chapters, the structure and the pharmacological profile of the mGlu1 were the first to be 
described in the literature (see for further details Kunishima et al., 2000; Nicoletti et al., 
2011). In addition, the research on mGlu5 receptor firstly elucidated the dimerization 
processes (Romano et al., 1996). Indirectly, these studies confirmed that the mGlu1 and 
the mGlu5 receptors share most of the mechanism of activation and of signal 
transduction (Nicoletti et al., 2011).  
Both the mGlu1 and the mGlu5 receptor proteins exist in different isoforms. For 
instance, mGlu1 exists in the mGlu1α and the mGlu1β forms. The mGlu1α isoform was 
proposed to be implicated in some important events requiring receptor 
heterodimerization. It is notably to observe that isoforms and splice variants mainly 
differ in the C-terminus domain. This fact has important pharmacological consequences 
in the regulation of the cell surface expression and internalization of these receptors. 
Nonetheless, this characteristic was found to be quite distinctive of the Group I mGlu 
receptors (Nisweender and Conn, 2010; Nicoletti et al., 2011). 
Group I mGlu receptors possess a large extracellular VFT domain linked to the 7TM 
domain and C-terminal tail that includes a cysteine sequence or CRD domain (see the 
chapter of structure for further details and references). These receptors form 
constitutively dimers via disulfide bond and other specific interactions at the VFT 
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domain (Romano et al., 2001; Muto et al., 2007). The binding of one molecule of 
glutamate is sufficient to partially change the structure of one of the VFT domains and 
to induce the activation of the receptor but two molecules are necessary to achieve the 
full activity (Kniazeff et al., 2004; Muto et al., 2007). In particular, orthosteric agonists 
induce the closure of the VFT domain activating the receptors. It is the case of the 
ACPD and then of the derivate S)-3,5-Dihydroxyphenylglycine [(S)-3,5-DHPG], i.e. the 
first selective agonist of the Group I mGlu receptors.  
Differently, orthosteric antagonists, i.e. R,S a- methyl-4-carboxyphenylglycine (MCPG) 
and more recently the mGlu1 antagonist (S)-(+)-α-Amino-4-carboxy-2-
methylbenzeneacetic acid (LY 367385), prevent the closure of the VFT domain. 
Interestingly, the Group I mGlu receptors can adopt an active state even in the absence 
of the ortosteric agonist and, in this case, the receptor activation is not prevented by 
competitive antagonist but can be blocked by inverse agonists like MPEP derivates 
(Prézeau et al., 1996; Pin et al., 2004). In addition to the orthosteric binding site, Group 
I glutamatergic receptor induced effects can be modulated by compounds acting at the 
7-TM domains, the so called “positive or negative allosteric modulator” (PAM or 
NAM). One example is the 7-(Hydroxyimino) cyclopropa[b]chromen-1a-carboxylate 
ethyl ester (CPCOOEt), a high selective mGlu1 NAM compound (Annoura et l., 1996). 
 
Signal transduction, receptor-mediated effects and clinical implications 
Group I mGlu receptors mainly couple Gq/G11 proteins leading to the activation of the 
coupled intracellular pathways. Activation of the mGlu1 and 5 receptors leads to the 
mobilization of intracellular Calcium, overproduction of diacylglycerol (DAG) and 
inositol phosphate (IP) and activation of protein kinase C. The receptors also can cause 
the formation of cAMP and trigger mitogen-activated protein kinase (MAPK) mediated 
pathways (Bruno et al., 2001; Ferraguti et al., 2008;). Meanwhile it is reported that these 
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receptors negatively modulate the K
+
 channels and the “tandem voltage gated K+ 
channels” (Ikeda et al., 1995). In term of neurotransmission, the activation of 
phosphorylative mechanisms and the increase of intracellular calcium due to the 
activation of these receptors elicits the stimulation of exocytosis then controlling 
positively synaptic transmission (Bruno et al., 2001). As to the latter functions, the 
activation of both mGlu1 and mGlu5 receptors facilitate the glutamate exocytosis from 
nerve terminals isolated from different regions in CNS (Musante et al., 2008). Also, 
these receptors are crucially involved in important synaptic events like LTP and LTD 
(Nicoletti et al., 2010). 
On the other hand, the activation of second messengers modulates a variety of cytosolic 
pathways that in turn control the protein expression in plasma membranes and the 
function of Group I mGlu receptors themselves. For instance, the G protein coupled 
receptors kinases (GRKs) family can induce the desensitization of these receptors 
(Iacovelli et al., 2003). In the context of the control of receptors expression, the C-
terminal domain plays a pivotal role. This was well demonstrated by the studies 
performed with Homer proteins, which contains both PDZ and EVH-1 domains within 
the C-terminal tail of both mGlu1 and mGlu5 receptors (Kato et al., 1998; Nicoletti et 
al., 2011). By interacting with the C-terminal coiled-coil domains, Homer proteins 
family can modulate a cascade of events which leads to the modification of cell surface 
expression and signal transductions of Group I mGlu receptors. In addition, other 
Calcium dependent proteins like calmodulin or protein kinases can influence the 
receptors functions (Bortolotto and Collingridge, 1998 and 2000). 
From a clinical point of view, the involvement of mGlu1 and mGlu5 receptors in 
pathological processes in the CNS is quite impressive. In particular, altered expression 
or functions of Group I receptors were proposed to play a role in schizophrenia, Fragile 
X syndrome, ataxia, Parkinson‟s disease, chronic pain, drug addiction, anxiety and 
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stress (Nicoletti et al., 2011). In addition, evidences were also provided indicating the 
involvement of mGlu1 and mGlu5 receptors in others diseases including cancer, 
Malignant Melanomas and Gastroesophageal reflux disorders (Nicoletti et al., 2011). In 
addition, the mGlu1 subunits play a key role in many neuroprotective and synaptic 
events, i.e. in “post ischemic” degeneration (Pellegrini-Giampietro, 2003). On the other 
side, mGlu5 receptor is strictly involved in many pathological processes modulating the 
deregulations of other receptors, including the NMDA ones (Nicoletti et al., 1999, 
2011).  
 
Localization, synaptic distribution and dimerization 
Group I mGlu receptors possess a widespread distribution in the CNS. The mGlu1 
receptor subtype is extensively detected in the cerebellum at the level of Purkinje Cells 
where it plays a key role in controlling glutamatergic synapses. In addition, it is also 
strongly expressed in the substantia nigra, globus pallidum, thalamic nuclei and in the 
hippocampus, cortex and hypothalamus (Ferraguti et al., 2008; Nicoletti et al., 2011). 
The mGlu5 expression is high in cortex, corpus striatum and hippocampus (Romano et 
al., 1996). In general, a diffuse overlapping in the expression of these two receptor 
subunits can be observed in the CNS. Interestingly, these two receptors can reciprocally 
modulate one each other their functions and expression. This was already observed for 
the cerebellum, where the epigenetic down regulation of mGlu5 receptors mediated by 
mGlu1 receptors activation in the post natal days of mice cerebellum was disserted 
(Notartomaso et al., 2018). In addition, the expression of mGlu1 and mGlu5 receptors 
can be altered in different pathological conditions, like multiple sclerosis (Fazio et al., 
2008) or ataxia (Rossi et al., 2013). Altogether these studies underline a thin balance 
between these two receptors, that could bring important pharmacological consequences. 
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It is well recognized that these receptors are highly localized at the postsynaptic site 
where mGlu1 receptors mainly controls LTD and mGlu5 receptors mainly controls LTP 
in the hippocampus circuits (Nicoletti et al., 2011). They also control postsynaptic 
effects that rebound onto the presynaptic compartment like the modulation of the 
endocannabinoid system (Kano et al., 2008; Chiarlone et al., 2014). However, it is now 
recognized that these receptors have a strong and functional expression also at the 
presynaptic site where they control the release of several transmitters (Sánchez-Prieto et 
al., 1996; Pittaluga, 2016). Knocked out mouse model for the mGlu1 or mGlu5 
receptors show general defects in the control of intracellular pathways, and develop 
different neurological and defects as well as locomotors impairments (Rossi et al., 2008; 
Bossi et al., 2018). 
The Group I mGlu receptors represent a good model to study the impact of dimerization 
in the receptor activities. As described before, these receptors, as other mGlu receptors,  
dimerize after activation by agonists. The presence of homodimers is necessary for the 
fully activation of the receptors (Kniazeff et al., 2011; Møller et al., 2017). However, 
Group I receptors also form heterodimers involving the Group I mGlu receptors or other 
receptors, but not with Group II and III mGlu receptors (Doumazane et al., 2011), even 
if nowadays there are some evidence which put in discussion this dogma (Di Menna et 
al., 2018; Joffe et al., 2019). Specifically, the heterodimers mGlu1/5 has been observed 
in the mouse cortex even if the pharmacological consequences are not completely 
elucidated (Sevastyanova and Kammermier, 2014). In addition, it is worth to remember 
some of the heterodimerization of functional receptor-receptor interactions linking 
Group I and other type of receptors: NMDA (Bruno et al., 2001; Perroy et al., 2008), A1 
(Vázquez et al., 1995; Ciruela et al., 2001) and GABAB receptors (Tabata et al., 2004; 
Vergassola et al., 2018). 
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1.3.3 Group II mGlu receptors 
Definition, structure and pharmacology 
The second group of mGlu receptors consists of mGlu2 and mGlu3 receptors coupled to 
Gi/Go. The high sequence homology, about 70% of the amino acid sequence, and the 
overlapping of the receptors expression in the CNS made hard to distinguish the 
respective pharmacological contribution of the two receptors (Niswender and Conn, 
2010). However, in the last decade new compounds and innovative approaches started 
to elucidate the respectively contribution of the mGlu2 and the mGlu3 receptors in 
receptor expression also permitting their pharmacological characterization (Hanna et al., 
2013; Di Prisco et al., 2016; Olivero et al., 2017). 
As stated, the Group II mGlu receptors show the common structure of the Class C 
GPCRs (Muto et al., 2007). Nowadays, there are no full selective ligands acting as 
orthosteric agonists and antagonists that can distinguish for the mGlu2 and the mGlu3 
receptors with the exception of N-acetyl-aspartyl-glutamate (NAAG), which has been 
demonstrated to selectively activate mGlu3 receptors (Neale et al., 2011; Di Prisco et 
al., 2016). 
The orthosteric agonists of the Group II mGlu receptors include 2R,4R-APDC, and the 
carboxycyclopropylglycine derivatives, DGC-IV. However, these drugs also show an 
activity at NMDA receptors (Schoepp et al., 1999). More recently, Jim Monn at Eli 
Lilly laboratories described two potent and selective mGlu2/3 orthosteric agonists: LY 
354740 and LY 379268 (Cartmell and Schoepp, 2000). For instance, a pharmacological 
analogous of LY 379268, the (-)-(1R,4S,5S,6S) -4-Amino-2-
sulfonylbicyclo[3.1.0]hexane- 4,6- dicarboxylic acid (LY 404039) is under clinical 
evaluation for the treatment of schizophrenia. Moreover, a number of other compounds 
were undergone to clinical trials like LY 2140023 and LY 544344, two mGlu2/3 
agonists. 
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From the same laboratory, LY 341495 and other derivates were synthesized as potent 
orthosteric antagonists. Recently, other ligands for the  mGlu2/3 receptors were 
introduced that include allosteric modulators which show different selectivity for 
mGlu2 and mGlu3 receptors. It is the case of 2,2,2-Trifluoro-N-[4-(2-
methoxyphenoxy)phenyl]-N-(3-pyridinylmethyl) ethanesulfonamide hydrochloride (LY 
487379) that is a selective mGlu2 PAM and of [2-Fluoro-4-[2-(4-
methoxyphenyl)ethynyl]phenyl][(3R)-3-hydroxy-1-piperidinyl]methanone (ML-337) 
that is a selective NAM mGlu3 (Niswender and Conn, 2010). 
 
Signal transduction, receptor-mediated effects and clinical implications 
Differently from the Group I mGlu receptors, mGlu2 and mGlu3 receptors are coupled 
to Gi/Go proteins, which in turn negatively modulate the intracellular pathways 
involved in neurotransmitter exocytosis (Tanabe et al., 1992). The activation of 
mGlu2/3 receptors is linked to the inhibition of cAMP production, of the voltage-
sensitive Ca
2+
 channels and PI hydrolysis. These receptors also induce the activation of 
K
+
 channels, MAPK proteins and PtdIns-3-K pathway (Pin and Duvoisin, 1995). Like 
the other metabotropic receptors, their surface expression, internalization and 
desensitation is finely tuned. For instance, one of the most studied desensitation 
pathway controlling mGlu2/3 insertion in the plasma membrane is the GRK2/β-arrestin 
complex. Interestingly, it has been demonstrated that mGlu2 receptors could be resistant 
to this mechanism of desensitization (Iacovelli et al., 2009). In addition, both mGlu2 
and mGlu3 receptors can interact with calmodulin, with protein phosphatase 2C and 
Ran binding protein which regulate their trafficking (Niswender and Conn, 2010). 
Group II mGlu receptors inhibit the neurotransmission and favour membrane 
hyperpolarization. Specifically, mGlu2/3 receptors can be activated by an excess of 
synaptic glutamate released from neurons and from astrocytes. The mGlu2/3 receptors 
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can also modulate glutamate availability by controlling the expression of the cysteine-
glutamate antiporter, which is critically involved in drug addiction. This event strictly 
correlates to the observation that mGlu2 negatively regulate the reward pathway activity 
in the mesolimbic dopaminergic system and that mGlu2 receptors knockout mice show  
increased reinforcing properties towards cocaine and derivates (Nicoletti et al., 2011). 
The development of mGlu2/3 receptor agonists is attractive for their ability to inhibit 
the glutamate release and, consequently, the excitotossicity due to hyperglutamatergic 
events. There are also evidence that mGlu2/3 receptor agonists reduce the side effects of 
drug abuse like phencycline on working memory and locomotion (Moghaddam and 
Adams, 1998). As already said, the agonist LY 404039, a derivate of the orthosteric 
agonist LY 379268, is under clinical studies as antipsychotic. It was observed that it did 
not cause the side effects elicited by olanzapine, an approved antipsychotic drug, 
including the increase of body weight and blood triglyceride levels. 
Beyond schizophrenia and drug addiction, mGlu2/3 receptors are involved in different 
kind of central disorders and neurodegenerative diseases. Specifically, these receptors 
have been implicated in chronic pain, anxiety and depression. For example the agonist 
LY 354740 has potent effects in several models of anxiety and pain without showing 
the classical desensitation processes, an event that is explained by considering the role 
of mGlu2/3 receptors in amygdala circuits, where these receptors strictly control 
GABAergic transmission (Swanson et al., 2005). mGlu2/3 antagonists are under 
evaluation for their antidepressive activity, because of their modulation of dopaminergic 
release in hippocampal network (Pilc et al., 2008). Finally, Group II mGlu receptors 
were found to play a role in controlling the impact of different type of stress in 
preclinical studies, including prenatal stress (Zuena et al., 2008; Marrocco et al., 2012). 
The neuroprotective effect of these receptors is intensively studied in different 
neurodegenerative disorders. It has been shown that in a mouse model of Multiple 
 61 
Sclerosis these receptors could be critically altered and that their activation carries out 
beneficial effects (Besong et al., 2002; Di Prisco et al., 2016). Alzheimer‟s disease, 
taupathologies and dementia are other important examples of diseases where mGlu2/3 
receptors can have an active role. However, the available studies in literature show 
contrasting results about these diseases (Nicoletti et al., 2011). 
 
Localization, synaptic distribution and dimerization 
Group II mGlu receptors are widely expressed in all the regions of the CNS without 
significant differences between mGlu2 and mGlu3 receptors. The mGlu3 receptors were 
also found in embryonic stem cells and glioma-initiating cells, where their activation 
decreases cell differentiation by acting on type-4 bone-morphogenetic protein (BMP-4) 
receptor signalling (Melchiorri et al., 2007). 
These receptors mainly show a presynaptic localization where they can be activated by 
glutamate. However, the presence of these receptors at the postsynaptic level in some 
CNS regions has been also demonstrated (Muly et al., 2007). Group II mGlu receptors, 
especially mGlu3 receptor subtype, were observed also in non neuronal cell like 
astrocytes and glial cells. The glial mGlu3 receptors are neuroprotective in Alzheimer‟s 
disease, because of the activation of TGF-β proteins which in turn protect from the β-
amyloids toxicity (Caraci et al., 2009). The mGlu3/TFG-β axis was found to be also 
involved in the physio-pathology of Huntington‟s disease (Battaglia et al., 2010).   
Both the mGlu2 and mGlu3 receptors have an important role in the modulation of 
synaptic events like LTD, neuroprotection and synaptic plasticity (Nicoletti et al., 
2011). For instance, the crucial role of mGlu2 receptor in synaptic plasticity is well 
demonstrated in the olfactory system where it is accepted that this receptor can directly 
control a kind of specific olfactory memory linked to pheromones activity (Kaba et al., 
1994). 
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Like the Group I mGlu receptors, also Group II mGlu receptors show an extensive 
homodimerization of their single receptor subunits. Dimers of mGlu2 and mGlu3 
receptors were detected in different CNS areas and their engagement after activation by 
agonists is already demonstrated. Moreover, it has been observed the presence of 
mGlu2/3 heterodimers in different regions, especially in the cortex (Olivero et al., 
2017). Differently from the first group, the Group II mGlu receptors can heterodimerize 
with mGlu receptors from the Group III (Doumazane et al., 2011). It is the case of the 
heterodimer between mGlu2 and mGlu4 receptors which, surprisingly, show a peculiar 
response to the orthosteric/allosteric agonists. For instance, the orthosteric mGlu2/3 
agonist LY 379268 is less potent to activate this heterodimer than mGlu2/3 receptors 
(Yin et al., 2014). 
It has been also demonstrated that mGlu2/3 receptor can also heterodimerize with non 
glutamatergic receptors. In particular, one of the most characterized receptor 
heterodimer is the complex between mGlu2 and 5-HT2a receptors (Prezeau et al., 2010; 
Murat et al., 2018; Hideshima et al., 2018) that was proposed to play a main role in 
schizophrenia (Benneyworth et al., 2007; Gonzales Maeso et al., 2008). 
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1.4. GABAB RECEPTORS IN THE CNS 
The γ-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the 
mammalian CNS, ensuring the normal brain function and mediating a contrasting 
activity to the excitatory processes. GABA mediates its effects by acting at two different 
classes of receptors: GABAA receptors channels and GABAB metabotropic receptors. 
GABAA receptors are heteropentameric GABA gated chloride channels and they are 
generally associated to a fast inhibitory tone on neurotransmission (Benke et al., 2012). 
This channel has a widespread distribution in the CNS and it is the target of many drugs 
approved for anxiety, depression and other neurological diseases (Chua et al., 2017).  
GABAB receptors are obligatory heterodimeric G protein coupled receptors belonging 
to the Class C GPCRs. The GABAB receptor carries out the slow and prolonged 
inhibitory transmission, showing different and peculiar characteristics compared to 
other metabotropic receptors. It is largely studied, and it represents a model for its 
structure when referring to the dimerization processes.  
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1.4.1 GABAB heterodimeric receptor 
Definition, structure and pharmacology 
The GABAB receptor is an inhibitory receptor that still represent an interesting target 
for drug discovery. It shares many characteristics with other Class C GPCRs but it also 
has peculiar features. 
The GABAB receptor was first discovered in the 1979 by Dr. Norman Bowery (Bowery 
et al., 1979), who opened the way to further researches leading to the publication of 
thousands of papers and to the development of many compounds, underlining its 
undoubted role as mediator of the slow and prolonged inhibitory tone of central 
transmission (Trist G et al., 2010).  
The GABAB receptor belongs to the Class C GPCR proteins and it shares with other 
members of this class some classical structural features like the presence of the large 
VFT domain and the 7-TM domain. However, it possesses some unique characteristics 
in the structure and function. The first important characteristic is that GABAB receptor 
is an obligatory heterodimeric receptor composed of the GABAB1 and the GABAB2 
receptor subunits. Both these subunits are required to transmit the signal from the VFT 
domain to the coupled G protein. Specifically, GABAB1 contains the active VFT 
domain which binds the orthosteric agonist and the GABAB2 is correlated to the 
induction of the G coupled protein (Pin and Bettler, 2016). The second important 
feature of GABAB receptor is the lack of CRD domain: the activation mechanism 
mediated by the agonist goes directly from the VFT domain to the 7-TM because of 
specific interactions linking the two receptors subunits involved (Kniazeff et al., 2011).  
Notably, the evidence that both GABAB1 and GABAB2 receptors subunits show the 
structure of an entire receptor appears to be conflicting with the mechanism of 
activation of the GABAB receptor. In fact GABAB1 receptor possesses the 7-TM domain 
and GABAB2 also has the VFT domain. Even if these domains share a good percent of 
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sequence homology with the respective sequence of the other receptor subunits, they are 
not strictly necessary for the activation of the GABAB receptor. During the activation, 
orthosteric ligands bind the VFT domain of GABAB1 receptor subunit. Then, the change 
of conformation mediated by the agonist influences the 7-TM domain of GABAB2 
receptor subunit through specific interactions. For this reason, this process is named 
trans-activation and it is present also in other heterodimers receptors (Galvez et al., 
2001). This event seems to be quite different from the mechanism of homodimerization 
of mGlu receptors. In mGlu receptors, despite the presence of dimers is necessary for 
the full activation of the receptors, the monomeric structure is sufficient to trigger a 
partial activation of the mGlu receptor (Kniazeff et al., 2011). In contrast, the missing of 
the specific domains, i.e. the VFT domain for GABAB1 and the 7-TM domain for 
GABAB2, results in an non functional GABAB receptor. Indeed, it has been already 
observed that the deletion of GABAB2 VFT domain, which is not involved in the 
mechanism described, results in a functional GABAB receptors. These changes in 
receptor functionality are equally obtained with the selective deletion of the GABAB1 7-
TM domain. Altogether, these data confirm the fact that the signal induced by the 
agonist proceeds from the GABAB1 VFT domain to the GABAB2 7-TM domain 
(Monnier et al., 2011). However, the cooperativity between the domains of the GABAB1 
and GABAB2 receptors subunits is necessary in order to have a functional and 
responsive GABAB receptor. Indeed, it has been demonstrated that GABAB1 7-TM 
domain increases the efficiency of GABAB2 to couple with the G protein (Galvez et al., 
2001) while the GABAB2 VFT domain improves the agonist affinity mediated by the 
VFT domain of GABAB1 (Kaupmann et al., 1998). 
Like other metabotropic receptors, also GABAB receptors have different isoforms and 
splice variants. It is worth to remember two different isoforms of the GABAB1 
receptors: the GABAB1a and GABAB1b subunits. The GABAB1a isoform was found in the 
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presynaptic terminal while the GABAB1b isoform was detected in the postsynaptic 
component (Kaupmann et al., 1997). These isoforms differ because of the presence of 
two protein sequences, or sushi domains, in the N-terminus sequence of the GABAB1 
receptor, although both the receptor proteins undergo comparable activation 
mechanisms and express identical VFT conformation (Kaupmann et al., 1997; Frangaj 
et al., 2017). 
As far as the pharmacology of the GABAB receptor is concerned, one of the best 
described agonist of GABAB receptor is Baclofen, an analogue of GABA (Bowery et 
al., 2002). Baclofen is a drug approved for muscle spasticity but also finds other 
applications in drug addiction and muscle spasms. Beyond this well-known compound, 
a relative high number of compounds are available acting as orthosteric agonists, 
antagonists and allosteric modulators, which interact with GABAB1 or GABAB2 receptor 
subunits in specific regions (Kniazeff et al., 2011; Frangaj et al., 2017). Interestingly, 
activation by allosteric modulators of the GABAB2 receptor subunit is sufficient to 
trigger some intracellular events like the activation of the ERK/CREB pathway, 
underlining a possible therapeutic role for this class of compounds (Tu et al., 2007; 
Frangaj et al., 2017). 
 
Signal transduction, receptor-mediated effects and clinical implications 
The GABAB protein shows a lifecycle similar to that of other Class C GPCRs proteins, 
starting from the post-transcriptional modifications of the proteins to the insertion in the 
cell surface. The regulation of all these events alters the number of functional the 
GABAB receptors in the plasma membrane (Benke et al., 2012). A crucial step of the 
GABAB protein trafficking is the early heterodimerization of the GABAB1 and GABAB2 
proteins in the ER of the cells. Specifically, GABAB1 possesses an arginine-based ER 
retention/retrieval signal (RXR) in the C-terminal domain which prevents the trafficking 
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of the receptor subunits. This block is mediated by the coat protein complex I (COP I) 
which binds the RXR sequence (Calver et al., 2001; Brock et al., 2005). The 
heterodimerization with the GABAB2 subunit masks this retention site and allows the 
GABAB1
 
receptor subunits to leave the ER. In contrast, GABAB2 receptor subunits do 
not show this type of control (Benke et al., 2012).  
Heterodimerization of the receptor subunits is also implicated in the endocytosis and 
degradation of the protein. In fact, GABAB receptors internalize as heterodimers and 
GABAB2 receptor subunit seems to control this event (Grampp et al., 2008). Little is 
known about the degradation processes but what is crucial is the fine and fast control of 
the balance between degradation and recycling of the GABAB receptors (Benke et al., 
2012) In conclusion, the data so far available suggest that GABAB receptors 
constitutively participate to events of trafficking and internalization/transport to the cell 
surface at a high rate, mediated by different factors like the activation of the classical 
clathrin-dependent pathway. The physiological consequences of these movements are 
the presence of a pool of intracellular receptors which can be rapidly recruited and 
transported to the cell surface by shifting the balance from degradation/recycling to the 
expression in plasma membrane (Benke et al., 2012). 
The desensitation events participate to control and regulate the membrane GABAB 
receptor availability. There are three main different mechanisms that were suggested to 
be involved in the desensitation of the GABAB receptors (Kanaide et al., 2007; Benke et 
al., 2012). In the cerebellum, the main mechanism of desensitation is mediated by the G 
protein coupled receptors kinase (GRKs) 4 and 5 which promote agonist-induced 
desensitation of GABAB receptors by direct association between GRK4/5 with GABAB2 
proteins. For this reason, this process is indicated as phosphorylation-independent 
desensitation event (Kainade et al., 2007). In the cortex and hippocampus, the 
predominant desensitation mechanism is a phosphorylation-dependent process. This 
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kind of desensitation is mediated by protein kinase C (PKC) and NEM-sensitive fusion 
protein (NSF). Specifically, PKC promotes the phosphorylation of specific sites in the 
GABAB receptors to induce the desensitation. The NSF sequence masks this site and 
avoids the desensitation. The characteristics of this process are not completely clarified, 
but the entire event seems to be influenced by activation of intracellular pathway 
involving Ca
2+ 
signal and PKC induction (Pontier et al., 2006). Finally, the third main 
mechanism of desensitization depends on the binding of the GABAB receptors to the 
potassium channel tetramerization domain-containing protein (KCTD). This interaction 
creates a sort of proteasome which can modify many pharmacological parameters of the 
GABAB receptor, like agonist affinity, and promotes its desensitation. The precise 
mechanism is not completely understood, and it seems to acquire unique characteristics 
among regions in the CNS (Schwenk et al., 2010). Opposite to these mechanisms of 
desensitation, it is worth to remember that some phosphorylative events are implicated 
in the stabilization of the GABAB receptor in the plasma membrane. One example is the 
PKA-AMPK phosphorylation of the serine 783 in the C terminus domain of the 
GABAB1 and the GABAB2 receptor subunits, which stabilize the activity of the 
orthosteric agonist Baclofen (Kuramoto et al., 2007). 
The GABAB receptors are generally coupled to the Gαi and Gαs proteins and they can 
regulate three different signal pathways: G protein activated inwardly-rectifying K
+
 
channels (GIRK), inhibition of the voltage-gated Ca
2+
 channels (Cav) and inhibition of 
the PKA-adenylyl cyclase pathway (Bettler et al., 2004). In general, the GABAB 
receptor activation leads to the inhibition of cAMP production mediated by the Gα 
subunit of the G protein. This event carries out a repression of the activation of 
intracellular pathway and a block of the mobilization of neurotransmitter vesicles. In 
opposite, GABAB receptors coupled to the Gαs protein can induce the production of the 
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cAMP and this dualistic activity seems to be important for the synaptic plasticity 
(Terunuma, 2014 and 2018).  
The Gβγ subunit is linked to the modulation of GIRK channels and Cav channels 
(Fernández-Alacid et al., 2009). The GABAB receptor can strongly induce the activation 
of GIRK proteins which in turn favour the inhibition of neurotransmitters release by 
causing hyperpolarization (Ladera et al., 2008). This event is preferentially a 
postsynaptic event while the block of Cav channels is mainly a presynaptic process. The 
CaV channels, particularly the P/Q ad N-type Ca
2+
 channels, are robustly blocked by the 
action of GABAB agonists. This process leads to the repression of Calcium influx and 
neurotransmitters release beyond the inhibition of calcium-dependent processes. 
Consequently, these events explain why Baclofen is used to block muscle spasticity and 
spasms (Benke et al., 2012; Terunuma, 2018). However, it is worth reminding that these 
processes are not generally strictly correlated to their pre/post synaptic localization 
(Benke et al., 2012). 
These events and the different mechanisms of the activation of the GABAB receptors 
have a strong influence in the effects carried out by these receptors in physiological and 
pathological condition. The GABAB receptor mediates both the slow and the prolonged 
inhibition which is important for different mechanisms of neuronal plasticity and 
memory formation (Terunuma, 2018). The GABAB receptors are altered in different 
neurological disorder like epilepsy, depression, drug addiction and pain. These findings 
confirm why, beside its use to treat muscle spasticity and spasms, Baclofen is 
considered for other therapeutic applications like the control of pain. Drug addiction as 
well as the inhibition of cognitive process still represent an important field of 
application of GABAB receptors, due to the positive effects obtained with Baclofen 
(Bowery, 2016). 
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Localization, synaptic distribution and dimerization 
The GABAB receptor is one of the most widespread inhibitory receptor in the CNS. It is 
widely expressed in the cortex, cerebellum and hippocampus, especially in the 
interneurons, where it can alter the excitability of neuronal circuits. The GABAB 
receptors are presynaptic receptors but they can be found also at the postsynaptic site. 
This different synaptic localization reflects structural and functional characteristics. In 
fact, presynaptic receptors possess the GABAB1a isoform while the postsynaptic 
receptors possess the GABAB1b isoform. In addition, postsynaptic GABAB receptors is 
strictly bind to the GIRK protein family which in turn promotes hyperpolarization and 
synaptic plasticity (Terunuma et al., 2018). 
Until its discovery, the GABAB receptor draw attention due to its heterodimeric nature. 
Indeed, the GABAB receptor is an obligatory heterodimer. It has been already discussed 
the implication of heterodimerization of GABAB1 and GABAB2 receptors subunits in all 
the receptor processes, from the mechanism of modification from the ER to the 
internalization / trafficking events. The trend of the GABAB receptors to heterodimerize 
is also reflected by its capability to find different interactions with other receptors, even 
if they do not belong to the Class C GPCR.  
First, the GABAB receptor can strictly interact with GABAA channels and it can carry 
out a positive or negative interaction in inhibiting neurotransmission (Tao et al., 2013). 
In addition, it has been observed that GABAB receptor can interact with different 
glutamatergic receptors. The NMDA and AMPA ionotropic receptors can modulate the 
activity of GABAB receptors as well as the mGlu1 receptor activity can strictly 
influence the GABAB receptor activation and life cycle. In the same manner, the 
GABAB receptor can modulate mGlu1 receptors through a direct interaction or by 
alterating the intracellular pathways (Kantamneni et al., 2013; Vergassola et al., 2018). 
Finally, it has been demonstrated that the GABAB receptors can heterodimerize with 
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several other receptors like tyrosine kinase receptor (RTKs) and insulin like growth 
factor-1 receptor (IGF-1R) (Terunuma, 2016). 
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AIM OF THE RESEARCH 
During my PhD student course, my research aimed at characterizing from a 
pharmacological and functional point of view the metabotropic glutamate receptors in 
the presynaptic nerve terminals (here referred as synaptosomes) of different area of 
rodents CNS. I focused on two main research projects: 
 The first one was dedicated to the pharmacological characterization of mGlu2/3 
autoreceptors in cortical and spinal cord nerve endings. Starting from previous 
work (Di Prisco et al., 2016), the novelty of the study I was involved in relied on 
the use of new ligands able to differentiate between the mGlu2 and the mGlu3 
receptor proteins and of a new experimental approach which allowed the 
“immuno-pharmacological characterization” of the two receptors under 
investigation.  
Based on the results from these experiments and considering previous data it 
was concluded that homomeric mGlu3-preferring autoreceptors dimers 
preferentially account for the modulation of glutamate release from spinal cord 
synaptosomes while mGlu2-preferring, mGlu3-containing heteromeric assembly 
are present in cortical synaptosomes where they control glutamate overflow.  
During my PhD training, this study was also extended to investigate whether the 
presynaptic mGlu2/3 autoreceptors in spinal cord nerve endings colocalize and 
functional cross-talk with the presynaptic 5-HT2A heteroreceptors. The results 
suggested the existence of the physical association between these two receptors 
that cross-talk in an antagonist-like fashion. This interaction could have 
important therapeutic implications for the treatment of spinal cord diseases 
typified by excess of glutamate. 
Finally, I started to characterize the mGlu2/3 receptors in the mouse 
hippocampus. In collaboration with Professor Emanuele Sher at Ely Lilly 
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laboratories, I approached the pharmacological characterization of these 
receptors by an electrophysiological approach. Specifically, I recorded the 
excitatory post synaptic potential from CA1 and DG hippocampal slices in order 
to evaluate the impact on the glutamatergic transmission of Group II mGlu 
receptors in this area. 
 The second project aimed at confirming the presence and at demonstrating the 
functional role of presynaptic mGlu1 heteroreceptors controlling GABA release 
in cortical nerve endings. The study unveiled the colocalization and the 
functional cross-talk linking presynaptic mGlu1 heteroreceptors and GABAB 
autoreceptors in GABAergic nerve endings. Differently from the mGlu2/3- 
5-HT2A receptor complex, mGlu1 and GABAB receptors do not physically 
interact, but functionally cross-talk to control glutamate and GABA release in 
cortical nerve endings. We proposed that this interaction is mediated by 
functional processes which control the GABAB expression and trafficking in-out 
the cell surface, affecting the efficacy of the orthosteric agonist Baclofen at the 
GABAB receptors. The use of mice lacking mGlu1 receptor confirmed our 
studies. These overall results suggest a complex mechanism of interaction 
linking mGlu1 and GABAB receptors in the cortical presynaptic nerve terminal 
which could have important physio-pathological consequences.  
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RESULTS AND DISCUSSION 
The mGlu2/3 receptors structural and functional 
characterization  
The mGlu receptors are strictly involved in the development of several neurological 
diseases and neuropsychiatric disorders (Nicoletti et al., 2011), which in most of the 
cases are typified by an excess of glutamate or by the hyperactivity of neurotransmitters 
exocytosis. In this context, the role of mGlu receptors belonging to the second group is 
particularly attractive because of the negative feedback mechanism of control they can 
exert at presynaptic terminals where the release of transmitters occurs. Here, they can be 
activated by external glutamate, when its concentration increases pathologically in the 
synaptic cleft, leading to the reduction of exocytosis. 
The pharmacological characterization of mGlu2/3 receptors has been slowed down by 
the lack of ligands able to discriminate between the two receptor proteins. The mGlu2 
and the mGlu3 receptor proteins share about the 70% of sequence homology and most 
of the ligands that bind these receptors interact with both the receptor proteins. The lack 
of selective ligands for the two receptor proteins also limited so far to evaluate the homo 
and heterodimerization of these receptors.  
In recent years, new ligands were synthesized able to recognize the mGlu2 and the 
mGlu3 receptors. Furthermore, anti-mGlu2 and anti-mGlu3 receptors antibodies 
became available to be used for deciphering the protein composition of the native 
receptors in selected neuronal populations (Gupta et al., 2008). Taking advantage from 
these new tools, I investigated the pharmacological profile of presynaptic release-
regulating mGlu2/3 autoreceptors and their possible homo/heterodimerization in mouse 
cortex and spinal cord. In particular, the research aimed at understanding the expression 
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and the pharmacological profile of these receptors in different CNS regions as well as 
their homodimerization or heterodimerization with other receptors.   
To achieve this aim, I used the technique of the superfusion of a monolayer of 
synaptosomes in order to characterize the contribution of the mGlu2 and the mGlu3 
receptors in the release-regulating activity of presynaptic Group II mGlu receptors. 
Synaptosomes were also used in biochemical/immunocitochemical studies to confirm 
the presence of the two receptor proteins in this compartment of chemical synapses. 
Please refers to the section “Methods” for technical details. 
 
On the existence of mGlu2 and mGlu3 receptor proteins in cortical 
synaptosomes  
Experiments were first performed to confirm the expression of the mGlu2/3 receptor 
proteins in cortical nerve endings and possibly to evidentiate different associations of 
the two receptor proteins (Cartmell and Schoepp, 2000, Niswender and Conn, 2010). 
The results from Western Blot analysis unveiled the presence of mGlu2/3 receptor 
proteins in cortical synaptosomes (Figure 1A). As a first approach I used an antibody 
able to recognize both the mGlu2 and the mGlu3 receptor proteins. This anti-mGlu2/3 
antibody recognized proteins having a mass consistent with the presence of both the 
monomeric and the dimeric form of the mGlu2/3 receptors. The analysis was then 
carried out with selective anti-mGlu2 and anti-mGlu3 antibodies. The specificity of the 
two antibodies was confirmed thank to a collaboration with Ferdinando Nicoletti and 
Giuseppe Battaglia (Neuromed, see Olivero et al., 2017, Figure 4, also for the negative 
controls), by using knocked out mice lacking respectively the mGlu2 or the mGlu3 
receptor proteins. The selective anti-mGlu2 antibody unveiled a mGlu2-
immunoreactivity compatible with the monomeric (about 100 kDa) and the dimeric 
(about 200 kDa) form of the receptor protein (Figure 1B) in cortical lysates. 
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Concomitantly, the selective anti-mGlu3 antibody highlighted a clear immunopositivity 
corresponding to the dimeric form (about 200 kDa) of the protein and a slight signal for 
the monomeric form (about 100 kDa) of mGlu3 receptor protein (Figure 1C).  
 
 
 
Figure 1: Western Blot analysis with selective anti Group II mGlu receptor antibodies in cortical 
synaptosomes. Western blot analysis of cortical synaptosomal lysates by using the selective anti-
mGlu2/3 antibody (A), anti-mGlu2 antibody (B) and anti-mGlu3 antibody (C). β-butulin was used as 
neuronal marker and loading control. The figure shows a representative image of five analysis carried out 
in different days. A) The anti-mGlu2/3 antibody recognizes a band size compatible with the monomeric 
(about 100 kDA) and dimeric (about 200 kDa) form of the mGlu2/3 receptor proteins in cortical 
synaptosomes. B) The selective anti-mGlu2 antibody recognizes a band size compatible with the 
monomeric (about 100 kDA) form and more pronounced band size compatible with the dimeric (about 
200 kDa) form of the mGlu2 receptor proteins in cortical synaptosomes. C) The selective anti-mGlu3 
antibody recognizes a band size compatible with the monomeric (about 100 kDA) form and more 
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pronounced band size compatible with the dimeric (about 200 kDa) form of the mGlu3 receptor proteins 
in cortical synaptosomes. 
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Confocal analysis was then carried out to confirm the presence of the mGlu2/3 receptor 
proteins in cortical glutamatergic synaptosomes (see also Di Prisco et al., 2016). 
Experiments were aimed at highlighting the colocalization of the mGlu2/3 
immunopositivity with the syntaxin-1α (Stx-1α) immunofluorescence (Figure 2, line 1), 
here used as a marker of presynaptic particles, as well as with the immunopositivity for 
the vesicular glutamate transporter 1 (VGLUT1), here used as a selective marker of 
glutamatergic synaptosomes (Figure 2, line 2). The quantification of the protein 
colocalization revealed that 71 ± 2% of VGLUT1-positive synaptosomes also expressed 
mGlu2/3-immunoreactivity (Figure 2, line 1 panel “c”), and that the 64±4% of the 
sintaxin1α-positive synaptosomes were mGlu2/3-immunoreactive (Figure 2, line 2 
panel “f”).  
Then, the distribution of the mGlu2 and the mGlu3 receptor proteins was analyzed by 
quantifying the colocalization of the mGlu2-/mGlu3-immunoreactivities with the 
VGLUT1 immunofluorescence by using the selective antibodies (Figure 2, line 3 and 
4). The quantification of the protein colocalization revealed that 91±4% of VGLUT1-
positive synaptosomes also expressed mGlu2-immunoreactivity (Figure 2, line 3, panel 
“i”), while the 74±4% of the VGLUT1-positive synaptosomes were also mGlu3-
immunoreactive (Figure 2, line 4, panel “l”). 
Finally, I analysed the colocalization of mGlu2 and mGlu3 receptor proteins in cortical 
glutamatergic synaptosomes (Figure 2, line 5). The quantification indicated that 83±4% 
of the mGlu2-positive particles were also positive for mGlu3-immunoreactivity, while 
the 71±3% of the mGlu3-positive synaptosomes were also mGlu2-immunoreactive 
(Fgure 2, line 5, panel “o”). 
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Figure 2: Confocal analysis of Group II mGlu receptor proteins in cortical synaptosomes. Confocal 
analysis of the colocalization of mGlu2/3 receptor proteins with syntaxin-1A (line 1), with VGLUT1 (line 
2) and of the mGlu2 and of the mGlu3 receptor proteins immunoreactivities with VGLUT1 (line 3 and 4) 
in cortical nerve endings. The image also report the colocalization of mGlu2-positive particles with 
mGlu3-immunoreactivity in cortical nerve endings (line 5). The figures show representative images of 
five experiments carried out on different days. 
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On the existence of mGlu2 and mGlu3 receptor proteins in spinal cord 
synaptosomes  
I then performed a comparable analysis of the Group II mGlu receptors in mouse spinal 
cord synaptosomes.  
Again, Western Blot analysis was carried out to confirm the expression of mGlu2/3 
receptor proteins in spinal cord synaptosomal lysates (see also Di Prisco et al., 2016). 
Results unveiled the presence of mGlu2/3 receptor proteins in spinal cord synaptosomes 
(Figure 3A). In the synaptosomal lysates the anti-mGlu2/3 antibody recognized proteins 
having a mass consistent with the presence of both the monomeric and the dimeric form 
of the mGlu2/3 receptor proteins. The analysis was then carried out with the selective 
anti-mGlu2 and anti-mGlu3 antibodies (see also Olivero et al., 2017). The anti-mGlu2 
antibody confirmed the presence of mGlu2-immunoreactivity compatible with the 
monomeric (about 100 kDa) and dimeric (about 200 kDa) form of the receptor protein 
(Figure 3B). Similarly, the selective anti mGlu3 antibody unveiled a clear 
immunopositivity corresponding to the dimeric form (about 200 kDa) of the protein but 
a slight immunopositivity for the monomeric form (about 100 kDa) of the receptor 
protein (Figure 3C). 
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Figure 3: Western Blot analysis with selective anti Group II mGlu receptor antibodies in spinal 
cord synaptosomes. Western blot analysis in spinal cord synaptosomal lysates with the anti-mGlu2/3 
antibody (A), the anti-mGlu2 antibody (B) and the anti-mGlu3 antibody (C). β-butulin was used as a 
neuronal marker and loading control. The figure shows a representative image of five analysis carried out 
in different days. A) The anti-mGlu2/3 antibody recognizes a band size compatible with the monomeric 
(about 100 kDA) and dimeric (about 200 kDa) form of the mGlu2/3 receptor proteins in spinal cord 
synaptosomes. B) The selective anti-mGlu2 antibody slightly recognizes a band size compatible with the 
monomeric (about 100 kDA) form and a more pronounced band compatible with the dimeric (about 200 
kDa) form of the mGlu2 receptor proteins in spinal cord synaptosomes. C) The selective anti-mGlu3 
antibody recognizes a band compatible with the monomeric (about 100 kDA) form but a more 
pronounced band compatible with the dimeric (about 200 kDa) form of the mGlu3 receptor proteins in 
spinal cord synaptosomes. 
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Confocal analysis was then performed to confirm the presence of the mGlu2/3 receptor 
proteins in spinal cord glutamatergic synaptosomes (see also Di Prisco et al., 2016). To 
highlight the presence of the mGlu2/3-immunoreactivity in spinal cord glutamatergic 
particles I carried out experiments to unveil the colocalization of the mGlu2/3-positive 
particles with the syntaxin-1α (Stx-1α) immunofluorescence (Figure 4, line 1) and the 
colocalization of mGlu2/3-positive particles with VGLUT1 immunofluorescence 
(Figure 4, line 2). The quantification of the signalling revealed that 80±3% of 
VGLUT1-positive synaptosomes also expressed mGlu2/3-immunoreactivity (Figure 4, 
line 1, panel “c”), while the 68±4% of the sintaxin1α-positive synaptosomes were also 
mGlu2/3-immunoreactive (Figure 4, line 2, panel “f”).  
Then, the presence of the mGlu2 and the mGlu3 receptor proteins was confirmed in the 
spinal cord glutamatergic presynaptic terminals by analysing the colocalization of the 
mGlu2-positive and the mGlu3-positve particles with the VGLUT1 fluorescence 
(Figure 4, line 3 and 4). The quantification of the protein colocalization revealed that 
56±3% of VGLUT1-positive synaptosomes also expressed mGlu2-immunoreactivity 
(Figure 4, line 3, panel “i”), while the 47±7% of the VGLUT1-positive synaptosomes 
were also mGlu3-immunoreactive (Figure 4, line 4, panel “l”). 
Finally, I analysed the colocalization of mGlu2 and mGlu3 receptor proteins in spinal 
cord synaptosomal particles (Figure 4, line 5). The quantification indicated that 33±6% 
of the mGlu2-positive particles also expressed mGlu3-immunoreactivity, while the 
52±9% of the mGlu3-positive synaptosomes were also mGlu2-immunoreactive (Figure 
2, line 5, panel “o”). 
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Figure 4: Confocal analysis of Group II mGlu receptors in spinal cord synaptosomes Confocal 
analysis of the colocalization of mGlu2/3 receptor proteins with syntaxin-1A (line 1), with VGLUT1 (line 
2) and of the mGlu2 and the mGlu3 receptor protein immunoreactivities with VGLUT1 (line 3 and 4) in 
spinal cord nerve endings. The figure also reports colocalization of mGlu3-positive with mGlu2-
immunoreactivities in spinal cord nerve endings (line 5). The figure shows representative images of five 
experiments carried out on different days. 
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To briefly summarize, the confocal microscopy of the mGlu2 and the mGlu3 receptor 
proteins unveiled that these proteins are robustly expressed in cortical glutamatergic 
synaptosomes, with an apparent slight predominance of the mGlu2 receptor proteins. 
This could suggest the existence of a heterodimeric association of mGlu2 and mGlu3 
proteins in the same particles. This conclusion is well in line with the results from 
Western blot analysis with the mGlu2/3 antibody and the selective anti-mGlu2 or the 
anti-mGlu3 antibodies, although the possibility that mGlu2 and mGlu3 homodimers 
also colocalize in the same particles deserves confirmation. Comparable conclusions 
could be proposed based on the results from Western blot analysis and confocal 
microscopy in spinal cord synaptosomes, although the percentage of colocalization of 
the two receptor proteins in these regions differs from that observed in the cortex. 
 
The pharmacological characterization of the mGlu2/3 receptors in cortical 
and spinal cord synaptosomes  
To definitively assess whether the Group II mGlu autoreceptors in cortical and spinal 
cord synaptosomes differ in term of protein composition and pharmacological profile, I 
approached the pharmacological characterization of the two receptors by a functional 
point of view, by using “the up-down superfusion of a thin layer of synaptosomes“ to 
monitor the activity of selected agonists/antagonists on the release of glutamate.  
The “Up and down perfusion of a thin layer of synaptosomes” technique is a suitable 
approach to study the modulation of neurotransmitters release mediated by presynaptic 
receptors. The technique was first described by Maurizio Raiteri and colleagues (Raiteri 
et al., 1974) and it is nowadays used, with minor modification, to characterize by a 
functional point of view the subunit composition and the role of presynaptic release-
regulating receptors. Briefly, synaptosomes are layered as a monolayer on microporous 
filters and up-down superfused with physiological solutions. Then, the superfusate 
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fractions are collected to monitor the release of preloaded tritiated or endogenous 
transmitters. The continuous up-down superfusion of these particles assures the rapid 
removal of any endogenous compounds actively released by synaptosomes, before they 
can interact and activate structures such as receptors or carriers present on the nerve 
endings, thereby excluding any indirect effects. The activation of receptors on the 
synaptosomal membranes only can be achieved by adding selective receptor ligands to 
the perfusion medium. Under these experimental conditions, any ligand-induced 
changes to the transmitter release can be attributed exclusively to the interaction of the 
ligands with the respective receptors on nerve endings. In the experiments described 
below, the release of glutamate was triggered by exposing synaptosomes transiently (90 
sec) to a mild depolarizing stimulus (12 mM or 15 mM KCl solution). The efficiency of 
the presynaptic mGlu2/3 autoreceptors in controlling glutamate exocytosis was 
measured by quantifying the changes in the depolarization evoked transmitter 
exocytosis elicited by the concomitant presence of mGlu2/3 receptor ligands and the 
KCl solution (Fig 5, see also the section “Methods”).  
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Figure 5: Time-schedule of the superfusion experiments. Schematic representation of the time course 
in an “up down superfusion” experiments. A) After labelling with radioactive tracer (i.e. [3H]D-ASP to 
monitor glutamate exocytosis), synaptosomes are layered at the bottom of thermostated superfusion 
chambers (Raiteri et al., 1974, see also the section “Methods”). Synaptosomes are then exposed 
transiently (90 sec) to KCl enriched solution in the presence (B bottom, right) or in the absence (B 
bottom, left) of receptor agonist(s). Fractions are collected as follows: b1, a 3 min fraction before (t = 36-
39 min) and b3, a 3 min fraction after ( t = 45-48 min) a six min fraction b2 (t = 39-45 min) containing 
the KCl-evoked transmitter overflow. B) Schematic representation of the time course of the transmitter 
release elicited by the depolarizing stimulus alone (left) or in the presence of the mGlu2/3 agonist 
LY379268 (right).  
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Ligands  Properties  
LY 379268  mGlu2/3 agonist  
LY 341495  mGlu2/3 antagonist  
NAAG  mGlu3 agonist  
LY 541850  mGlu2 agonist 
mGlu3 antagonist 
LY 566332  mGlu2 PAM  
LY 2389575  mGlu3 NAM  
BINA  mGlu2 PAM  
ML337  mGlu3 NAM  
Anti mGlu2 antibody  Anti NH
2
-mGlu2 antibody  
Anti mGlu3 antibody  Anti NH
2
-mGlu3 antibody  
 
Table 1: The list of the mGlu2/3 ligands used for the pharmacologically characterization of the 
native Group II mGlu receptors. The table reports the compounds used to perform the functional 
superfusion studies, including orthosteric, allosteric molecules and selective antibodies for the mGlu2/3 
receptor proteins. For each ligand is reported the predicted membrane target. 
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Effects of mGlu2/3 orthosteric ligands on the mGlu2/3 autoreceptors in 
cortical and spinal cord nerve endings 
Previous studies (see Di Prisco et al., 2016) unveiled the activity of different orthosteric 
ligands at the mGlu2/3 autoreceptors in cortical (Table 2) and spinal cord (Table 3) 
nerve terminals. 
The first main finding of the study was that LY 379268, a broad spectrum orthosteric 
agonist acting at both mGlu2 and mGlu3 receptors (Schoepp et al., 1999), dramatically 
decreases the glutamate exocytosis in a region-dependent, concentration-sensitive 
fashion. LY 379268 inhibited in a concentration-dependent manner the [
3
H]D-ASP 
overflow evoked by 12 mM KCl solution from cortical nerve endings with an apparent 
EC50 of 1.50±1.15 nM and reaching the maximal inhibitory activity when added up to 
10 nM (Table 2). Similarly, LY 379268 also inhibited in a concentration-dependent 
manner the [
3
H]D-ASP overflow evoked by 15 mM KCl solution from spinal cord 
nerve endings. In this case the apparent EC50 amounted to 0.15±0.37 pM and a maximal 
inhibitory effect exerted by the agonist was when added up to 0.1 nM (Table 3). In both 
cortical and spinal cord synaptosomes, the broad spectrum orthosteric antagonist LY 
341495 efficiently prevented the inhibitory effect elicited by LY 379268 (Table 2 and 
3).  
Although the LY 379268 robustly activates mGlu2/3 receptors in both cortical and 
spinal cord synaptosomes, the impressive difference in the potency of the agonist in the 
two synaptosomal preparations seems best interpreted by assuming the involvement of 
two different mGu2/3 receptor subtypes. Specifically, it was proposed the presence of a 
high affinity LY 379268-sensitive binding site in spinal cord terminals and of a low 
affinity LY 379268-sensitive binding site in cortical terminals.  
Di Prisco and colleagues (2016) also tested the impact of two other orthosteric ligands: 
the N-acetylaspartylglutamate (NAAG) and the (1S,2S,4R,5R,6S)-2-amino-4-
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methylbicyclo[3.1.0]hexane-2,6-dicarboxylic acid (we refer to as LY 541850). Both in 
vivo and in vitro studies suggested that NAAG is a selective agonist at the mGlu3 
receptors (Neale et al., 2011). Differently, LY 541850 is typified by a double-faced 
profile since it acts as an agonist at the mGlu2 receptors and as an antagonist at the 
mGlu3 receptors (Sanger et al., 2013; Hanna et al., 2013). 
Differently from the effect of LY 379268, the ligand NAAG was unable to inhibit the 
12 mM KCl evoked [3H]D-ASP overflow from cortical synaptosomes, even when 
added at higher concentration (100 nM) (Table 2). In opposite, NAAG efficiently 
inhibited glutamate release from spinal cord synaptosomes with an apparent EC50 
amounting to 0.16±0.28 pM, comparable to EC50 of LY 379268 in the same 
synaptosomal preparation (Table 3). To note, the NAAG-induced inhibition of the KCl-
evoked release of tritium in spinal cord synaptosomes was prevented by the 
concomitantly exposure to LY 341495 (Table 2 and 3). 
The effect of LY 541850 was also tested both in cortical and spinal cord presynaptic 
terminals. As far as double-faced compounds are concerned, the technique of the “up-
down superfusion of synaptosomes” represents a method of choice to evaluate the 
efficacy of compound with a double activity (agonist/antagonist). In superfused 
synaptosomes, the functional effects elicited by receptors can be only induced by 
agonists exogenously added to the superfusion medium, because antagonists are 
expected to be inactive on their own (Raiteri et al., 1974; Marchi et al., 2015), providing 
evidence that the receptors they bind do not adopt a constitutive active state (Musante et 
al., 2008). Accordingly, the results observed when testing LY 541850 are well in line 
with the previous observations. LY 541850 mimicked LY 379268 in controlling 
glutamate exocytosis from cortical synaptosomes, compatible with an agonist-like 
activity at mGlu2 autoreceptors in these terminals. In contrast, LY 541850 failed to 
modulate glutamate exocytosis from spinal cord synaptosomes but it efficiently 
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prevented the effect of the mGlu2/3 agonist LY 379268, compatible with an antagonist-
like activity on the mGlu3 autoreceptors in these terminals (Table 2 and 3).  
The previous results so far described allowed the authors to propose the presence of 
Group II mGlu receptors with a different pharmacological profile in the two CNS 
regions. The functional results seemed best interpreted by assuming the existence of 
presynaptic release regulating mGlu2-preffering autoreceptors in cortical nerve endings 
and of a presynaptic mGlu3-preferring autoreceptors in spinal cord glutamatergic nerve 
endings. Despite the difficulty to predict the composition and the relative contribution 
of the mGlu2 and the mGlu3 receptors in both synaptosomal preparations, the results 
from Confocal microscopy and from Western blot analysis in synaptosomal lysates 
seemed predictive of the presence of mGlu3 homodimers in spinal cord nerve endings 
and of mGlu2/3 heterodimeric association in cortical synaptosomes (Di Prisco et al., 
2016). 
Stimulus 
[3H]D-ASP 
overflow 
% of change 
12 mM KCl 1.13 ± 0.09 / 
0.1 nM LY 379268 0.63 ± 0.12 -44.25 (*) 
0.1 nM LY 379268 
100 nM LY 341495 
1.27 ± 0.10 +12.38 
100 nM LY 541850 0.58 ± 0.07 -48.68 (*) 
100 nM NAAG 1.18 ± 0.02 +4.42 
100 nM LY 541850 
100 nM LY 341495 
1.22 ± 0.03 +7.96 
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Table 2: Effect of orthosteric ligands of mGlu2/3 receptors on the 12 mM KCl-evoked [
3
H]D-ASP 
release from cortical synaptosomes. The table reports the effect of orthosteric agonists of mGlu2/3 LY 
379268, NAAG and LY 541850 and the competitive antagonist LY 341495 added concomitantly to the 
12 mM KCl-evoked release from cortical nerve endings. Based on previous results, LY 541850 was used 
as an agonist in cortical synaptosomes.* significant difference (at least P < 0.05) versus 12 mM KCl 
evoked release (see also Di Prisco et al., 2016).  
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Stimulus  
[
3
H]D-ASP 
overflow  
% of change  
15 mM KCl  1.92 ± 0.13 / 
0.1 nM LY 379268  0.76 ± 0.13 -60.42 (*) 
0.1 nM LY 379268 
100 nM LY 341495  
1.89 ± 0.08 -1.57 
100 nM LY 541850  1.85 ± 0.08 -3.65 
0.01 nM NAAG  0.82 ± 0.1 -57.3 (*) 
100 nM LY 541850 
0.1 nM LY 379268  
1.82 ± 0.23 -5.2 
0.01 nM NAAG 
100 nM LY 341495  
1.55 ± 0.14 -19.27 
 
Table 3: Effect of orthosteric ligands of mGlu2/3 receptors on the 15 mM KCl-evoked [3H]D-ASP 
release from spinal cord synaptosomes. The table reports the effect of orthosteric agonists of mGlu2/3 
LY 379268 and NAAG and competitive antagonists LY 341495 and LY 541850 when added up with the 
15 mM KCl-evoked release from spinal cord nerve endings. Based on previous results, LY 541850 was 
used as an antagonist in spinal cord synaptosomes. *significant difference (at least P < 0.05) versus 15 
mM KCl evoked release (see also Di Prisco et al., 2016).  
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Effects of mGlu2/3 allosteric modulators on the mGlu2/3 autoreceptors in 
cortical and spinal cord nerve endings  
Based on the results obtained with the study of mGlu2/3 orthosteric ligands, I carried 
out superfusion experiments aimed at further implement the pharmacological 
characterization of the presynaptic release regulating mGlu2/3 receptors in both cortical 
and spinal cord nerve endings. To achieve this aim I used a double approach: one is the 
use of ligands that could discriminate the participation of the two receptor proteins to 
the receptor assemblies and the other one is the innovative immuno-pharmacological 
approach by using selective antibodies. Selective positive (PAM) and negative (NAM) 
allosteric modulators, namely the mGlu2 PAMs LY 566332 and BINA, and the mGlu3 
NAMs LY 2389575 and ML337, were used to this aim. 
Before showing results obtained, however, some aspects deserve discussion. It is 
recognized that positive allosteric modulators or PAMs increase the receptor mediated 
activation elicited by submaximal concentration of orthosteric agonists while negative 
allosteric modulators prevent the activation mediated by the orthosteric agonists 
regardless the amount of agonist applied. On the other hand, in order to select a suitable 
concentration of ligands used in our study we considered the concentration-effect 
relationship of LY 379268 in the cortex and in the spinal cord nerve terminals (Di 
Prisco et al., 2016). Specifically, I used selected concentrations of the orthosteric 
agonist leading to a partial inhibition (for the experiments to test the efficacy of PAMs) 
and to an almost total inhibition (for the experiments to test the efficacy of NAMs). 
The first ligands tested are from the LY series synthesized by Jim Moon and colleagues 
in the Eli Lilly laboratories. These ligands are the compounds LY 566332 and LY 
2389575 which behave as almost pure mGlu2 receptor PAM and mGlu3 receptor NAM 
respectively.  
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The results of functional experiments showed that both LY 566332 and LY 2389575 
were not able to modify on their own the KCl evoked glutamate exocytosis both in 
cortical and spinal cord synaptosomes. In the same experiments, 1 μM LY 566332 
amplified the 3 nM LY 379268-induced inhibition at cortical presynaptic terminals but 
at the same concentration it did not modify the 30 pM LY 379268-induced inhibition in 
spinal cord presynaptic terminals, even when added concomitantly to a lower 
concentration of the orthosteric agonist. On the other side, 1 μM LY 2389575 recovered 
the inhibition of the glutamate release mediated by 30 pM of LY 379268 from spinal 
cord synaptosomes. Interestingly, the same concentration of LY 2389575 partially 
blocked the 10 nM LY 379268 in cortical synaptosomes.  
Comparable results were also obtained with the two others allosteric modulators: the  
mGlu2 receptor PAM BINA and the mGlu3 receptor NAM ML-337 (not shown, see 
Olivero et al., 2017).  
Altogether, these results appear well in line with previous findings with the mGlu2/3 
orthosteric agonists. They confirmed the preferential role of mGlu3 in controlling the 
glutamate exocytosis in spinal cord presynaptic nerve endings and the role of the mGlu2 
receptors in the cortical nerve endings. However, the capacity of the mGlu3 NAMs to 
decrease the LY 379268-induced inhibition in presynaptic cortical nerve endings also 
suggested that mGlu3 participates to the control of the Group II mGlu receptors activity 
in cortical nerve endings. 
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Figure 6: Effect of mGlu2/3 allosteric modulators in cortical synaptosomes. Effect of the allosteric 
modulators LY 566332, PAM mGlu2, and LY 2389575, NAM mGlu3, on the inhibition of 12mM KCl-
evoked [
3
H]D-ASP overflow elicited by the mGlu2/3 agonist LY 379268 in cortical nerve endings. The 
12 mM KCl evoked release of tritium over the basal release amounted to 1.39±0.36 nCi (% of control). 
Data are the ± SEM of at least four experiments run in triplicate. *P < 0.05 versus the 12 mM KCl-evoked 
tritium overflow; °P < 0.05 versus the 12 mM KCl/1μM LY 566332 evoked tritium overflow; #P < 0.05 
versus the 12 mM KCl/3 nM LY 379268 evoked tritium overflow; §P < 0.05 versus the 12 mM KCl/10 
nM LY 379268 evoked tritium overflow (see also Olivero et al., 2018, figure 1). 
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Figure 7: Effect of mGlu2/3 allosteric modulators in spinal cord . Effect of allosteric modulators LY 
566332, PAM mGlu2, and LY 2389575, NAM mGlu3, on the inhibition of 15 mM KCl-evoked [
3
H]D-
ASP overflow elicited by the mGlu2/3 agonist LY 379268 in mouse spinal cord synaptosomes. The 15 
mM KCl-evoked release of tritium over the basal release amounted to 4.23±0.79 nCi. Results are 
expressed as a percentage of the 15 mM KCl-evoked tritium overflow (% of control). Data are the mean ± 
SEM of at least four experiments run in triplicate. *P < 0.05 versus the 15 mM KCl-evoked tritium 
overflow; °P < 0.05 versus the 15 mM KCl/1μM LY 566332-evoked tritium overflow; #P < 0.05 versus 
the 15 mM KCl/30 pM LY 379268-evoked tritium overflow (see also Olivero et al., 2018, figure 2). 
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Effects of selective anti-mGlu2 and anti-mGlu3 antibodies on the mGlu2/3 
autoreceptors in cortical and spinal cord nerve endings  
Beside the classic pharmacological approach used to characterize the mGlu2/3 
autoreceptors profile in the spinal cord and the cortical mouse synaptosomes, the 
innovative “immuno-pharmacological approach” was used to implement the analysis. 
This approach relies on the use of selective antibodies to define the pharmacological 
profile of GPCRs proteins (Gupta et al., 2008; Musante et al., 2008; Di Prisco et al., 
2016). Specifically, the binding of a selective antibody to a ligand binding pocket in the 
extracellular domain can cause the activation or the block of the receptor activity, 
consequently mimicking the effect of an agonist or antagonist at the receptor involved 
(Musante et al., 2008; Olivero et al., 2017). These considerations are well in line with 
the observation that circulating autoantibodies in patients suffering from different 
autoimmune diseases are associated to a downstream of the action of selective GPCRs 
in CNS (Makita et al., 2007; Lancaster et al., 2010). 
In our superfusion experiments, the synaptosomal particles are incubated with selective 
anti-mGlu2 antibody (1:1000) and anti-mGlu3 antibody (1:1000) before adding the 
radioactive tracer (for further details see section “Methods”). Then, the impact of the 
incubation with antibodies was evaluated on the inhibitory effect exerted by the 
orthosteric agonist LY 379268 on the KCl evoked release.  
The first result observed was that anti-mGlu2 and anti-mGlu3 antibodies did not modify 
on their own the 12 mM or 15 mM KCl evoked release from both cortical and spinal 
cord nerve terminals respectively (Figure 8 and 9). It was found that anti-mGlu2 
antibody abolished the inhibitory effect of LY 379268 in cortical synaptosomes but, in 
the same experimental condition, it was ineffective in spinal cord synaptosomes. In 
contrast, the anti-mGlu3 antibody blocked the LY 379268-induced inhibition of 
glutamate release in spinal cord synaptosomes, but it less, although significantly, 
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blocked the LY 379268-induced inhibition of glutamate release in cortical 
synaptosomes (Figure 8 and 9, see also Olivero et al., 2017, figure 8 and 9). Altogether, 
these results suggest that selective antibodies preferentially act as antagonists in these 
experiments. 
To conclude, the selective anti-mGlu2 and anti-mGlu3 confirmed the previous results 
obtained by using orthosteric and allosteric modulators of the mGlu2/3 receptors. In 
fact, they suggest that the mGlu3 receptors are crucial in the control of the LY 379268-
induced inhibition in spinal cord nerve endings while the mGlu2 receptors play a main 
role in the LY 379268-induced inhibition in cortical synaptosomes, where also the 
mGlu3 receptors participate. 
 
 
Figure 8: Effect of the selective anti-mGlu2 and anti-mGlu3 antibodies in cortical synaptosomes. 
Effects of the incubation of cortical synaptosomes with the anti-mGlu2 or the anti-mGlu3 antibodies on 
the 12 mM KCl/LY379268-evoked release of [
3
H]D-ASP. The 12 mM KCl-evoked release of tritium 
amounted to the following: control synaptosomes, 1.48±0.43 nCi; anti-mGlu2 antibody incubated 
synaptosomes, 1.63±0.27 nCi; anti-mGlu3antibody incubated synaptosomes 1.48±0.29 nCi. Results are 
expressed as percentage of the 12 mM KCl-evoked [
3
H]D-ASP release (% of control). Data are the mean 
± SEM of at least four experiments run in triplicate. *P < 0.05 versus the 12 mM KCl-evoked tritium 
overflow from control cortical synaptosomes; °P < 0.05 versus the 12 mM KCl/3 nM LY 379268-evoked 
tritium overflow from control cortical synaptosomes; #P < 0.05 versus the 12 mM KCl-evoked tritium 
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overflow from cortical synaptosomes incubated with the anti-mGlu3receptor antibody; §P < 0.05 versus 
the 12 mM KCl/3 nM LY379268-evoked tritium overflow from control cortical synaptosomes (see also 
Olivero et al., 2018, figure 8). 
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Figure 9: Effect of the selective anti-mGlu2 and anti-mGlu3 antibodies in spinal cord 
synaptosomes. Effects of the incubation of spinal cord synaptosomes with the anti-mGlu2 or the anti-
mGlu3 antibodies on the 15 mM KCl/LY 379268-evoked release of [
3
H]D-ASP. The 15 mM KCl-evoked 
release of tritium amounted to the following: control synaptosomes 4.76±0.69 nCi; anti mGlu2 antibody 
incubated synaptosomes, 3.21±0.55 nCi; anti mGlu3antibody incubated synaptosomes 3.98±0.42 nCi. 
Results are expressed as percentage of the 15 mM KCl-evoked [
3
H]D-ASP release. Data are the mean ± 
SEM of at least four experiments run in triplicate. *P < 0.05 versus the 15 mM KCl-evoked tritium 
overflow from control spinal cord synaptosomes; °P < 0.05 versus the 15 mM KCl-evoked tritium 
overflow from spinal cord synaptosomes incubated with the anti-mGlu2receptor antibody; #P < 0.05 
versus the 15 mM KCl/30 pM LY 379268 evoked tritium overflow from control spinal cord 
synaptosomes (see also Olivero et al., 2018, figure 9). 
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The mGlu2/3 and 5-HT2A heterodimerization in spinal cord 
nerve terminals 
The term heterodimerization refers to the association of two receptor proteins, 
independently if the two receptors involved belong to the same group (mGlu2/3 
receptor heterodimer) or to receptors that are activated by different transmitters, as in 
the case of the mGlu2/3 and 5-HT2A receptor-receptor interaction.  
The 5-hydroxytryptamine2A receptors (5-HT2A) is a serotonergic metabotropic receptor 
of the 5-HT receptor family. Beyond its involvement in a number of a physiological 
processes like the modulation of learning and memory and the control of excitatory 
events, this receptor attracted the interest of scientists because of its role as specific 
target of therapeutics against antipsychotic disorders. Contrasting results are present in 
literature concerning the role of the 5-HT2A receptor as modulator of chemical 
transmission. In particular, evidence have been provided suggesting both excitatory and 
inhibitory activity of this receptor. Actually, electrophysiological studies unveiled that 
the activation of this receptor can induce excitatory postsynaptic currents in layer V 
pyramidal cells (Aghahanian and Marek, 1999). In addition, it was demonstrated that 
this receptor is expressed in glutamatergic synapse with a presynaptic distribution were 
this receptor was associated to an inhibitory activity on glutamatergic transmission 
(Marcoli et al., 2001; Wang et al., 2006). 
In recent years it was demonstrated that Group II mGlu receptors and 5-HT2A receptors 
can heterodimerize in the cortex of mammals (Delille et al., 2012). Surprisingly and in 
way unexpectedly, it was proposed that the two receptors interact in antagonist-like 
manner (Delille et al., 2013), as suggested by the finding that activation of mGlu2/3 
receptors reduced the 5-HT2A receptor-induced EPSCs, while mGlu2/3 
antagonist/negative allosteric modulators reinforces the 5-HT2A mediated excitations of 
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L5P cells (Marek et al., 2000). Starting from the data supporting the existence of the 
mGlu2/3 receptors in spinal cord glutamatergic nerve endings, I investigated whether 
these terminals also possess 5-HT2A receptors and if mGlu2/3 and 5-HT2A receptors can 
be functionally coupled to control glutamate release in spinal cord synaptosomes. 
The results demonstrated that 5-HT2A receptors are expressed in the spinal cord 
glutamatergic terminals where they colocalize with mGlu2/3 receptors. This conclusion 
relies on functional studies supported by immunochemical evidence. In fact, 
superfusion experiments unveiled that the inhibitory effects on the 15 mM KCl-evoked 
release of [
3
H]D-ASP elicited by either LY 379268 (0.1 nM), used in a concentration 
causing a submaximal inhibition, or by (±)DOI (100 nM), used in a concentration 
eliciting the maximal inhibition, was almost abolished when the two agonists were 
concomitantly added (not shown, see Olivero et al., 2018). The loss of function in 
controlling glutamate release of both agonists when concomitantly added was best 
interpreted by assuming the colocalization and the functional cross-talk of the two 
receptors and also supported that the two receptors interact in an antagonist-like fashion. 
Indeed, it is known that the activation of two colocalized receptors controlling the 
exocytosis of the same transmitter should lead to an inhibitory effect amounting to the 
sum of the two effects elicited by the agonists alone (Musante et al., 2008; Pittaluga, 
2016; Olivero et al., 2018). However, the concomitant activation of the two receptors 
blocked the presynaptic release-regulating activity of both the two agonists consistent 
with a reciprocal antagonism of the releasing function. The close localization of the two 
receptors was further supported by results from Confocal microscopy showing a large 
colocalization of mGlu2/3 and 5-HT2A receptor proteins in spinal cord synaptosomes  
and from Western blot analysis (not shown, see Olivero et al., 2018). 
In order to confirm the possible heterodimerization of the mGlu2/3 and the 5-HT2A 
receptors, immunoprecipitation studies were performed in spinal cord terminals to 
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demonstrate the physical interaction between these receptors. The results showed a 
strong physical linking anti mGlu2/3 antibody immunoprecipitate from spinal cord 
synaptosomal lysates were also positive for 5-HT2A receptors (not shown, see Olivero et 
al., 2018, figure 5). In addition, when 5-HT2A antagonist were concomitantly added to 
the stimulus in the presence of a low, ineffective, concentration of LY 379268 (1 pM), 
the broad spectrum mGlu2/3 agonist became efficacious and was able to induce a 
marked inhibition of glutamate release in these terminals. In other words, these 
experiments demonstrated that blocking the 5-HT2A receptors increases the response of 
the mGlu2/3 receptors agonist LY 379268 in spinal cord nerve terminals (not shown, 
see Olivero et al., 2018).  
The oligomerization between mGlu2/3 and 5-HT2A receptors is an example of 
antagonist like cross-talk linking two receptors belonging to different group which can 
tune the release of glutamate and involve the activation of mGlu2/3 receptors. This may 
be particularly important in those diseases that are typified by an hyperglutamatergicity 
in spinal cord. Hypothesis could be also proposed for the mechanism of receptor 
heterodimerization and for the control of glutamate facilitation mediated by the Group II 
mGlu receptors/5-HT2A receptor complex. The main hypothesis is that 5-HT2A can 
modulate the trafficking and the insertion of mGlu2/3 receptors in the spinal cord 
synaptosomal plasma membranes. According to this view, the exposure of 
synaptosomes to 5-HT2A antagonists causes a significant increase in the amount of 
mGlu2/3 receptor proteins in the plasma membranes of synaptosomes (Olivero et al., 
2018). The increased expression of the mGlu2/3 receptor protein could be consistent 
with a rapid changes in the number and, possibly, in the composition of presynaptic 
mGlu2/3 autoreceptors. This observation is particularly intriguing since it indirectly 
implies some important consequences. First, there is the possibility that a ready-
releasable pool of mGlu2/3 receptor proteins exists in spinal cord glutamatergic nerve 
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endings. Second, mGlu2/3 receptor proteins could rapidly traffic in-out terminal plasma 
membranes. Third, antagonist activity of non-glutamatergic receptors linking to 
mGlu2/3 receptors can modulate these rapid in-out movements, controlling the insertion 
of these receptors in plasma membranes. However, this kind of effect could be more 
complex in vivo (De La Fuente Revenga et al., 2019). 
 In conclusion, the fact that the mGlu2/3 receptors can oligomerize with 5-HT2A 
receptor opens the possibility to have a new way to indirect control the glutamatergic 
transmission in spinal cord. However, the exact nature of this interaction and which 
receptor between mGlu2 and mGlu3 forms the physical link with 5-HT2A need further 
investigation.  
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Electrophysiological characterization of mGlu2/3 receptors in 
mouse hippocampus slices 
Building from the characterization of mGlu2/3 in cortical and spinal cord synaptosomes  
(Di Prisco et al., 2016; Olivero et al., 2017) but also from data in the literature (Gu et 
al., 2008) I designed, with the help of my supervisors Francesca Pasqui and Emanuele 
Sher, a study to characterize the effects of mGlu2/3 receptors modulators in mouse 
hippocampal slices, utilizing electrophysiological readouts. This is the gold standard 
technique to study synaptic transmission. In the hippocampus, mGlu2/3 receptors were 
already reported to have an important role in the control of glutamate release and to 
participate to different events like long-term synaptic plasticity (Upreti et al., 2013). 
In this section I am going to report the results obtained during my foreign experience at 
Eli Lilly laboratories (Erl Wood Manor, Sunninghill Road, Windlesham , GU20 6PH, 
UK), where my work is followed and led by Dr. Emanuele Sher. It was focused on the 
recording of excitatory postsynaptic potential (fEPSP) from the Cornu Ammonis-1 
(CA1) and the Dentate Gyrus (DG) of hippocampal slice of adult mice, in order to 
characterize the mGlu2/3 receptors expressed in these areas and their contribution to the 
modulation of synaptic transmission. The results were obtained utilizing two different 
protocols, which are shown below. Based on these preliminary observations, we 
suggested that both mGlu2 and mGlu3 participate to the modulation of synaptic 
transmission of these regions. 
 Protocol A: In these experiments, fEPSPs were recorded in the DG or in the 
CA1 areas of mouse hippocampal slices. After stable responses were obtained 
for at least 20 minutes, I applied different compounds for a suitable time. We 
call this “Protocol A”. Minor modification were made in some experiments to 
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the time of drug application, in order to obtain a stable response. A general 
example of the protocol is reported below 
 
 
 
 Protocol B: In these experiments, fEPSPs were recorded only in the DG of 
mouse hippocampal slices. Briefly, the following protocol was used to perform 
most of the experiments shown in this report: after the dissection and after at 
least 1 h with the slices recovering in normal aCSF (recovery time), between 2 
and 4 slices were incubated with ACSF and antibodies at defined concentrations 
for 1-2 h. Then, the experiments were carried out starting from a stable response 
(for at least 20 minutes) followed by addition of the compounds (40 minutes per 
compound). The protocol is reported below in details. In this “Protocol B” two 
types of compounds were used: Abcam mGlu2 antibodies 15672 and anti 
Alomone anti mGlu3 antibodies AGC-017 (the same antibodies used for the 
characterization of mGlu2/3 in cortical and spinal cord synaptosomes, see also 
Di Prisco et al., 2016 and Olivero et al., 2018). For the first antibody two 
different concentrations were used: 6.5 mg/ml and 13 mg/ml. For the second 
only one concentration was used: 13 mg/ml. In addition, we performed an 
incubation in the same manner with only ACSF as vehicle control. The time and 
temperature of incubation were the same for both antibodies and vehicle. As 
mentioned above, in order to reduce the amounts of antibodies used, and to 
improve the incubation, we carefully put between 2 and 4 slices in a small well 
of a 24 multi wells filled with ACSF constantly bubbled O2 95% / CO2 5%.  
 
 
Dissection Recovery time  
T= 1h 
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T= 1 -2 h 
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response 
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T=40 min 
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20 min 30 min 
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The results will be reported below, following the same protocols just described. For 
each compound, antibodies and peptides experiments the fEPSPs time course and traces 
will be shown. I will finally summarise all the data (treatments and controls) in bar 
histograms graphs.  
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Figure 10: Different effect of the mGlu2/3 agonist LY 379268 in the CA1 and DG of hippocampus 
slice. The effect of the mGlu2/3 agonist LY 379268 on the synaptic transmission in the CA1 and DG of 
hippocampus slice.  
A: Pooled data (n=4) for the fEPSP slope time course, recording from stratum radiatum. Each point 
represents the average of 4 sweeps and the mean ±SEM of 4 indipendent slices. Compounds were applied 
for the time indicated by the bars: at 20 min the LY 379268 100 nM in yellow; at 50 min the LY 379268 
1 µM in red. 
B: Pooled data (n=3) for the fEPSP Amplitude time course, recording from the molecular layer of DG. 
Each point represents the average of 4 sweeps and the mean ±SEM of 3 independent slices. Compounds 
were applied for the time indicated by the bars: at 20 min the 100 nM LY 379268 in yellow; at 50 min 
the1 µM LY 379268 in red. 
C: Example traces from an individual experiment recording from stratum radiatum of CA1. Each trace 
represents the last point for each condition in the experiment: baseline in blue, 100 nM LY 379268 in 
yellow and 1 µM LY 379268 in red. 
D: Example traces from an individual experiment recording from molecular layer of DG. Each trace 
represents the last point for each condition in the experiment: baseline in blue, 100 nM LY 379268 in 
yellow and 1 µM LY 379268 in red. 
E: Graph summarising the results for the agonist applied in CA1. Each column represents the average of 
the average of the last 3 points (6 minutes) for each concentration application for each individual 
experiment. 
-100 nM LY 379268 slightly decrease the synaptic transmission by 6.9% (93.1% of baseline recorded). 
-1 μM LY 379268 slightly although significantly depressed the synaptic transmission by 14.6% (85.4% of 
baseline recorded). 
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F: Graph summarising the results for the agonist applied in DG. Each column represents the average of 
the average of the last 3 points (6 minutes) for each concentration application for each individual 
experiment. 
-100 nM LY 379268 significatly decrease the synaptic transmission by 44.2% (55.8% of baseline 
recorded). 
- 1 μM LY 379268 significatly depressed the synaptic transmission by 61.8% (38.2% of baseline 
recorded). 
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Figure 11: Effect of the mGlu2/3 antagonist LY 3020371 in DG. The effect of the mGlu2/3 antagonist 
LY 3020371 against the agonist LY379268 at the higher concentration in the DG of hippocampus slice. 
The vehicle DMSO 0.1% was evaluated for possible interaction with the synaptic transmission.  
A: Pooled data (n=4) for the fEPSP Amplitude time course, recording from molecular layer of DG. Each 
point represents the average of 4 sweeps and the mean ±SEM of 4 independent slices. Compounds were 
applied for the time indicated by the bars: at 20 min the 10 µM LY 3020371 in light green and at 50 min 
the 1 µM LY 379268 + 10 µM LY 3020371 in green. 
B: Pooled data (n=4) for the fEPSP Amplitude time course, recording from molecular layer of DG. Each 
point represents the average of 4 sweeps and the mean ±SEM of 4 independent slices. Compounds were 
applied for the time indicated by the bars: at 20 min the DMSO 0.1% in light green and at 50 min the 
DMSO 0.1% + 1 µM LY 379268 in green. 
C: Example traces from an individual experiment recording from molecular layer of DG. Each trace 
represents the last point for each condition in the experiment: baseline in blue, 10 µM LY 3020371 in 
light green and 1 µM LY 379268 + 10 µM LY 3020371 in green.  
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D: Example traces from an individual experiment recording from molecular layer of DG. Each trace 
represents the last point for each condition in the experiment: baseline in blue, DMSO 0.1% in light green 
and DMSO 0.1% + 1 µM LY 379268 in green. 
E: Graph summarising the results for the antagonist. Each column represents the average of the average 
of the last 3 points (6 minutes) for each concentration application for each individual experiment. 
- 10 μM LY 3020371 did not affect the synaptic transmission: +5.3% (105.3% of baseline recorded). 
- 10 μM LY 3020371 + 1 μM LY 379268 did not depress the synaptic transmission: -0.2% (99.8% of 
baseline recorded). 
F: Graph summarising the results for the vehicle DMSO 0.1%. Each column represents the average of the 
average of the last 3 points (6 minutes) for each concentration application for each individual experiment. 
- DMSO 0.1% did not affect the synaptic transmission: +3.8% (103.8% of baseline recorded). 
- DMSO 0.1% + 1 μM LY 379268 depressed the synaptic transmission by -53.3% (46.7% of baseline 
recorded). 
  
 116 
 
 
 
Figure 12: Pharmacological LTD mediated by mGlu2/3 agonist in DG. The graphs show the effect of 
the agonist LY 379268 at the higher concentration after the wash out of the compound in the DG of 
mouse hippocampal slices. The vehicle DMSO 0.1% was evaluated to avoid possible interaction with the 
synaptic transmission and compounds  
A: Pooled data (n=4) for the fEPSP Amplitude time course, recording from the molecular layer of DG. 
Each point represents the average of 4 sweeps and the mean ±SEM of 4 independent slices. Compounds 
were applied for the time indicated by the bars: at 20 min the DMSO 0.1% in light green, at 50 min the 
DMSO 0.1% + 1 µM LY 379268 in green and at 90 min the ACSF in black. 
B: Example traces from an individual experiment recording from the molecular layer of DG. Each trace 
represents the last point for each condition in the experiment: baseline in blue, DMSO 0.1% in light 
green, DMSO 0.1% + 1 µM LY 379268 in green and ACSF in black. 
C: Graph summarising the results for the vehicle DMSO 0.1% and the following Pharmacological LTD 
induced byt the agonist LY 379268. Each column represents the average of the average of the last 3 
points (6 minutes) for each concentration application for each individual experiment. 
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- DMSO 0.1% did not affect the synaptic transmission: +1.8% (101.8% of baseline recorded). 
- DMSO 0.1% + 1 μM LY 379268 depressed the synpatic transmission: -55.9% (44.1% of baseline 
recorded). 
- After ACSF applied, the synaptic transmission was not able to recover for the rest of the experiment -
48.2 % (51.8 % of baseline recorded). 
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Figure 13: Effect of the mGlu3 NAM LY 2389575 in DG. The effect of the mGlu3 NAM LY 2389575 
versus the agonist LY 379268 at the higher concentration in the DG of hippocampus slice.  
A: Pooled data (n=5) for the fEPSP Amplitude time course, recording from molecular layer of DG. Each 
point represents the average of 4 sweeps and the mean ±SEM of 5 independent slices. Compounds were 
applied for the time indicated by the bars: at 20 min the 10 µM LY 2389575 in purple and at 50 min the 
10 µM LY 2389575 + 1 µM LY 379268 in green.  
B: Example traces from an individual experiment recording from molecular layer of DG. Each trace 
represents the last point for each condition in the experiment: baseline in blue, 10 µM LY 2389575 in 
purple and 10 µM LY 2389575 + LY 379268 1 µM LY 379268 in green. 
C: Graph summarising the results for the NAM mGlu 3. Each column represents the average of the 
average of the last 3 points (6 minutes) for each concentration application for each individual experiment. 
- LY 2389575 10 µM did not affect the synaptic transmission: +3.2% (103.2% of baseline recorded). 
- LY 2389575 10 µM + LY 379268 1 µM decrease the synaptic transmission: -33.3% (66.7% of baseline 
recorded).  
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Figure 14: Effect of mGlu2/3 NAM LY 2535850 in the DG. These experiments show the effect of the 
mGlu2/3 NAM LY 2535850 versus the agonist LY 379268 at the higher concentration in the DG of 
hippocampus slice.  
A: Pooled data (n=5) for the fEPSP Amplitude time course, recording from molecular layer of DG. Each 
point represents the average of 4 sweeps and the mean ±SEM of 5 independent slices. Compounds were 
applied for the time indicated by the bars: at 20 min the 10 µM LY 2535850 in purple and at 50 min the 
10 µM LY 2535850 + 1 µM LY 379268 in green.  
B: Example traces from an individual experiment recording from molecular layer of DG. Each trace 
represents the last point for each condition in the experiment: 20 min baseline in blue, 10 µM LY 
2389575 in purple and 10 µM LY 2389575 + 1 µM LY 379268 in green. 
C: Graph summarising the results for the NAM mGlu2/3 LY 2535850. Each column represents the 
average of the average of the last 3 points (6 minutes) for each concentration application for each 
individual experiment. 
- LY 2535850 10 µM did not affect the synaptic transmission: -0.5% (99.5% of baseline recorded). 
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- LY 2535850 10 µM + LY 379268 1 µM depressed the synaptic transmission: -44.8% (55.2% of baseline 
recorded).  
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Figure 15: Effect of mGlu2/3 PAM LY 566332 in DG. The effect of the mGlu 2 PAM LY 566332 1 
µM and 10 µM followed by the agonist LY 379268 at the lower concentration (10 nM and 30 nM) in the 
DG of hippocampus slice.  
A: Pooled data (n=4) for the fEPSP Amplitude time course, recording from molecular layer of DG. Each 
point represents the average of 4 sweeps and the mean ±SEM of 4 independent slices. Compounds were 
applied for the time indicated by the bars: at 20 min the 10 nM LY 379268 in purple and at 50 min the 30 
nM LY 379268 in red. 
mGlu2/3 agonist 10 nM and 
30 nM
Baseline
LY 379268 10 nM
LY 379268 30 nM
5 ms
0.2 mV
mGlu2 PAM 10 microM
Baseline
LY 566332 10 microM
LY 566332 10 microM 
+ LY 379268 10 nM
LY 566332 10 microM 
+ LY 379268 30 nM5 ms
0.2 mV
0
20
40
60
80
100
120
fE
P
S
P
 A
m
p
li
tu
d
e 
(%
)
mGlu2 PAM 1 µM
Baseline
LY 566332 1 microM
LY 566332 1 microM 
+LY 379268 10 nM
LY 566332 1 microM 
+ LY 379268 30 nM
*
mGlu2 PAM 1 µM
Baseline
LY 566332 1 microM
LY 566332 1 microM 
+ LY 379268 10 nM
LY 566332 1 microM 
+ LY 379268 30 nM
5 ms
0.2 mV
0
20
40
60
80
100
120
fE
P
S
P
 A
m
p
li
tu
d
e 
(%
)
mGlu2/3 agonist 10 nM and 
30 nM
Baseline
LY 379268 10 nM
LY 379268 30 nM
-7.4
- 40.3*
+ 1.8 
- 17.1 
- 54.9 
0
20
40
60
80
100
120
fE
P
S
P
 A
m
p
li
tu
d
e 
(%
)
mGlu2 PAM 10 microM
Baseline
LY 566332 10 microM
LY 566332 10 microM 
+ LY 379268 10 nM
LY 566332 10 microM 
+ LY 379268 30 nM
*
-5.1 
-31.3 
-57.6 
D
 A
E
 A
F
 A
G
 A
H
 A
I
 A
 123 
B: Pooled data (n=3) for the fEPSP Amplitude time course, recording from molecular layer of DG. Each 
point represents the average of 4 sweeps and the mean ±SEM of 3 independent slices. Compounds were 
applied for the time indicated by the bars: at 20 min the 1 µM LY 566332 in dark purple, at 50 min the 1 
µM LY 566332 + 10 nM LY 379268 in purple and at 90 min the 1 µM LY 566332 + 30 nM LY 379268 
in red. 
C: Pooled data (n=4) for the fEPSP Amplitude time course, recording from molecular layer of DG. Each 
point represents the average of 4 sweeps and the mean ±SEM of 4 independent slices. Compounds were 
applied for the time indicated by the bars: at 20 min the 10 µM LY 566332 in dark purple, at 50 min the 
10 µM LY 566332 + 10 nM LY 379268 in purple and at 90 min the 10 µM LY 566332 + 30 nM LY 
379268 in red. 
D: Example traces from an individual experiment recording from molecular layer of DG. Each trace 
represents the last point for each condition in the experiment: baseline in blue, 10 nM LY 379268 in 
purple and 30 nM LY 379268 in red. 
E: Example traces from an individual experiment recording from molecular layer of DG. Each trace 
represents the last point for each condition in the experiment: baseline in blue, 1 µM LY 566332 in dark 
purple, 1 µM LY 566332 + 10 nM LY 379268 in purple and 1 µM LY 566332 + 30 nM LY 379268 in 
red.  
F: Example traces from an individual experiment recording from molecular layer of DG. Each trace 
represents the last point for each condition in the experiment: baseline in blue, 10 µM LY 566332 in dark 
purple, 10 µM LY 566332 +10 nM LY 379268 in purple and 10 µM LY 566332 + 30 nM LY 379268 in 
red.  
G: Graph summarising the results for the agonist LY 379268 at 10 nM and 30 nM. Each column 
represents the average of the average of the last 3 points (6 minutes) for each concentration application 
for each individual experiment. 
- LY 379268 10 nM slightly reduced the synaptic transmission: -7.4% (92.6% of baseline recorded). 
- LY 379268 30 nM depressed the synaptic transmission: -40.3% (59.7% of baseline recorded). 
H: Graph summarising the results for the PAM mGlu2 LY 566332 at 1 µM. Each column represents the 
average of the average of the last 3 points (6 minutes) for each concentration application for each 
individual experiment. 
- LY 566332 1 µM did not affect the synaptic transmission: +1.8% (101.8% of baseline recorded). 
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- LY 566332 1 µM + LY 379268 10 nM slightly depressed the synaptic transmission: -17.1% (82.9% of 
baseline recorded). 
- LY 566332 1 µM + LY 379268 30 nM significantly depressed the synaptic transmission: -54.9% 
(45.1% of baseline recorded). 
I: Graph summarising the results for the mGlu2 PAM LY 566332 at 10 µM. Each column represents the 
average of the average of the last 3 points (6 minutes) for each concentration application for each 
individual experiment. 
- LY 566332 10 µM did not affect the synaptic transmission: -5.1% (94.9% of baseline recorded). 
- LY 566332 10 µM + LY 379268 10 nM depressed the synaptic transmission: -31.3% (68.7% of baseline 
recorded). 
- LY 566332 10 µM + LY 379268 30 nM significantly depressed the synaptic transmission: -57.6% 
(42.4% of baseline recorded). 
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Figure 16: Effect of two concentrations of mGlu 2/3 agonist LY 379268, 100 nM and 1 µM, on 
vehicle treated slices. These experiments represent the Control for antibodies experiments. 
A: Pooled data (n=5) showing the fEPSP Amplitude time course, recording from molecular layer of DG. 
Each point represents the average of 4 sweeps and the mean ±SEM of 5 independent slices. Compounds 
were applied for the time indicated by the bars: at 20 min the 100 nM LY 379268 in yellow and at 50 min 
in the 1 µM LY 379268 in orange. 
B: Example trace from an individual experiment recording from molecular layer of DG. Each sweep 
represents the last point for each condition in the experiment: baseline in blue, 100 nM LY 379268 in 
yellow and 1 µM LY 379268 in orange. 
C: Graph summarising the results for the synaptic blocking effects of the mGlu2/3 agonist LY 379268. 
Each column represent the average of the average of the last 3 points (6 minutes) for each concentration 
application for each individual experiment. 
- LY 379268 100 nM significatly depressed the synaptic transmission: -55.5% (44.4 of baseline 
recorded). 
- LY 379268 1 µM significatly depressed the synaptic transmission: -64.2% (35.8 of baseline recorded). 
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Figure 17: Effects of pre-incubation with the anti mGlu2 antibody (6.5 µg/ml) on LY 379268 (100 
nM and 1 µM) responses. There is no prevention of the inhibition mediated by the agonist LY 379268. 
A: Pooled data (n=3) for the fEPSP Amplitude time course, recording from molecular layer of DG. Each 
point represents the average of 4 sweeps and the mean ±SEM of 3 independent slices. Compounds were 
applied for the time indicated by the bars: at 20 min the 100 nM LY 379268 in yellow and at 60 min the 1 
µM LY 379268 in red. 
B: Example traces from an individual experiment recording from molecular layer of DG. Each sweep 
represents the last point for each condition in the experiment: baseline in blue, 100 nM LY 379268 in 
yellow and 1 µM LY 379268 in red. 
C: Graph summarising the results with the mGlu2 antibody. Each column represents the average of the 
average of the last 3 points (6 minutes) for each concentration application for each individual experiment. 
- LY 379268 100 nM signifincatly depressed the synaptic transmission: -69.4% (30.6 of baseline 
recorded). 
- LY 379268 1 µM signifincatly depressed the synaptic transmission: -69.4% (30.6 of baseline recorded). 
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Figure 18: Effects of pre-incubation with the anti mGlu2 receptor antibody (13 µg/ml) on LY 
379268 (100 nM and 1 µM) responses. This concentration of antibody partially prevents the agonist-
induced inhibition of synaptic transmission. 
A: Pooled data (n=4) for the fEPSP Amplitude time course, recording from molecular layer of DG. In this 
and subsequent figures, each point represents the average of 4 sweeps and the mean ±SEM of 4 
independent slices. Drugs were applied for the time indicated by the bars: at 20 min the 100 nM LY 
379268 in yellow and at 60 min the 1 µM LY 379268 in red. 
B: Example traces from an individual experiment recording from molecular layer of DG. Each sweep 
represents the last point for each condition in the experiment: baseline in blue, 100 nM LY 379268 in 
yellow and 1 µM LY 379268 in orange.  
C: Graph summarising the results with the mGlu2 antibody. Each column represents the average of the 
average of the last 3 points (6 minutes) for each concentration application for each individual experiment. 
- LY 379268 100 nM depressed the synaptic transmission: -42.9% (57.1 of baseline recorded). 
- LY 379268 1 µM depressed the synaptic transmission: -51.2% (48.8 of baseline recorded).  
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Figure 19: Effects of pre-incubation with the anti mGlu 3 receptor antibody (13 µg/ml) on LY 
379268 (100 nM and 1 µM) responses. This antibody did not prevent the agonist inhibitory effects on 
synaptic transmission. 
A: Pooled data (n=4) for the fEPSP Amplitude time course, recording from molecular layer of DG. Each 
point represents the average of 4 sweeps and the mean ±SEM of 4 independent slices. Drugs were applied 
for the time indicated by the bars: at 20 min the 100 nM LY 379268 in yellow and at 60 min the 1 µM LY 
379268 in red. 
B: Example traces from an individual experiment recording from molecular layer of DG. Each sweep 
represents the last point for each condition in the experiment: baseline in blue, 100 nM LY 379268 in 
yellow and 1 µM LY 379268 in red.  
C: Graph summarising the results with the mGlu3 antibody. Each column represents the average of the 
average of the last 3 points (6 minutes) for each concentration application for each individual experiment. 
- LY 379268 100 nM depressed the synaptic transmission: -65.6% (34.4 of baseline recorded). 
- LY 379268 1 µM drammaticly depressed the synaptic transmission: -74.4% (25.6 of baseline recorded). 
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Our goal was to use a gold standard technique to investigate the modulation of synaptic 
transmission by mGlu2/3 receptors, using a pool of different compounds and antibodies. 
At the beginning, the experiments were performed, separately, in two different mouse 
hippocampal area, CA1 and Dentate Gyrus. The fEPSPs were measured in both regions 
and fEPSP Slopes were analysed for CA1 while fEPSP Amplitudes were analysed for 
DG. We started by using the well known agonist LY 379268 in both regions and we 
obtained different results, as shown in Figure 10. We observed a major impact of this 
compound in the DG with minimal effects in CA1. The strong effects of this mixed 2/3 
agonist in the perforant pathway to the Dentate Gyrus brought us to focus all subsequent 
experiments on this area.  
Figure 11 shows the second step of our study: evaluating the effects of the antagonist 
LY 3020371. This novel compound has already been shown to display a potent and 
selective antagonist action on mGlu2/3 receptor (Witkin J.M. et al., 2015). Here we 
found that the antagonist completely blocked the effect of the agonist (used at the higher 
concentration of 1 µM) in the DG. Two important things have to be noted to fully 
appreciate the selective effects of the antagonist. The first was that this compound had 
no effect by itself on synaptic transmission, as shown in the 30 minutes of perfusion 
after the baseline. The second was that DMSO 0.1%, here used as vehicle to solubilize 
the antagonist, had no effects either, nor on the baseline nor on the inhibition mediated 
by the agonist.  
The inhibition of synaptic transmission mediated by the agonist LY 379268 is a 
complex event and one of the consequence is the promotion of a so-called  
pharmacological Long Term Depression (LTD). This was demonstrated by the 
experiments reported in Figure 12. After the agonist was applied for a short time, the 
slice was washed for 90 min with normal aCSF and we showed that the inhibition was 
still present long after removal of the agonist. 
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Once established the effects of mGlu2/3 agonists and mGlu2/3 antagonists on acute and 
long term synaptic depression, we tried to better understand the relative contribution of 
mGlu2 versus mGlu3 receptors. 
As mentioned before, these receptors subtypes have a high sequence homology which, 
in part, explain the low number of selective compounds available (Niswender and Conn, 
2010; Nicoletti et al., 2011). In order to further characterize the individual contribution 
of these two receptor subtypes, we evaluated a pool of novel compounds. In particular, 
we focused on the negative allosteric modulators (NAMs) LY 2389575 and LY 
2535850, and the positive allosteric modulator (PAM) LY 566332. 
The mGlu3 NAM LY 2389575 (Figure 13) and mGlu2/3 NAM LY 2535850 (Figure 
14) showed a similar and limited ability to prevent the effect of the agonist LY 379268 
utilised at 1 µM, even if LY 2389575 was slightly more potent. Figure 20 summarises 
the results of the comparison between NAMs and the agonist. The robust inhibition 
induced by LY 379268, was still observed in the presence of the NAMs, in contrast to 
our previous results with the orthosteric antagonist. 
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Figure 20: Effects of mGlu NAM in DG The graph shows a summary of the effects of the NAMs LY 
2389575 (10 µM) and LY 2535850 (10 µM) versus the agonist LY 379268 (1 µM). Data are the mean 
±SEM of 4 experiments. * significantly different from the baseline (p<0.05). 
 
Only the mGlu3 NAM had a statistically significant effect in preventing the agonist 
effects, but the effects were small and unlikely to suggest a preferential role of mGlu3. 
The error bars are pretty large and we only tested one concentration of each NAM. 
Therefore, any conclusion would be premature, at this stage. 
On the other hand, Figure 15 showed the interesting effects of the mGlu 2 PAM LY 
566332 which showed a nice enhancement of the inhibition mediated by low 
concentrations of the agonist LY 379268. The figure shows in order the effect of LY 
379268 at 10 nM and 30 nM, then two different concentrations of the PAM 1 µM and 
10 µM alone and in the presence of the agonist. As before, PAM has no effect by itsef 
but it increased the inhibition at both concentrations of agonist. 
 
Figure 21: Effects of mGlu 2 PAM in DG. The graph shows a summary of the effect of the mGlu2 
PAM (10 µM) versus the agonist LY 379268 (1 µM). Data are the mean ±SEM of 4 experiments. 
*significantly different from baseline (p<0.05); #significantly different from LY 379268 10 nM (p<0.05). 
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The bar graph above (Figure 21) shows a summary of the effects of the mGlu2 PAM. 
The PAM was effective at 1 µM, but the higher concentration of 10 µM showed a 
slightly more pronounced effect and less variable results. After these experiments with 
various pharmacological agents, in order to further evaluate the individual contribution 
of mGlu2 and mGlu3 receptors in the modulation of glutamatergic synaptic 
transmission in the mouse hippocampal DG, we used selective antibodies directed 
against the extracellular domain of the receptors. The antibodies used are the same 
antibodies utilised for the “immuno-pharmacological” characterization of the mGlu2/3 
receptors in cortical and spinal cord synaptosomes (see also Olivero et al., 2017). As 
described above, the pre incubation with selective antibodies was used to try to induce a 
selective block of one of these receptor subtypes, and therefore a prevention of the 
inhibitory effects of the dual mGlu2/3 agonist LY 379268.  
As a control, as shown in Figure 16, we performed experiments to show that similar 
pre-incubations with the vehicle alone was not affecting the ability of LY379268 to 
inhibit synaptic transmission.  
Figure 17 shows that pre-incubation with a lower concentration of the anti mGlu 2 
receptor antibody (6.5 µg/ml) did not prevent the inhibition mediated by the agonist LY 
379268 at either 100 nM or 1 µM. 
More interesting, Figure 18 and 19 show the effects of anti mGlu 2 and 3 receptor 
antibodies, respectively, after pre-incubations with higher antibody concentrations (13 
µg/ml).
 133 
  
Figure 22: Effects of anti mGlu2/3 effects in DG. The graph shows a summary of the effects of mGlu 2 
and 3 receptor antibodies (13 µg/ml) against the effects of the agonist LY 379268 at 100 nM and 1 µM. 
Data are the mean ±SEM of at least 3 experiments. * Significantly different from Baseline (p<0.05).  
 
As shown in the summary graph (Figure 22), all the LY 379268 effects, with or without 
antibody pre-incubation, are significantly different from baseline. We can conclude that 
the two antibodies did not prevent synaptic inhibition mediated by this agonist. 
However, in contrast with the lower antibody concentration, after pre-incubation with a 
higher concentration of the anti mGlu 2 receptor antibody, LY379268 was causing 
slightly less inhibition. More experiments and with different antibody concentrations 
and/or pre-incubation times would be needed to substantiate this trend. This small 
inhibitory effect was not seen with the mGlu3 receptor antibody (if anything, a trend 
towards an enhanced agonist effect was seen). 
Altogether these results suggest some points for discussion: 
 There is a stronger control of synaptic transmission by mGlu2/3 receptors in the 
DG rather than in CA1 of the mouse hippocampus. However, the identification 
of the individual contribution of mGlu2 and mGlu3, carried out with NAMs, 
PAMs and antibodies was less clear cut. 
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 The antibodies experiments may suggest a differential impact of the two 
antibodies on the modulation of synaptic transmission by mGlu receptors in the 
DG area. The trend in the data suggests that blocking mGlu2 receptors, but not 
mGlu3 receptors, with selective antibodies could partially prevent LY 379268 
effects. The effects were small but consistent with the partial potentiation of 
LY379268 effects which we found using the selective mGlu2 receptor PAM 
LY566332. 
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mGlu1 and GABAB in cortical synaptosomes: a receptor-
receptor functional cross talk. 
The second part of my work aimed at investigating the presence and the role of mGlu1 
receptors in the GABAergic terminals and to assess whether these receptors can 
functionally interact with GABAB autoreceptors in these terminals.  
The GABAB and mGlu1 receptors have a widespread distribution in the CNS where 
they control glutamate and GABA transmission. Both receptors are expressed at the 
presynaptic level (Ladera et al., 2008; Pittaluga, 2016, Vergassola et al., 2018). 
Specifically, the GABAB receptor exists as autoreceptor in GABAergic nerve terminals 
and as heteroreceptor in non-GABAergic terminals (Bowery et al., 2002). Differently, 
the mGlu1 receptors exist as autoreceptor in cortical glutamatergic presynaptic 
terminals (Pittaluga, 2016), but, despite the clear localization of these receptors in 
cortical GABAergic interneurons, the possibility that mGlu1 receptors control GABA 
exocytosis still is matter of debate.  
As a first approach, Western blot analysis was carried out to confirm the presence of the 
mGlu1 and of GABAB receptor proteins in the cortical synaptosomal lysates, as 
described in figure 23.  
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Figure 23: Western Blot analysis of the GABAB1, GABAB2 and mGlu1 receptor proteins in cortical 
synaptosomes. The picture shows the Western Blot analysis of cortical synaptosomal lysates with the 
selective anti-GABAB1, anti-GABAB2 and anti-mGlu1 antibodies. Actina was used as neuronal marker 
loading control. The figure shows a representative images of five analysis carried out in different days. 
  
 137 
Then we analysed with Confocal microscopy whether the two receptors colocalize in 
vesicular GABA transporter (VGAT)-positive GABAergic particles (not shown, see 
Vergassola et al., 2018, figures 1 and 8). The results were largely confirmatory of the 
presence of both receptors in presynaptic GABAergi and glutamatergic particles. 
These findings were predictive of the existence of both receptors in cortical nerve 
endings. In order to confirm their existence at this level but also owing to evidentiate 
their functional interaction, we moved to the functional studies performed with the “up 
and down superfusion” system. It was investigated whether mGlu1 ligands can modify 
on their own the GABA exocytosis from cortical synaptosomes (Musante et al., 2010, 
Zucchini et al., 2013). Figure 24 shows that neither 3,5-DHPG nor LY 367385 caused 
significant changes in the 12 mM KCl evoked [
3
H]GABA release from cortical 
GABAergic terminals. However, when concomitantly added to (±)baclofen the two 
ligands significantly influenced the effect of the orthosteric agonist GABAB agonist. In 
particular, the mGlu1 agonist 3,5-DHPG (30 μM) significantly reduced the inhibition 
induced by the GABAB agonist baclofen (3 μM) while the mGlu1 antagonist LY 
367385 (0.03, 0.1 and 1 μM) significantly reinforced it (Figure 24). These observations 
led to propose the existence of presynaptic mGlu1 receptors on cortical GABAergic 
nerve terminals and their functional cross talk with the GABAB autoreceptors 
(Vergassola et al., 2018). 
This conclusion was further supported by data obtained with cortical synaptosomes 
isolated from the Grm1
crv4/crv4
 mice (Bossi et al., 2016; Vergassola et al., 2018). This is 
a mouse mutant model bearing a genetic inactivation of the mGlu1 receptor coding gene 
resulting in the lack of the mGlu1 receptor proteins. We found that in mouse cortical 
synaptosomes from the inhibitory effect elicited by (±)baclofen on the 12 mM KCl 
[
3
H]GABA release was more pronounced when compared to wild type animals (not 
shown, see Vergassola et al., 2018, figure 5). In addition, Western Blot analysis 
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indicated a significant increase of the GABAB2 receptor proteins expression in the 
synaptosomal lysates, that would account for the increased activity of the GABAB 
autoreceptors in controlling GABA exocytosis (Moller et al., 2017). Even if further 
studies are required to completely elucidate the mechanism in these mutant mice, our 
data are well line with the antagonist-like cross-talk linking the mGlu1 and the GABAB 
receptors in GABAergic cortical nerve endings. 
Evidence in literature suggested that GABAB receptors and mGlu1 receptors can 
physical interact at least in some regions of the CNS like hippocampus (Tabata et al., 
2004) and that this interaction could depend on Ca
2+
 ions. In release experiments, the 
physical interaction between the GABAB and the mGlu1 receptors was so far excluded 
by immunoprecipitation studies. Moreover, we could not investigate the role of external 
calcium because this ion is essential to transmitter exocytosis. 
Nonetheless, the results above described claims for a receptor cross-talk linking mGlu1 
and the GABAB receptors in an antagonist-manner. The impact of this functional cross-
talk deserves further study to be clarified.  
 
 
 
 
 139 
0
20
40
60
80
100
120
1
2
 m
M
 K
C
l-
ev
o
k
e
d
 [
3
H
]G
A
B
A
 
o
v
er
fl
o
w
 (
p
er
ce
n
t 
o
f 
re
si
d
u
a
l)
°
*
***
***
***
° °°
*
(+/-) Baclofen (M)3333
LY367385 (M)10.10.03
- 3,5-DHPG (M)
-
-
30
-
---
-
-
1
30
-
3
 
 
Figure 24: Effect of mGlu1 receptor ligands on the GABAergic transmission. Effects of 3 mM (±) 
baclofen, 30 mM 3,5-DHPG and LY 367385 (0.03–1 mM) alone or concomitantly added on the 12 mM 
KCl-induced [
3
H]GABA overflow from mouse cortical nerve terminals. Results are expressed as 
percentage of the 12 mM KCl-induced [
3
H]GABA overflow (percent of residual). Data are the means 
SEM of five experiments run in triplicate.*p < 0.05 vs 12 mM KCl overflow; ***p < 0.001 vs 12 mM 
KCl overflow; °p < 0.05 vs 12 mM KCl/3 mM (±)baclofen overflow;°°°p < 0.001 vs the 12 mM KCl/3 
mM (±) baclofen overflow. 
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CONCLUSION 
The aim of my PhD course and of this work was to approach the study of the 
neurotransmission in the CNS and, in particular, the mechanisms of control of 
transmitter release from selected populations of nerve endings. 
I worked at different projects dedicated either to the pharmacological characterization of 
presynaptic release-regulating mGlu receptors and to analyse their interactions with 
other receptors. The main model used to perform these studies was the model of isolate 
nerve endings or synaptosomes. I focused on the pharmacological profiles of the 
mGlu2/3 receptors in selected regions of the CNS as well as on their ability to 
hetero/oligodimerization with other receptors.  
The results debated in this thesis brings new insights about the mechanisms of the 
receptor oligomerization as well as on the receptor-receptor cross-talk in the CNS, in 
particular at the presynaptic terminals. The overall data unveil new possibilities to 
control glutamatergic and GABAergic transmission, in particular in the cortex and the 
spinal cord of adult rodents. Beyond the limits of our studies, my results lead to the 
following main conclusions: 
 The integration of signals derived from glutamatergic and GABAergic 
neurotransmission can finely modulate one each other through the activation of  
oligomeric receptors assemblies that carry out complex “non conventional” responses. 
 The dimerization processes can produce signals which can deeply modify the 
intraterminal pathways in cells and should be taken into considerations either in 
physiological and pathological conditions.  
 The “up-down superfusion of a thin monolayer of synaptosomes“ represents, 
with biochemical support studies, a suitable approach to investigate receptor 
dimerization and receptor-receptor cross talk in the CNS.  
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“The scientist is not a person who gives the right answers, he's one who asks the right 
questions.” (Claude Levi-Strauss) 
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METHODS 
Animals 
Adult mice (male and female, 3-6 months, strain C57BL/6J) and adult rats (female and 
male, 3-6 months, strain Sprague Dawley) were obtained from Charles River (Calco, 
Italy) and were housed in the animal facility of DIFAR, Section of Pharmacology and 
Toxicology. The experimental procedures were in accordance with the European 
legislation (European Communities Council Directive of 2010/63/EU) and the ARRIVE 
guidelines, and they were approved by the Italian Ministry of Health. All animals were 
kept under environmental controlled conditions (ambient temperature= 22°C, humidity= 
40%) on a 12 h light/dark cycle with food and water available ad libitum. Animals were 
killed by cervical dislocation followed by decapitation and tissue were rapidly removed. 
In line with the 3Rs rules (replacement, refinement and reduction) any effort was made 
to reduce the number of animals to obtain statistically reliable results.  
The mGlu2 receptor knockout (mGlu2
-/-
) mice, the mGlu3 receptor knockout (mGlu3
-/-
) 
mice, the double mGlu2/3 receptor knockout (mGlu2/3
-/-
) mice on a CD1 genetic 
background and their CD1 wild-type (WT) counterparts were kindly provided by Eli 
Lilly & Company (Indianapolis, IN, USA) (Linden et al., 2005) and housed at IRCSS 
Neuromed. These mice were individually genotyped for the mGlu2 and the mGlu3 
receptors gene by PCR analysis. The experimental procedures were in accordance with 
the European legislation (European Communities Council Directive of 24 November 
1986, 86/609/EEC) and were approved by the Italian Ministry of Health (DDL 26/2014 
and previous legislation; protocol number no.50/2011-B). Experiments were performed 
following the Guidelines for Animal Care and Use of the National Institutes of Health. 
Animal studies were reported in compliance with the ARRIVE guidelines (see British 
Journal of Pharmacology, McGrath and Lilley, 2015). 
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The Grm1
crv4
 mice bearing the spontaneous recessive crv4 mutation were also used. The 
crv4 mutation occurred in the BALB/c/Pas inbred strain and consisted of an intronic 
insertion of a retrotransposon LTR (Long Terminal Repeat) fragment that disrupted the 
Grm1 gene splicing, causing the absence of mGlu1 receptor protein. The Grm1
crv4/crv4
 
homozygous mice presented mainly motor coordination deficits and bone defects (Conti 
et al., 2006; Musante et al., 2017). The affected (Grm1
crv4/crv4
) and the control [Grm1
+/+
, 
wild type (WT)] mice were maintained on the same genetic background by intercrossing 
Grm1
crv4/+
 mice. The procedures for breeding and genotyping of Grm1
crv4/crv4
 mice were 
reviewed and approved by the Animal welfare ethical committee of the IRCCS-AOU 
San Martino-IST National Cancer Research Institute (Genoa, Italy), and the definitive 
approval obtained by the Italian Ministry of Health (DDL 26/2014 and previous 
legislation; protocol number 371). To obtain the genotype of the mouse progeny, DNA 
was extracted from ear clippings according to the manufacturer‟s protocol (KAPA 
Mouse Genotyping Kits). Crv4 mutation was detected by DNA polymerase chain 
reaction (PCR) amplification using specific primers as previously described (Musante et 
al., 2010; Rossi et al., 2013). 
 
Preparation of synaptosomes 
Mouse or rat purified synaptosomes were prepared with a standard percoll gradient 
protocol from a selective nervous tissue (Dunkely et al., 2008, Summa et al., 2013). The 
selected CNS tissue was homogenized in 10 volumes of 0.32 M sucrose, buffered to pH 
7.4 with Tris-(hydroxymethyl)-amino methane (TRIS, final concentration 0.01 M) with 
a glass/Teflon tissue grinder (clearance 0.25 mm). The homogenate was centrifuged 
(1,000 x g for 5 min) to remove nuclei and debris, and the supernatant was gently 
layered on a discontinuous percoll gradient (6%, 10%, and 20% v/v in Tris-buffered 
sucrose). After centrifugation at 33,500 x g for 5 min, the layer between 10% and 20% 
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percoll (synaptosomal fraction) was collected and washed by centrifugation (20,000 x g 
for 16 min). Synaptosomes were resuspended in a physiological medium having the 
following composition (mM): NaCl, 140; KCl, 3; MgSO4, 1.2; CaCl2, 1.2; NaH2PO4, 
1.2; NaHCO3, 5; HEPES, 10; glucose, 10; pH 7.4. 
Synaptosomes still represent one of the most suitable preparation to study neurotransmitter 
exocytosis from presynaptic compartment and, consequently, the modulation of release by 
presynaptic receptors. The formation of synaptosomes is due to a sequence of precise steps 
based on centrifugation and percoll separation and based on the properties of the plasma 
membrane. In fact, isolate nerve endings can be separated from the axon of neurons and, then, 
they can independently generate small circle bodies. Synaptosomes have a diameters about 1-
1.5 μm and they preserve all the structures of the synaptic bottom, keeping alive for few hours 
in appropriate condition. Therefore, this model can be used to perform neurochemical studies 
like evaluation of neurotransmitter release or biochemical analysis like Confocal microscopy 
and Western Blot analysis (Pittaluga, 2016, 2019). 
 
Preparation of mouse hippocampal slices.  
Adult male wild type mice (6-10 weeks) were anaesthetized by isoflurane and killed by 
decapitation. The brain was rapidly removed and placed into ice-cold sucrose cutting solution 
comprising in (mM): NaCl (87), D-glucose (25), sucrose (75), NaHCO3 (25), KCl (2.5), 
NaH2PO4 (1.25), ascorbic acid (3), CaCl2 (0.5) and MgCl2 (7), saturated with 95% O2 and 5% 
CO2.The hippocampi were removed from the brain, paying attention to the preservation of the 
whole structure, and transverse slices (350 μm thick) were prepared from the hippocampi 
isolated from each cerebral hemisphere using a Leica VT1200 S vibrating microtome 
according to the manufacturer‟s instructions. Then, slices were transferred to normal artificial 
cerebrospinal fluid (aCSF) at room temperature, comprising of in (mM): NaCl (124), D-
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glucose (10), NaHCO3 (26), KCl (3), NaH2PO4 (1.25), ascorbic acid (3), CaCl2 (2) and 
MgSO4 (1), continuously bubbled with 95% O2 / 5% CO2. 
 
Release experiments 
After the separation and the isolation from a selected tissue of CNS, synaptosomes were 
incubated for 15 min at 37°C in a rotary water bath in the presence of [
3
H]D-Aspartate, 
an analogous of glutamate (indicated as [
3
H]D-ASP,f.c.: 50 nM), or [
3
H]GABA (f.c: 20 
nM). In the experiment dedicate to the studies of the impact of selective anti-mGlu 
antibodies on the modulation of glutamate exocytosis by mGlu receptors, the 
synaptosomes were incubated for 30 min in the presence of the following antibodies: 
polyclonal rabbit anti-mGlu3 (1:1000) or monoclonal mouse anti-mGlu2 (1:1000). In 
these experiments, the radioactive tracer was added at t=15 min of incubation.  
Identical portions of the synaptosomal suspension were layered on microporous filters 
at the bottom of parallel thermostated chambers in a Superfusion System (Raiteri et al., 
1974, Pittaluga, 2016; Ugo Basile, Comerio, Varese, Italy). Synaptosomes were 
transiently (90 s) exposed, at t=39 min, to high KCl-containing medium (12 mM KCl 
for cortical synaptosomes or 15 mM KCl for spinal cord synaptosomes, NaCl 
substituting for an equimolar concentration of KCl; Zucchini et al., 2013) in the absence 
or in the presence of the agonists and/or antagonists. Allosteric or enzymatic modulators 
were always added at t=39 min concomitantly with agonists or alone. Fractions were 
collected as follows: two 3 min fractions (basal release), one before (t=36–39 min) and 
one after (t=45–48 min) and a 6 min fraction (t=39–45 min; evoked release). The 
collected fractions and the superfused synaptosomes were measured for radioactivity. 
The amount of radioactivity released into each superfusate fraction was expressed as a 
percentage of the total radioactivity. The KCl-evoked overflow was estimated by 
subtracting the neurotransmitter content in the first and the third fractions collected 
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(basal release, b1 and b3) from that in the 6 min fraction collected during and after the 
depolarization pulse (evoked release, b2). The effect of agonists/antagonists is 
expressed as percentage of the KCl evoked overflow of tritium in the absence of 
receptor agonists and antagonists (% of control). Data are always presented as the mean 
± SEM of n (numbers indicate in the legend of the figure) independent determinations 
obtained in separate experiments run in triplicate (three superfusion chambers for each 
experimental conditions) on different days. 
 
Electrophysiological recordings 
Slices were allowed to recover for at least 1h at room temperature prior to commencing 
the recordings (recovery time). Meanwhile, the multi slice rig was prepared. This setting 
allows to record simultaneously from two slices in separate chambers and condition. 
Slice were transferred to submerged recording chambers continuously perfused at 3.5 
mL/min with aCSF and maintained at 30-32 °C by means of an inline heater. Slices 
were secured in place by adherence to a poly-d-lysine coated coverslip and visualized 
using four digital microscopes (Dino-Lite), one for each chamber. A glass recording 
electrode [1.5 or 1.2 mm OD, 0.86 mm ID glass, with filament, resistance 1-4 MΩ, 
filled with aCSF and a bipolar stimulating electrode [made from Ni:Cr (80:20) formvar-
coated wire] were put in place. In different experiments, I recorded separately from two 
different hippocampal areas, the Cornu Ammonis (CA1) and the Dentate Gyrus (DG), 
respectively. For CA1 recordings, both electrodes were placed in the stratum radiatum 
while stimulating the shaffer collateral pathway; for DG recordings, the electrodes were 
placed in the molecular layer of the Dentate Gyrus while stimulating the perforant path. 
Responses were evoked by monophasic constant current stimulation of 0.1 ms duration. 
Electrodes were carefully advanced into the slice so as to achieve the maximal response. 
The maximal amplitude (for the DG recordings) and slope (for the CA1 recordings) of 
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the field excitatory postsynaptic potential (fEPSP) were used as measure of synaptic 
strength. Stimulus intensity was set to a level eliciting a response about 50% in size of 
that where a population spike was first observed. In the DG recordings, correct 
positioning of the electrodes was verified by application of a paired-pulse protocol: 
application of paired pulses at an inter-stimulus interval of 50-100 ms induces paired-
pulse depression in the Medial Perforant Pathway (MPP) but paired-pulse facilitation in 
the Lateral Perforant Pathway (LPP). Data were filtered at 3 kHz and amplified 500x by 
the amplifier and digitized at 10 kHz. fEPSP were evoked every 30s (0.03 Hz) and 
averages of 4 successive trails were analyzed on- and off- line with WinLTP software 
(Anderson and Collingridge, 2007). 
 
Biotinylation (mGlu2/3 receptor studies) 
The amount of mGlu2/3 receptors proteins in synaptosomal plasmamembranes was 
evaluated by performing surface biotinylation and subsequent immunoblot analysis 
(Salamone et al., 2014). Briefly, purified synaptosomes were divided into 2 aliquots: the 
first aliquot was incubated for 20 min with 100 nM MDL11,939 at 37 °C under mild 
shaking (T), while the other one was kept as control (C). Synaptosomes (T and C) were 
then treated with sulfo-NHS-SS-biotin (2 mg/ml) in PBS/Ca-Mg of the following 
composition (mM): 138 NaCl, 2.7 KCl, 1.8 KH2PO4, 10 Na2HPO4, 1.5 MgCl2, 0.2 
CaCl2, pH 7.4 for 1 h at 4 °C and then incubated in PBS/Ca-Mg with 100 mM glycine 
for 15 min at 4 °C to quench the reaction. Biotinylated synaptosomes were then lysed in 
RIPA buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton 
X-100, protease inhibitors). Samples (100 mg) were incubated with NeutrAvidin 
agarose beads for 1 h at room temperature under shaking. Beads were added to the 
biotinylated synaptosomes to pull down the biotinylated proteins, as well as to non-
biotinylated synaptosomes, to evaluate the specificity of neutravidin pull-down (B). 
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After extensive washes, samples were boiled for 5 min at 95 °C in SDS-PAGE loading 
buffer to separate biotinylated proteins from the beads. Eluted fractions were analysed 
through immunoblot assay (see section “Western blot analysis”). The immunoreactivity 
of the mGlu2/3 receptors was monitored in the total lysate (L), in the control and in the 
antagonist-pretreated biotinylated synaptosomes (respectively C and T) and in the 
streptavidin pulldown of the non-biotinylated synaptosomal lysate (B). β-actin (Sigma 
Milan, Italy), a cytosolic protein, was used as control to evaluate the specificity of 
biotinylation reaction. 
 
Immunoprecipitation 
Purified synaptosomes were lysed in ice-cold lysis buffer having the following 
composition: 140 mM NaCl, 20 mMTris, 0.5% Triton X-100, protease inhibitors, pH 
7.4. Protein A Dynabeads were incubated with anti-mGlu2/3 1:500, anti-GABAB1 1:500 
and anti-GABAB2 1:500 antibodies diluted in PBS containing 0.02% Tween 20 (t-PBS) 
for 10 min at room temperature. Synaptosomal lysate (200 mg) was added to antibody-
bound Protein A Dynabeads (I.P.), as well as to beads without antibody (negative 
control, B). After an incubation for 25 min at room temperature under shaking, beads 
were washed three times in t-PBS and then resuspended in SDS-PAGE loading buffer. 
Samples were boiled at 95 °C for 5 min in order to elute proteins from beads and 
subjected to Western Blot analysis (see below section”Western blot analysis”). 
 
Western blot analysis  
The purified synaptosomes were lysed in ice-cold lysis buffer (150 mM NaCl, 50 mM 
Tris, 1% Triton X-100, protease inhibitors, pH 8.0) and quantified for the protein 
content with Bradford protocol. Samples were boiled for 5 min at 95°C in SDS-PAGE 
loading buffer. Proteins were then separated by SDS 7.5% or 10% PAGE and 
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transferred onto PVDF membranes. Membranes were incubated for 1 h at room 
temperature in Tris-buffered saline-Twee (t-TBS: 0.02 M Tris, 0.150 mM NaCl and 
0.05% Tween 20), containing 5% (w.v-1) non-fat dried milk and then probed with 
different primary antibodies (see below for entire list) overnight at 4°C. After extensive 
washes in t-TBS, the membranes were incubated for about 1 h at room temperature with 
appropriate horseradish peroxidise-linked secondary antibodies (see below for entire 
list). 
In the experiments carried out to verify the specificity of the anti-mGlu2 and anti-
mGlu3 antibodies, mouse cerebral cortices (from WT and knockout mice) were 
dissected out and homogenized at 4°C in Tris–HCl pH 7.5, 10 mM; NaCl, 150 mM; 
SDS 0.1%, EDTA, 5 mM and complete TM protease cocktail tablets. Proteins (20 μg) 
from supernatants were separated by 8% SDS-PAGE and transferred on immuno-blot 
PVDF membranes. Membranes were incubated with mouse anti-mGlu2 (1 h at room 
temperature, in t-TBS), rabbit anti-mGlu3 receptor (1 h at room temperature, in t-TBS) 
and mouse anti β-tubulin (overnight at 4°C) antibodies and then for 1 h with the 
appropriate peroxidise coupled secondary antibodies. Immunoblots were visualized with 
an enhanced chemiluminescence plus Western blotting detection system. Images were 
acquired using the Alliance LD6 images capture system (Uvitec, Cambridge, UK) and 
analysed with UVI-1D software (Uvitec, Cambridge, UK). 
Primary antibodies: mouse monoclonal anti mGlu 1 receptor antibody 1:250 (BD 
Biosciences (San Jose, CA, United States), mouse monoclonal anti-GABAB1 receptor 
antibody 1:500 (Santa Cruz Biotechnology, Dallas, TX, United States), mouse 
monoclonal anti-GABAB2 receptor antibody 1:500 (Santa Cruz Biotechnology, Dallas, 
TX, United States), mouse monoclonal anti-mGlu2 receptor antibody 1:1000 for 
cortical synaptosomes and 1:500 for spinal cord synaptosomes (Abcam Cambridge, 
UK), rabbit monoclonal anti-mGlu3 receptor antibody 1:1000 (Alomone Labs 
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Jerusalem, Israel), rabbit monoclonal anti-mGlu2/3 receptor antibody 1:2000 (Novus 
Biologicals Littleton CO, USA), rabbit monoclonal anti-5-HT2A receptor antibody 1:500 
(Immunostar Hudson,WI, USA), mouse polyclonal anti-β-tubulin antibody 1:800 
(Sigma Milan, Italy), mouse monoclonal anti-β-actin antibody 1:5000 (Sigma Milan, 
Italy), mouse monoclonal anti-Gapdh antibody 1:10000 (Sigma Milan, Italy). 
All horseradish peroxidase-coupled anti-mouse and anti-rabbit secondary antibodies 
were from Sigma (Milan, Italy).  
 
Confocal analysis 
Purified synaptosomes were fixed with 2% paraformaldehyde for 15 min, permeabilized 
with 0.05% Triton X-100 PBS for 5 min and incubated with primary antibodies (see 
below for entire list): After extensive washes, synaptosomes were incubated for 1 h at 
room temperature with the antibodies reported below. Synaptosomes were then applied 
to coverslips (Musante et al., 2008). Fluorescence images (512×512×8 bit) were then 
visualized by use of a sixchannel Leica TCS SP5 laser-scanning confocal microscope, 
equipped with 458, 476, 488, 514, 543 and 633 nm excitation lines, through a plan-
apochromatic oil immersion objective 63X/1.4NA. Light collection configuration was 
optimized according to the combination of chosen fluorochromes. Sequential channel 
acquisition was performed to avoid crosstalk. A Leica „LAS AF‟ software package was 
used for image acquisition, storage and visualization. The quantitative estimation of co-
localized proteins was performed as described previously (Musante et al., 2008; Summa 
et al., 2013), by calculating the „co-localization coefficients‟ (Manders et al., 1993). 
They express the fraction of colocalizing molecular species in each component of a dual 
colour image and are based on the Pearson‟s correlation coefficient, a standard 
procedure for matching one image with another in pattern recognition. If two molecular 
species are colocalized, the overlay of their spatial distributions has a correlation value 
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higher than what would be expected by chance alone. Costes et al. (2004) developed an 
automated procedure to evaluate the correlation between the green and red channels 
with a significance level >95%. The same procedure automatically determines an 
intensity threshold for each colour channel based on a linear least-square fit of the green 
and red intensities in the image‟s 2D correlation cytofluorogramme. Costes‟s approach 
was carried out by macro routines integrated as plugins (WCIF Colocalization Plugins, 
Wright Cell Imaging Facility, Toronto Western Research Institute, Canada) in the 
ImageJ 1.51p software (Wayne Rasband, NIH, USA). 
For mGlu2/3 studies: I used the following primary antibodies: mouse anti-mGlu2 
receptor 1:1000 (Abcam Cambridge, UK), rabbit anti-mGlu3 receptor 1:1000 (Alomone 
Labs Jerusalem, Israel) and guinea pig anti vesicular glutamate transporters type 1 or 
VGLUT1 1:500 (Millipore Corporation, Billerica, MA, USA). I used the following 
conjugated antibodies: donkey anti-rabbit AlexaFluor-488 and goat anti-guinea pig 
AlexaFluor-633 (1:1000 both, confocal analysis aimed at identifying co-localization of 
mGlu3 receptor and VGLUT1 proteins), with donkey anti mouse AlexaFluor-488 and 
goat anti guinea pig AlexaFluor-633 (1:1000 both, confocal analysis aimed at 
identifying co-localization ofmGlu2 receptor and VGLUT1 proteins), with donkey anti-
rabbit AlexaFluor-488 with goat anti-mouse AlexaFluor-633 (1:1000 both, confocal 
analysis aimed at identifying co-localization of mGlu2 and mGlu3 receptor proteins). 
All AlexaFluor antibodies are purchased from Sigma, Milan, Italy 
For mGlu2/3 and 5-HT2a studies: I used the following primary antibodies: rabbit anti-
mGlu2/3 receptor antibody 1:1000 (Novus Biologicals Littleton CO, USA), mouse anti-
5-HT2A receptor antibody 1:200 (Immunostar Hudson,WI, USA), and guinea pig anti-
vesicular glutamate transporters type 1 or VGLUT1 1:500 (Millipore Corporation, 
Billerica, MA, USA). I used the following conjugated antibodies: donkey anti-rabbit 
AlexaFluor-488 and goat anti-guinea pig AlexaFluor-633 (1:1000 both, confocal 
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analysis aimed at identifying colocalization of mGlu2/3 receptor and VGLUT1 
proteins), with donkey anti-mouse AlexaFluor-488 and goat anti-guinea pig 
AlexaFluor-633 (1:1000 both, confocal analysis aimed at identifying colocalization of 
5-HT2a receptor and VGLUT1 proteins), with donkey anti-rabbit AlexaFluor-488 with 
goat anti-mouse AlexaFluor-633 (1:1000 both, confocal analysis aimed at identifying 
colocalization of mGlu2/3 and 5-HT2A receptor proteins). All AlexaFluor antibodies 
are purchased from Sigma, Milan, Italy. 
For GABAB and mGlu1 studies: I used the following primary antibodies: rabbit anti-
mGlu1 receptor antibody 1:500 (BD Biosciences, San Jose, CA, United States), mouse 
anti-GABAB1 receptor antibody 1:500 (Santa Cruz Biotechnology, Dallas, TX, United 
States), mouse anti-GABAB2 receptor antibody 1:500 (Santa Cruz Biotechnology, 
Dallas, TX, United States), guinea pig anti-vesicular GABA transporter or VGAT 1:300 
(Alomone Labs Jerusalem, Israel), and guinea pig anti-vesicular glutamate transporter 
type 1 or VGLUT1 1:500 (Millipore Corporation, Billerica, MA, USA). I used the 
following conjugated antibodies: donkey anti-mouse AlexaFluor-647, goat anti-guinea 
pig AlexaFluor-488, goat anti-rabbit AlexaFluor-555 as appropriate, purchased by Life 
Technologies Corporation Carlsbad, CA, United States (for colocalization see “Results 
and Discussion” sections). 
 
Calculations and statistical analysis 
Sigma plot 10 data analysis and graphing software package were used for data 
handling/statistics and for graph drawing. ANOVA was performed followed by 
Dunnett‟s test or Newman–Keulsmultiple comparisons test, as appropriate; direct 
comparisons were performed by Student‟s t-test. Post hoc tests were done only if F 
value was significant. Data were considered significant if P < 0.05 and reported as *P < 
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0.05, **P < 0.01 and *** P < 0.001 (*could be change with other symbols where 
necessary).  
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